

**Risk Factors Comparison 2025-03-18 to 2024-03-15 Form: 10-K**

**Legend:** New Text ~~Removed Text~~ Unchanged Text Moved Text Section

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item. ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Index to Financial Statements ~~Reports-~~ **Report** of Independent Registered Public Accounting Firm (PCAOB Firm ID: 726) Consolidated Balance Sheets Consolidated Statements of Operations Consolidated Statements of Comprehensive Loss Consolidated Statements of Shareholders' Equity Consolidated Statements of Cash Flows Notes to Consolidated Financial Statements REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and Board of Directors of XBiotech Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of ~~Xbiotech~~ **XBiotech** Inc. and subsidiaries (the "Company") as of December 31, **2024 and** ~~2023 and 2022~~, and the related consolidated statements of operations, comprehensive loss, shareholders' equity, and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, **2024 and** ~~2023 and 2022~~, and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. Basis for Opinion These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U. S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the ~~audits-~~ **audit** to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits ~~provide~~ **provides** a reasonable basis for our opinion. Critical Audit Matters Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters. / s / Whitley Penn LLP We have served as the Company's auditor since 2022. Austin, Texas March ~~15-18,~~ **2024-2025** XBiotech Inc. (in thousands, except share data) December 31, ~~2023-2024~~ December 31, ~~2022-2023~~ **2023** Assets Current assets: Cash and cash equivalents \$ **172,677** \$ 200,023 \$ ~~157,306~~ **Interest bearing time deposits-** ~~60,172~~ **Accrued interest receivable** **1,216** ~~Income tax receivable~~ **Prepaid expenses and other current assets** **1,032** Total current assets **174,567** ~~201,718~~ ~~219,843~~ Property and equipment, net **24,526** ~~24,897~~ ~~26,260~~ Total assets \$ **199,093** \$ 226,615 \$ ~~246,103~~ Liabilities and shareholders' equity Current liabilities: Accounts payable \$ **2,516** ~~223~~ \$ 2,408 ~~516~~ **Accrued expenses** **2,632** ~~3,501~~ ~~1,603~~ **Income tax payable** **1,720** ~~1,669~~ ~~1,576~~ **Convertible loan, related party** **10,000** ~~Convertible loan, third party-~~ Total current liabilities **15,105** ~~6,100~~ ~~4,066~~ Long-term liabilities: Income tax payable **1,720** ~~1,669~~ ~~1,576~~ **Deferred tax liability-** Total liabilities **16,825** ~~7,769~~ ~~5,701~~ Shareholders' equity: Preferred stock, no par value, unlimited shares authorized, no shares outstanding-- Common stock, no par value, unlimited shares authorized, **30,436** ~~487,964~~ ~~731~~ and **30,439** ~~436,275~~ ~~964~~ shares **issued and** outstanding at December 31, ~~2023-2024~~ and December 31, ~~2022-2023~~, respectively **273,105** ~~271,152~~ ~~267,325~~ **Accumulated other comprehensive income-** **Accumulated deficit** **(90,837)** ~~(52,306)~~ ~~(27,749)~~ Total shareholders' equity **182,268** ~~218,846~~ ~~240,402~~ Total liabilities and shareholders' equity \$ **199,093** \$ 226,615 \$ ~~246,103~~ See accompanying notes to consolidated financial statements. (in thousands, except share and per share data) Year Ended December 31, Revenue: Manufacturing revenue \$- \$ **4,010** Total revenue **4,010** Cost of goods sold: Manufacturing cost- Total cost of goods sold- Gross margin- **3,359** Operating expenses: Research and development \$ **37,757** \$ 32,848 ~~31,544~~ General and administrative **4,714** ~~4,662~~ ~~6,305~~ Total operating expenses **42,471** ~~37,510~~ ~~37,849~~ Loss from operations **(42,471)** ~~(37,510)~~ ~~(34,490)~~ Other income (expense): Interest income **9,812** ~~10,421~~ ~~3,823~~ **Interest expense (807)-** Other income (expense) **(121)** Foreign exchange (loss) gain **(loss 5,529)** ~~1,893~~ ~~(2,800)~~ Total other income **3,908** ~~13,197~~ Loss before income taxes **(38,563)** ~~(24,313)~~ ~~(33,588)~~ Income tax benefit (expense) benefit **(244)** Net loss \$ **(38,531)** \$ ~~(24,557)~~ ~~(32,900)~~ Net loss per share — basic **and diluted** \$ **(1.26)** \$ ~~(0.81)~~ ~~(1.08)~~ Shares used to compute basic **and net loss per share** **30,438,459** ~~30,439,275~~ Net loss per share — diluted \$ **(0.81)** \$ ~~(1.08)~~ Shares used to compute diluted net loss per share **30,460,980** ~~30,438,459~~ ~~30,439,275~~ (in thousands) Year Ended December 31, Net loss \$ ~~(24,557)~~ \$ ~~(32,900)~~ Realized comprehensive income- ~~(1,567)~~ Foreign currency translation adjustment ~~(252)~~ Reclassification of deferred tax assets ~~(574)~~ Comprehensive loss \$ ~~(25,383)~~ \$ ~~(34,045)~~ Consolidated Statements of Shareholders' Equity Number of Shares Common Stock Amount Accumulated Other Comprehensive Income Retained Earnings (Accumulated deficit) Total Balance at December 31, 2021 **30,439** \$ **267,325** \$ **1,971** \$ **5,151** \$ **269,385** Net loss--- ~~(32,900)~~ ~~(32,900)~~ Foreign currency translation adjustment--- Realized comprehensive income--- ~~(1,567)~~ ~~(1,567)~~ Share-based compensation expense- ~~5,062~~--- ~~5,062~~ Balance at December 31, 2022 **30,439** ~~267,325~~ ~~(27,749)~~ **240,402** Net loss--- ~~(24,557)~~ ~~(24,557)~~ Tender offer ~~(4)~~ ~~(14)~~--- ~~(14)~~ Foreign currency translation adjustment--- ~~(252)~~ ~~(252)~~ Reclassification of deferred tax assets- ~~(574)~~ Issuance of common stock under stock option plan--- Share-based compensation expense- ~~3,262~~--- ~~3,262~~ Balance at December 31, 2023 **30,436** ~~271,152~~ \$ ~~(52,306)~~ \$ **218,846** See accompanying notes to consolidated financial statements. **(in thousands) Year Ended December 31, Net loss \$ (38,531) \$ (24,557) Foreign currency translation adjustment- (252) Reclassification of deferred tax assets- (574) Comprehensive loss \$ (38,531) \$ (25,383) Consolidated Statements of Shareholders' Equity Accumulated Other Number of Common Stock Comprehensive Shares Amount Income Accumulated deficit Total Balance at December 31, 2022 30,439 \$ 267,325 \$ \$ (27,749) \$ 240,402 Net loss--- (24,557) (24,557) Tender offer (4) (14)--- (14) Foreign currency translation adjustment--- (252)- (252) Reclassification of deferred tax assets- (574)-- Issuance of common stock under stock option plan-- Share-based compensation expense- 3,262-- 3,262 Balance at December 31, 2023 30,436 271,152- (52,306) 218,846 Net loss--- (38,531) (38,531) Issuance of common stock under stock option plan-- Share-based compensation expense- 1,753-- 1,753 Balance at**

**December 31, 2024 30, 487 \$ 273, 105 \$- \$ (90, 837) \$ 182, 268 See accompanying notes to condensed financial statements.** Year Ended December 31, Operating activities Net loss \$ ( **38, 531** ) \$ ( 24, 557 ) \$ ( 32, 900 ) Adjustments to reconcile net loss to net cash (used in ) operating activities: Depreciation **1, 745** **1, 744** **2, 614** Foreign exchange **loss** (gain) **loss 5, 529** (1, 893) **2, 800** Share- based compensation expense **1, 753** **3, 262** **5, 062** Changes in operating assets and liabilities: Income tax receivable **8, 556** **(83)** Accrued interest receivable **(1, 216)** Prepaid expenses and other current assets **(271)** **(160)** Accounts payable **(364)** Accrued expenses **(877)** **1, 895** Income tax payable **(24)** Deferred tax liability **(59)** **(815)** Net cash (used in ) provided by operating activities ( **30, 963** ) ( 18, 725 ) ( 14, 824 ) Investing activities Purchase of property and equipment ( **1, 304** ) ( 362 ) ( 585 ) Proceeds from maturity (purchases of ) interest bearing time deposits **61, 859** **(63, 307)** Net cash (used in ) provided by (used in ) investing activities **(1, 304)** **61, 497** **(63, 892)** Financing activities **Proceeds from convertible loan, related party 10, 000- Proceeds from convertible loan, third party-** Cash paid in tender offer **(14)** - Issuance of common stock under stock option plan -Net cash **provided by** ( used in ) financing activities **10, 450** (9) -Effect of foreign exchange rate on cash and cash equivalents ( **5, 529** ) ( 46 ) ( 961 ) Net change in cash and cash equivalents **(27, 346)** **42, 717** **(79, 677)** Cash and cash equivalents, beginning of year **200, 023** **157, 306** **236, 983** Cash and cash equivalents, end of year **\$ 172, 677** **\$ 200, 023** **\$ 157, 306** Supplemental Information: **Accrued Purchases-purchases** of property and equipment in accounts payable **\$ \$ Cash paid for interest \$ \$ Cash paid for income taxes** \$ \$ 1. Organization XBiotech Inc. ( “ XBiotech ” or the “ Company ” ) was incorporated in Canada on March 22, 2005. The Company ’ s headquarters are located in Austin, Texas. XBiotech USA, Inc., a wholly- owned subsidiary of the Company, was incorporated in Delaware, United States in November 2007. XBiotech Germany GmbH, a wholly- owned subsidiary of the Company, was incorporated in Germany in January 2014. XBiotech Germany GmbH was dissolved in February 2023. Since its inception, XBiotech has focused on advancing technology to rapidly identify and clone antibodies from individuals that have resistance to disease. At the heart of the Company is a proprietary technical knowhow to translate natural human immunity into therapeutic product candidates. The Company has in its pipeline both anti- infective and anti- inflammatory candidate therapeutics derived from this technology. An area of medical focus for XBiotech are therapies that block a potent substance naturally produced by body, known as interleukin- 1 alpha (IL- 1a), that mediates tissue breakdown, angiogenesis, the formation of blood clots and inflammation. IL- 1a is a protein that is on or in cells of the body and is involved in the body ’ s response to injury or trauma. In almost all chronic and in some acute injury scenarios (such as stroke or heart attack), IL- 1a may mediate harmful disease- related activity. At the end of 2019, XBiotech sold a True Human <sup>TM</sup> antibody that blocked IL- 1a activity for \$ 750 million in cash and up to \$ 600 million in potential milestone payments (the “ Janssen Transaction ” ). **The potential milestone payments are contingent upon achieving** On February 2, 2022, XBiotech announced an addendum to the **required commercialization authorization for a product intended** 2019 Janssen Manufacturing Agreement. XBiotech continued to manufacture **Bermekimab** for use **in any non- dermatological indication** by Janssen in its clinical trials through November **within twelve years. As of December 31, 2022-2024, none of the milestone payments have been earned**. As part of the Janssen Transaction, XBiotech maintained the right to develop new antibodies that block IL- 1a and develop these therapeutics in all areas of medicine except dermatology. Moreover, **Janssen agreed that they would assert** all patents **they** acquired by Janssen relating to IL- 1a **would be asserted** for the benefit of XBiotech to protect **its-our** future IL- 1a **-related** therapies in all non- dermatological indications. **Consequently,** XBiotech is **pursuing---** **using its** the development of other True Human <sup>TM</sup> antibodies targeting IL- 1a for areas of medicine outside of dermatology. The Company ’ s True Human <sup>TM</sup> antibody discovery technology **has been used** to identify **and develop** new IL- 1a targeting product candidates and has already brought one such candidate into a clinical studies in oncology and rheumatology; and another **unique** anti- IL- 1a antibody into a Phase I study in neurology **-While the Company previously was focused on a single True Human <sup>TM</sup> antibody targeting IL- 1a, it is now developing more than one product candidate that targets IL- 1a to be used in different areas of medicine.** The Company is subject to a number of risks common to companies in clinical stage of development. Principal among these risks are the uncertainties of technological innovations, dependence on key individuals, development of the same or similar technological innovations by the Company ’ s competitors and protection of proprietary technology. The Company ’ s ability to fund its planned clinical operations, including completion of its planned trials, is expected to depend on the amount and timing of cash receipts from future collaboration or product sales and / or financing transactions. The Company believes that its cash and cash equivalents of \$ **200-172. 0-7** million at December 31, **2023-2024**, will enable the Company to achieve several major inflection points, including completion of clinical studies with lead product candidates. The Company expects to have sufficient cash through at least 12 months from the date of this report. 2. Significant Accounting Policies Basis of Presentation These consolidated financial statements have been prepared in conformity with U. S. Generally Accepted Accounting Principles ( “ US GAAP ” ). In the opinion of management, the accompanying consolidated financial statements reflect all adjustments (consisting only of normal recurring items) considered necessary to present fairly the Company ’ s financial position at December 31, **2024 and 2023 and 2022**, the results of its operations and comprehensive loss for the years ended December 31, **2024, and 2023, and 2022**, and the cash flows for the years ended December 31, **2024, and 2023, and 2022**. Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly- owned subsidiaries. All significant intercompany transactions have been eliminated upon consolidation. Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the U. S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates. **Revenue from the Janssen Agreements** The Company recognized revenues from its Janssen Agreements as follows: The Company entered into its clinical manufacturing and clinical trial services arrangements in connection with its sale of certain intellectual property on December 30, 2019. These contracts commenced January 1, 2020. The Company executed an addendum related to manufacturing agreement, which generated revenue through November 2022. While these agreements are not considered contracts with a customer based on the terms thereof, the Company has applied the revenue recognition guidance by analogy. XBiotech is still in the research and development phase. The eventual output of the Company ’ s intended ordinary activities will be the licensing of intellectual property and / or sale of commercialized compounds for use in pharmaceutical treatment of disease, not the performance of manufacturing of development stage compounds or clinical trials for others. Although Janssen was not a customer, as these services are not the output of XBiotech ’ s ordinary activities, the Company evaluated the terms of the agreements and analogized to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers ( “ ASC 606 ” ) for clinical manufacturing and clinical trial services revenue recognition. Under ASC 606, an entity recognizes revenue when (or as) its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606 (or for those analogized to it), the Company performs the following five steps: (i) identify the contract (s) with a customer ; (ii) identify the performance obligations in the contract ; (iii) determine the transaction price ; (iv) allocate the transaction price to the performance obligations in the contract ; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five- step model to contracts (including by analogy) when it is probable that the Company will collect the consideration it is entitled to

in exchange for the goods or services it transfers to the counterparty. At contract inception, once the contract is determined to be within the scope of or analogized to ASC 606, the Company assesses the goods or services promised within each contract and determine those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Manufacturing Revenue The Company had a Clinical Manufacturing Agreement that it accounted for by analogy to ASC 606. In 2022 the Company executed a new manufacturing agreement with a Janssen related company. The agreement generated \$ 4. 0 million in revenue through termination in November 2022. Research and Development Costs All research and development costs are charged to expense as incurred. Research and development costs include salaries and personnel- related costs, consulting fees, fees paid for contract clinical trial research services, the costs of laboratory consumables, equipment and facilities, license fees and other external costs. Costs incurred to acquire licenses for intellectual property to be used in research and development activities with no alternative future use are expensed as incurred as research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Clinical Trial Accruals Expense accruals related to clinical trials are based on **actual** the Company<sup>2</sup> s estimates of services received and efforts expended pursuant to contracts with third party service providers that which conduct and manage clinical trials on the Company’ s behalf. The financial terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. **In accruing The Company accrues costs based on the Company estimates actual services rendered in** the period over which services **were will be** performed and the level of effort **to be** expended in each period based upon patient enrollment, clinical site activations, or information provided to the Company by its vendors on their actual costs incurred. Any estimates of the level of services performed or the costs of these services could differ from actual results. Income Taxes **In December 2023, the FASB issued..... s consolidated financial statements and disclosures.** The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company measures deferred tax assets and liabilities using the enacted tax rates for the years and jurisdictions in which the temporary differences are expected to be recovered. A change to the tax rates used to measure the Company’ s deferred taxes is recognized in income during the period in which the new rate (s) were enacted. The Company recognizes deferred tax assets to the extent the Company’ s assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including the future reversals of existing taxable temporary differences, projected future taxable income exclusive of reversing temporary differences and carryforwards, tax- planning strategies, taxable income in prior carryback years if permitted under tax law, and the results from prior years. If the Company determines it is more likely than not, that all or a portion of a deferred tax asset will not be realized a valuation allowance is recorded with a charge to income tax expense. Alternatively, if the Company determines that all or a portion of a deferred tax asset previously not meeting the more likely than not threshold will be realized, the Company reduces its valuation allowance and recognizes a benefit in income tax expense. The Company recognizes and measures uncertain tax benefits in accordance with ASC 740 based on a two- step process in which (1) the Company determines whether it is more likely than not that the tax position will be sustained based on the technical merits of the position, and (2) for those tax positions that meet the more- likely- than- not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than fifty percent likely to be realized upon ultimate settlement with the related tax authority. The Company’ s policy is to recognize interest and penalties, if any, in income tax expense. Share- Based Compensation The Company accounts for its share- based compensation awards in accordance with ASC Topic 718, Compensation- Stock Compensation (“ ASC 718 ”). ASC 718 requires all share- based payments to employees, including grants of employee stock options, to be recognized in the statements of operations based on their grant date fair values. For stock options granted to employees and to members of the board of directors for their services on the board of directors, the Company estimates the grant date fair value of each option award using the Black- Scholes option- pricing model. The use of the Black- Scholes option- pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk- free interest rates, and expected dividend yields of the common stock. To determine the fair value of its common stock, the Company uses the closing price of the Company’ s common stock as reported by NASDAQ. For awards subject to service- based vesting conditions, the Company recognizes share- based compensation expense, equal to the grant date fair value of stock options, on a straight- line basis over the requisite service period. The Company accounts for forfeitures as they occur rather than on an estimated basis. Share- based compensation expense recognized for the years ended December 31, **2024, and 2023 ,and 2022** was included in the following line items on the **consolidated Consolidated statements Statements of operations Operations** (in thousands). Year Ended December 31, Research and development \$ **1, 127 \$** 2, 797 **\$ 3, 641** General and administrative **1, 421** Total share- based compensation expense \$ **1, 753 \$** 3, 262 **\$ 5, 062** The fair value of each option is estimated on the date of grant using the Black- Scholes method with the following assumptions: Year Ended December 31, Weighted- average grant date fair value per share \$ **3. 96 \$** 2. 89 **\$ 4. 92** Expected volatility **79 %- 83 %** 80 %- 82 % **82 %- 83 %** Risk- free interest rate **3. 6 %- 4. 4 %** 3. 3 %- 4. 6 % **1. 5 %- 4. 1 %** Expected life (in years) **5. 38 - 00** - 6. 25 5. 38 - 6. 25 Dividend yield-- Cash and Cash Equivalents The Company considers highly liquid investments with a maturity of 90 days or less when purchased to be cash equivalents. Cash and cash equivalents consisted primarily of cash on deposit in U. S., German, and Canadian banks. Cash and cash equivalents are stated at cost which approximates fair value. Interest Bearing Time Deposits **During As of December 31, 2022 2023**, the Company held guaranteed investment certificates **from with** a financial institution. The guaranteed investment certificates had a 12 -month term at origination with interest **payable-receivable** at maturity. The **guaranteed investment certificates matured** Company **obtained both the principal amount and accrued interest** in July 2023 upon maturity. **There has been no related activity in 2024**. Concentrations of Credit Risk Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly- rated financial institutions, and limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off- balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements. Fair Value Measurements The consolidated financial statements include financial instruments for which the fair value of such instruments may differ from amounts reflected on a historical cost basis. Financial instruments of the Company consist of cash deposits, time deposits, accounts and other receivables, accounts payable, and certain accrued liabilities. These financial instruments are held at cost, which generally approximates fair value due to their short- term nature. The Company follows ASC Topic 820, Fair Value Measurements and Disclosures, which establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on

market date (observable inputs) and the Company's own assumptions (unobservable inputs). The hierarchy consists of three levels: Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 — Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. Level 3 — Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. At December 31, 2024 and 2023 and 2022, the Company did not have any assets or liabilities that are measured at fair value on a recurring basis. The carrying amounts reflected in the consolidated balance sheets for cash and cash equivalents, interest-bearing time deposits, prepaid expenses and other current assets, accounts payable, and accrued expenses and debt approximate their fair values at December 31, 2024 and 2023 and 2022, due to their short-term nature. Property and Equipment Property and equipment, which consists of land, construction in process, furniture and fixtures, computers and office equipment, scientific equipment, leasehold improvements, vehicles, mobile facility and building are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, with the exception of land and construction in process which are not depreciated, using the straight line method. The useful lives are as follows: Furniture and fixtures 7 years Office equipment 5 years Scientific equipment 5 years Vehicles 5 years Mobile facility 27.5 years Building 39 years Scientific equipment 5 years Costs Vehicles 5 years Mobile facility 27.5 years Building 39 years Costs of major additions and betterments are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized. Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment. Potential impairment is assessed when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The recoverability of these assets is assessed based on undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends and product development cycles. If impairments are identified, assets are written down to their estimated fair value. The Company has not recognized any impairment through December 31, 2023-2024. Foreign Currency Transactions Certain transactions are denominated in a currency other than the Company's functional currency of the U. S. dollar, and the Company generates assets and liabilities that are fixed in terms of the amount of foreign currency that will be received or paid. At each balance sheet date, the Company adjusts the assets and liabilities to reflect the current exchange rate, resulting in a translation gain or loss. The only significant assets denominated in a foreign currency were certain cash accounts, which were remeasured into the functional currency (U. S. dollar) as of the end of the year, resulting in a foreign exchange loss of \$ 5.5 million for the year ended by December 31, 2024 and a foreign exchange gain of \$ 1.9 million for the year ended by December 31, 2023. The Transaction gains and losses are also realized upon a settlement of a foreign currency transaction in determining net loss for the period in which the transaction is settled. Comprehensive Income (Loss) ASC Topic 220, Comprehensive Income, requires that all components of comprehensive income (loss), including net income (loss), be reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including foreign currency translation adjustments. Segment and Geographic Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company's chief operating decision maker is the Chief Executive Officer. The Company and the chief operating decision maker view the Company's operations and manage its business as one operating segment. Substantially all of the Company's operations are in the U. S. geographic segment. Net Income/Loss per Share Net income / loss per share ("EPS") is computed by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted EPS is computed by dividing net income / loss by the weighted average number of common shares and common share equivalents outstanding (if dilutive) during each period. The number of common share equivalents, which include stock options, is computed using the treasury stock method. The Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive. For the year ended December 31, 2024, all stock options were not included in the computation of diluted net loss per share, as the impact of these items was anti-dilutive. In addition, 1,921,828 shares of common stock issuable upon conversion of the related party convertible loan (which was the maximum convertible amount based on ownership restrictions) were excluded from the computation of diluted net loss per share as their impact is anti-dilutive. For the year ended December 31, 2023, all stock options were not included in the computation of diluted net loss per share, as the impact of these items was anti-dilutive. Subsequent Events The Company considered events or transactions occurring after the balance sheet date but prior to the date the consolidated financial statements were available to be issued for potential recognition or disclosure in its consolidated financial statements. Recent Accounting Pronouncements Recently Issued Accounting Pronouncements In December 2023 June 2016, the Financial Accounting Standard Board ("FASB") issued Accounting Standards Update ("ASU" or "standard") No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. Subsequently, the FASB issued several clarifying standard updates ASU 2023- 09, "Income Taxes (Topic 740): Improvements to clarify Income Tax Disclosures" ("ASU 2023- 09"), which enhances the transparency and improve decision usefulness of income tax disclosures. Adjustments to the annual disclosure of income taxes include:(1) A tabular rate reconciliation comprised of eight specific categories,(2) Incomes- Income taxes paid,disaggregated between significant federal,national, state,and foreign jurisdictions,(3) Eliminates requirements to disclose the nature and estimate of reasonably possible changes to unrecognized tax benefits in the next 12 months or that an estimated range cannot be made,and (4) Adds a requirement to disclose income (or loss) from continuing operations before income tax expense (or benefit) and income tax expense (or benefit) from continuing operations disaggregated between domestic and foreign.The ASU is effective for public business -These ASUs significantly change how entities will measure credit losses for most financial assets fiscal years beginning on or after December 15, 2024 with early adoption permitted. The amendments in ASU 2023- 09 should be applied on a prospective basis and retrospective application certain other instruments that are not measured at fair value through net income. The most significant change in this standard is permitted a shift from the incurred loss model to the expected loss model that will be based on an estimate of current expected credit loss ("CECL"). Under the standard, disclosures are required to provide users of the financial statements with useful information in analyzing an entity's exposure to credit risk and the measurement of credit losses. The Company adopted is in process of evaluating the standard effective January 1, impact of adoption of ASU 2023 - 09 on -The impact of the Company's adoption was not considered material to the consolidated financial statements and disclosures. 3 -Revenue On February 2, 2022, the Company announced an addendum to the 2019 Janssen Manufacturing Agreement XBiotech continued to manufacture Bermekimab for use by Janssen in its clinical trials through November 2022. For the year ended December 31, 2022, the Company recorded \$ 4.0 million of

revenues, under the February 2022 agreement. The agreement was terminated in November 2022. 4. Property and Equipment and Building Construction in Progress Property and equipment consisted of the following as of December 31, 2024 and 2023 and 2022 (in thousands): Computer and office equipment \$ \$ Furniture and fixtures Land 1, 418 1, 418 Scientific equipment 16, 491 16, 367 16, 059 Vehicle Vehicles Building 24, 173 24, 173 Mobile facility Construction in process 1, 705 Accumulated depreciation ( 19, 985 ) ( 18, 239 ) ( 16, 495 ) \$ 24, 526 \$ 24, 897 \$ 26, 260 Depreciation expenses related to property and equipment amounted to approximately both \$ 1. 7 million and \$ 2. 6 million, for the years ended December 31, 2024, and 2023, and 2022, respectively. Construction in process is related to research and development and ~~manufacturing~~ **manufacturing** equipment. Depreciation expense is recorded to **allocated between** research and development and general and administrative expense line items on the Consolidated ~~consolidated~~ **consolidated** Statements ~~statements~~ **of Operations operations** (in thousands). 5. Accrued Expenses Accrued expenses consist of the following as of December 31, 2024, and 2023, and 2022 (in thousands): Accrued compensation and related expenses \$ \$ Accrued professional fees Accrued clinical trial expenses 1, 502 2, 826 **Accrued convertible loan interest- Other \$ 2, 632 \$ 3, 501** 5. Convertible Loan, Related Party On January 3, 2024, the Company entered into a Convertible Loan Agreement (the "Loan") with John Simard, the Company's Founder, President, Chief Executive Officer and Chairman. The Loan provided \$ 10 million in immediate funding for the construction of a new, state-of-the-art research and development facility at the Company's property at 5217 Winnebago Lane in Austin, Texas. The Loan was secured by the real estate and cash holdings of the Company, with interest to accrue at a simple rate equal to eight percent per year and interest-only payments to be made at six-month intervals. At Mr. Simard's election, the balance could be converted to XBiotech stock at any time the Loan balance was outstanding at a fixed conversion price equal to \$ 4. 048 per share. The conversion feature was subject to a 19. 9 % cap limiting the number of shares that could be converted under the Loan based on Mr. Simard's total stock ownership in the Company at the time of conversion. The Loan included an acceleration feature, allowing Mr. Simard to declare immediate cash repayment or conversion under specific acceleration events, including certain financial and non-financial measures, such as payment defaults, breaches of covenants, drop in stock price below \$ 3. 00 per share or drop in cash position below \$ 65, 000, 000. The Loan also allowed Mr. Simard to obtain immediate cash repayment of the Loan balance at his election one year after the loan is funded or upon certain other conditions set forth in the Loan. The Loan had a contractual maturity date of January 3, 2029. The Loan was negotiated, evaluated, and approved on behalf of the Company by a committee of independent and disinterested directors. During 2024, the Company paid \$ 400 thousand in interest and accrued \$ 400 thousand in interest as of December 31, 2024. If the loan had been settled on December 31, 2024, the outstanding balance could have been converted into 1, 603-930, 983 shares of XBiotech stock at a fixed conversion price of \$ 4. 048 per share. The remaining balance of \$ 2, 183, 380. 82 is paid in cash. On January 31, 2025, the Loan was terminated upon full repayment by the Company. As a result, all conversion rights to XBiotech stock associated with the Loan were extinguished. 6. Common Stock Pursuant to its Articles, the Company has an unlimited number of shares available for issuance with no par value. During the year ended December 31, 2024, 50, 767 shares of common stock were issued upon the exercise of stock options, at prices ranging from \$ 3. 38 to \$ 5. 62 per share, for total proceeds of \$ 200 thousand. On May 17, 2023, XBiotech announced that it had commenced a "modified Dutch auction" tender offer to purchase up to \$ 80. 0 million of its common shares, or such lesser number of common shares as are properly tendered and not properly withdrawn, at a price not less than \$ 3. 80 nor greater than \$ 4. 00 per common share, to the seller in cash. The tender offer expired on June 15, 2023. On June 20, 2023, the Company announced the final results of its "modified Dutch Auction" tender offer. The Company accepted for purchase 3, 561 shares of its common stock, at a price of \$ 4. 00 per share, for an aggregate cost of approximately \$ 14 thousand, excluding fees and expenses related to the tender offer. These shares represented an immaterial percent of the shares outstanding. The ~~These~~ **These** repurchased shares were retired and have been classified to reduce common stock in the accompanying consolidated balance sheet as of December 31, 2023. During the year ended December 31, 2023, 1, 250 shares of common stock were issued upon the exercise of stock options at a price of \$ 3. 84 per share for total proceeds of \$ 4, 800. ~~No stock options were exercised from January 1, 2022 through December 31, 2022.~~ 7. Common Stock Options On November 11, 2005, the Board of Directors of the Company adopted the XBiotech Inc. 2005 Incentive Stock Option Plan (the "2005 Plan"), and on March 24, 2015, the ~~board~~ **Board** of ~~directors~~ **Directors** of the Company adopted the XBiotech Inc. 2015 Equity Incentive Plan (the "2015 Plan" **and, together with the 2005 Plan, the "Plans"**) pursuant to which the Company may grant incentive stock and non-qualified stock options to directors, officers, employees or consultants of the Company or an affiliate or other persons as the Compensation Committee may approve. All options under ~~both the~~ **both the** Plans will be non-transferable and may be exercised only by the participant, or in the event of the death of the participant, a legal representative until the earlier of the options' expiration date or the first anniversary of the participant's death, or such other date as may be specified by the Compensation Committee. The term of the options is at the discretion of the Compensation Committee, but may not exceed 10 years from the grant date. The options expire on the earlier of the expiration date or the date three months following the day on which the participant ceases to be an officer or employee of or consultant to the Company, or in the event of the termination of the participant with cause, the date of such termination. Options held by non-employee Directors have an exercise period coterminous with the term of the options. The number of common shares reserved for issuance to any one person pursuant to the 2005 Plan shall not, in aggregate, exceed 5 % of the total number of outstanding common shares. The exercise price per common share under each option will be the fair market value of such shares at the time of the grant. Upon stock option exercise, the Company issues new shares of common stock. A summary of changes in common stock options issued under the 2005 Plan and under the 2015 Plan is as follows: Options Exercise Price Weighted- Average Exercise Price Options outstanding at December 31, 2024 4, 656, 677 \$ 2. 71- \$ 21. 74 \$ 10. 68 Granted 152, 600 3. 65- 11. 25 7. 07 Exercised -- Forfeitures (250, 375) 3. 27- 21. 74 12. 31 Options outstanding at December 31, 2023 4, 558, 902 \$ 2. 71- \$ 21. 74 \$ 10. 47 Granted 809, 600 3. 38- 6. 04 4. 2 12- 89 Exercised (1, 250) 3. 84 3. 84 Forfeitures (327, 734) 3. 84- 19. 09 10. 43 Options outstanding at December 31, 2023 5, 039, 518 \$ 2. 71- \$ 21. 74 \$ 9. 46 **Granted 262, 000 4. 05- 11. 81 6. 31 Exercised (50, 767) 3. 38- 5. 62 3. 92 Forfeitures (919, 166) 3. 84- 19. 92 11. 52 Options outstanding at December 31, 2024 4, 331, 585 \$ 2. 71- \$ 21. 74 \$ 8. 89** The weighted average fair value of the options issued to directors, employees and consultants during the fiscal years ended December 31, 2024, and 2023, and 2022, was \$ 2. 3, 89- 96 and \$ 4. 2, 92- 89, respectively. The total intrinsic value of options exercisable and total options outstanding at December 31, 2024, was approximately \$ 50 thousand ~~2. 2 million and \$ 70 thousand 4. 1 million.~~ The total intrinsic value of options exercisable and total options outstanding at December 31, 2022 was immaterial. The total fair value of options vested during the years ended December 31, 2024, and 2023, and 2022 was \$ 3- 1, 5- 6 million, and \$ 3. 5- 6 million, respectively. A summary of the activity in the Company's nonvested shares is as follows: Year Ended December 31, Shares Weighted Average Granted Date Fair Value Shares Weighted Average Granted Date Fair Value Nonvested at January 1, 571, 925 \$ 3. 30 429, 950 450 \$ 8. 25 1, 131, 458 8. 59 Granted during the period 262, 000 3. 96 809, 600 2. 89 152, 600 4. 92 Vested during the period ( 502, 675 ) 3. 42 ( 569, 100 ) 6. 17 ( 716, 491 ) 7. 86 Forfeited during the period ( 73, 750 ) 4. 42 ( 98, 025 ) 5. 14 ( 137, 617 ) 9. 40 Nonvested at end of period 257, 500 \$ 3. 35 571, 925 2- 3. 30 40 429, 950 8. 25 As of December 31, 2023-2024, there was

approximately \$ 1.4 million of unrecognized compensation cost, related to stock options granted under the Plan which will be amortized to stock compensation expense over the next 1.4 years. The weighted- average remaining contractual term of outstanding options as of December 31, 2023-2024 is 5.39-5 years. Total exercisable stock options as of December 31, 2023-2024 is 4.5-1 million. The weighted-average exercise price of options exercisable as of December 31, 2023-2024 is \$ 10.9. 07-15 per share and the weighted- average remaining contractual term is 4.5. 93-3 years. 8. Net Loss Per Share The following summarizes the computation of basic and diluted net income (loss) per share for the years ended December 31, 2024, and 2023, and 2022 (in thousands, except share and per share data): Year Ended December 31, Net loss \$ ( 38,531 ) \$ ( 24,557 ) \$ ( 32,900 ) Weighted- average number of common shares — basic 30,460,980 30,438,459 30,439,275 Net loss per share — basic \$ ( 1.26 ) \$ ( 0.81 ) \$ ( 1.08 ) Weighted- average number of common shares — diluted 30,460,980 30,438,459 30,439,275 Net loss per share — diluted \$ ( 1.26 ) \$ ( 0.81 ) \$ ( 1.08 ) The following potentially dilutive securities outstanding, prior to the use of the treasury stock method or if-converted method, have been excluded from the computation of diluted weighted- average common shares outstanding, because including them would have had an anti- dilutive effect due to the losses reported. Year Ended December 31, Stock options 5,039,518 4,558,902-9. Income Taxes The components of income before income taxes are as follows (in thousands): Years Ended December 31, United States \$ ( 26,313 ) \$ ( 27,144 ) \$ ( 28,161 ) Foreign ( 12,250 ) 2,831 ( 5,427 ) Total \$ ( 38,563 ) \$ ( 24,313 ) \$ ( 33,588 ) The components of the provision for income taxes are as follows for the years ended December 31, 2024, and 2023, and 2022 (in thousands): Current United States \$ ( 49 ) \$ Foreign ( 329 ) Total ( 32 ) Deferred United States-- Foreign ( 59 ) ( 816 ) Total ( 59 ) ( 816 ) Total income tax expense (benefit) \$ ( 32 ) \$ ( 688 ) The provision for income taxes differs from the amount computed by applying the Canada statutory rate to pre- tax income as follows for the years ended December 31, 2024, and 2023, and 2022 : Income tax benefit computed at federal tax rate 27.0 % Foreign operations ( 3.4 ) % ( 5.4 ) % ( 4.1 ) % Change in valuation allowance ( 22.8 ) % ( 26.1 ) % ( 14.6 ) % Tax credits generated 7.0 % 8.6 % 3.5 % Prior year adjustments 3.0 % ( 2.3 ) % 0.4 % Changes in uncertain tax positions ( 0.1 ) % ( 0.4 ) % ( 0.3 ) % Foreign exchange gain and loss ( 3.9 ) % 2.1 % ( 1.6 ) % Stock compensation ( 1.1 ) % ( 2.4 ) % ( 2.3 ) % Non- deductible compensation ( 5.8 ) % ( 6.8 ) % ( 5.8 ) % Foreign Liquidation 0.0 % 4.5 % 0.0 % Other 0.2 % 0.3 % ( Total 0.12 ) % Total ( 1.0 ) % 2.0 % The effective tax rate for the year periods ended December 31, 2024 and December 31, 2023 varied from the Canadian statutory rate primarily due to losses in jurisdictions for which a valuation allowance is recorded and a benefit may not be recognized. The effective tax rate for the year ended December 31, 2022 varied from the Canadian statutory rate primarily due to losses in jurisdictions for which a valuation allowance is recorded and a benefit may not be recognized, a shift in income between jurisdictions related to certain transfer pricing adjustments which impacted the benefit associated with available loss carrybacks, and non- deductible compensation. The tax effect of temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases that give rise to deferred tax assets and liabilities is as follows: Net operating loss carryforwards \$ 2,799 \$ 1,288 \$— Research and other credits 9,150 5,851 3,820 Stock based compensation 1,760 2,530 2,703 Capitalized research expenses 12,654 7,800 5,210 Share issuance costs — Accrued liabilities Foreign exchange—Deferred tax assets before valuation allowance 26,777 18,204 12,994 Valuation allowance ( 26,382 ) ( 17,576 ) ( 11,225 ) Deferred tax assets 1,719 Depreciation Prepaid assets Uncollectible debts—Deferred tax liability 1,777 Net deferred tax asset (liability) \$- ( 59 ) For the year ended December 31, 2023-2024, the Company has a USA federal net operating loss carryforward of \$ 6.3. 2M which will carryforward indefinitely. The Company has \$ 6.9. 6M-4 million of USA federal research and development tax credits carryforwards which are presented in the financial statements net of \$ 1. 4M-7 million of related uncertain tax positions, which will begin to expire in 2037. In addition, the Company has \$ 0-1 . 8M-8 million of Texas research and development tax credits carryforwards which are presented in the financial statements net of \$ 0. 2M-4M of related uncertain tax positions, which will begin to expire in 2042. The Company has a Canada net operating loss carryforward of \$ 1. 6 million, which will begin to expire in 2044. This amount excludes the \$ 0. 3 million expected to be carried back to the 2023 tax year. Also, after weighing all available and positive and negative evidence the Company determined a full valuation allowance for all jurisdictions was necessary. For the year ended December 31, 2023-2024, the Company has not recorded any outside basis difference deferrals given its intention to indefinitely reinvest earnings from its foreign operations. In addition, given the Company's estimated outside tax basis in its USA investment is in excess of book basis, therefore there is no unrecognized deferred tax liability. The Company is subject to income tax in multiple jurisdictions, including Canada, USA, and the state of Texas. The Company has Canadian, USA, and Texas income tax returns that are open to examination for the 2021, 2021, and 2020, 2020, and 2019 tax years, respectively. In addition, the utilization of tax carryforwards, from periods years prior to those previously mentioned may also be audited by the taxing authorities once utilized. As a result, the Company continuously monitors its current and prior filing positions in order to determine if any unrecognized tax positions need to be recorded. The analysis involves considerable judgement and is based on the best information available. A reconciliation of the beginning and ending amount of unrecognized tax benefits as of December 31, 2024 and 2023 and 2022 are as follows (in thousands): Balance as of January 1 \$ 2,864-973 \$ 2,389-864 Additions based on tax positions related to the current year Additions for tax positions of prior years Reductions for tax positions of prior years ( 4 ) — Settlements & statute of limitations ( 305 ) ( 536 ) — Balance at December 31 \$ 2-3,973-434 \$ 2,864-973 The Company recognized interest and penalties related to unrecognized tax benefits of \$ 93-98 thousand and \$ 63-93 thousand as a component of income tax expense for the years ended December 31, 2024 and 2023 and 2022, respectively. As of December 31, 2024 and December 31, 2023 and 2022, there are both \$ 1. 7 million 7M and \$ 1. 6M, respectively, of unrecognized tax benefits that if recognized would affect the annual effective tax rate. In addition, it is reasonably possible that approximately \$ 0. 4M-1 million of the unrecognized tax benefits may be recognized in the next 12 months as a result of a lapse of the statute of limitations. No other positions are expected to significantly decrease within the next 12 months. 10. Subsequent Event On January 3-31, 2024-2025, the Company entered into a Convertible Loan Agreement (the "Loan") with dated as of January 3, 2024, between XBiotech Inc. and John Simard, the Company's Founder, President, Chief Executive Officer, and Chairman. The, was terminated upon full repayment of the Loan and provides \$ 10 million in immediate funding for the construction of interest by the Company. As a new result, all conversion rights state-of-the-art research and development facility at the Company's property at 5217 Winnebago Lane in Austin, Texas. The Loan is secured by the real estate and cash holdings of the Company, with interest to accrue at a simple rate equal to eight percent per year and interest- only payments to be made at six- month intervals after the Loan is funded. At Mr. Simard's election, the balance may be converted to XBiotech stock at any time the Loan balance is outstanding at a fixed conversion price equal to the average Nasdaq Official Closing Price of the common stock (as reflected on Nasdaq.com) for the five trading days immediately preceding the signing of this Agreement, which is \$ 4. 048 per share associated with. The conversion feature is subject to a 19. 9 % cap limiting the number of shares that could be converted under the Agreement based on Mr. Simard's total stock ownership in the Company at the time of conversion. The Loan were extinguished also allows Mr. Simard to obtain immediate cash repayment of the Loan balance at his election one year after the loan is funded or upon certain other conditions set forth in the Loan. The Loan was negotiated, evaluated, and approved on behalf of the Company by a committee of independent and disinterested directors. 11. Selected Quarterly Financial Data (Unaudited)

Selected Quarterly Financial Data (Unaudited) for the years ended December 31, 2023 and 2022 is presented below (in thousands except per share data):

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
Loss from operations	\$ (7, 145)	\$ (13, 258)	\$ (8, 520)	\$ (8, 588)
Net loss	(3, 816)	(8, 742)	(7, 364)	(4, 635)
Net loss per share—basic and diluted	(0. 13)	(0. 29)	(0. 24)	(0. 15)

First Quarter Second Quarter Third Quarter Fourth Quarter Loss from operations \$ (7, 845) \$ (12, 094) \$ (6, 389) \$ (8, 162) Net loss (5, 395) (11, 644) (12, 658) (3, 203) Net loss per share—basic and diluted (0. 18) (0. 38) (0. 42) (0. 10)

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE ~~DISCLOSURE~~ ~~None~~ ~~None~~. ITEM 9A. CONTROLS AND PROCEDURES. Management's Evaluation of our Disclosure Controls and Procedures As of the end of the year covered by this Annual Report on Form 10-K, an evaluation was carried out by the Company's management, with the participation of the Chief Executive Officer and Principal Financial Officer, of the effectiveness of the Company's disclosure controls and procedures, as defined in Rule 13a-15 (e) and 15d-15 (e) under the Securities Exchange Act of 1934. Based on such evaluation, the Chief Executive Officer and Principal Financial Officer concluded that the Company's disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports the Company files or furnishes under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and regulations, and are operating in an effective manner. Management's Annual Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over **the Company's** financial reporting (as defined in Rule 13a-15 (f) under the Exchange Act). ~~We~~ **The Company's management, with the participation of the Chief Executive Officer and Principal Financial Officer,** conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on our **management's** assessment, we have concluded that our internal control over financial reporting was effective as of December 31, **2023-2024**, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. Changes in Internal Control Over Financial Reporting There was no change in our internal control over financial reporting that occurred during the **year quarter** ended December 31, **2023-2024** that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Limitations on Effectiveness of Controls and Procedures In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. ITEM 9B. OTHER INFORMATION ~~INFORMATION~~ ~~ITEM~~ ~~ITEM~~ ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS PART ~~III~~ ~~ITEM~~ ~~II~~ ~~ITEM~~ ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE ~~GOVERNANCE~~ ~~We~~ ~~We~~ incorporate by reference the information required by this ~~Item~~ ~~item~~ with respect to directors and the Audit Committee from the information under the caption "ELECTION OF DIRECTORS," including in particular the information under "Nominating and Corporate, Governance and Review Committee", "Audit Committee", "Report of the Audit Committee & the Board of Directors", "Code of Ethics" and "Delinquent Section 16 (a) Reports" and "EXECUTIVE OFFICERS" contained in our definitive Proxy Statement (the "Proxy Statement"), which we will file on or about April 28, **2024-2025** with the Securities and Exchange Commission in connection with the solicitation of proxies for our **2024-2025** Annual Meeting of Stockholders to be held on June **23-20, 2024-2025**. ITEM 11. EXECUTIVE COMPENSATION ~~COMPENSATION~~ ~~The~~ ~~The~~ information required by this item is incorporated herein by reference to the information contained under the sections captioned "EXECUTIVE COMPENSATION", "DIRECTOR COMPENSATION", "Compensation Committee Interlocks and Insider Participation," "Employment Arrangements" and "Compensation Committee Report" of the Proxy Statement. ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS ~~MATTERS~~ ~~The~~ ~~The~~ information required by this item will be set forth under the heading "Security Ownership of Certain Beneficial Owners and Management" in our Proxy Statement and is incorporated herein by reference. The information required by Item 201 (d) of Regulation S-K will be set forth in the section headed "Equity Compensation Plan Information" in our Proxy Statement and is incorporated herein by reference. ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE ~~INDEPENDENCE~~ ~~The~~ ~~The~~ information required by this item will be set forth in the section headed "Transactions with Related Persons" in our Proxy Statement and is incorporated herein by reference. ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES ~~SERVICES~~ ~~The~~ ~~The~~ information required by this item will be set forth in the section headed "Ratification of Selection of Independent Registered Public Accounting Firm" in our Proxy Statement and is incorporated herein by reference. PART ~~IV~~ ~~ITEM~~ ~~IV~~ ~~ITEM~~ 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES ~~SCHEDULES~~ ~~See~~ ~~See~~ Index to Consolidated Financial Statements under Item 8 of Part II. Financial Statement Schedules EXHIBIT INDEX Exhibit Number Description 2. 1 † Asset Purchase Agreement, dated as of December 7, 2019, between XBiotech Inc. and Janssen Biotech, Inc. (incorporated by reference to Exhibit 2. 1 to the Company's Current Report on Form 8-K filed on December 30, 2019) 3. 1 Certificate of Continuation dated September 23, 2005, issued by the Registrar of Companies, Province of British Columbia, Canada (incorporated by reference to Exhibit 3. 1 to the Company's Registration Statement on Form S-1 filed with the SEC on February 2, 2015) 3. 2 Notice of Articles, dated December 8, 2005, issued by the Registrar of Companies, Province of British Columbia, Canada (incorporated by reference to Exhibit 3. 2 to the Company's Registration Statement on Form S-1 filed with the SEC on February 2, 2015) 3. 3 Articles of XBiotech Inc. (incorporated by reference to Exhibit 3. 3 to the Company's Registration Statement on Form S-1 / A filed with the SEC on March 27, 2015) 4. 1 \* Description of Registrant's securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4. 1 to the Annual Report on Form 10-K filed with the SEC on ~~March 15, 2022~~) 10. 1 Executive Employment Agreement dated as of March 22, 2005 between XBiotech and John Simard (incorporated by reference to Exhibit 10. 1 to the Company's Registration Statement on Form S-1 filed with the SEC on February 2, 2015) 10. 2 Change in Control Agreement dated as of March 22, 2005 between XBiotech and John Simard (incorporated by reference to Exhibit 10. 2 to the Company's Registration Statement on Form S-1 filed with the SEC on February 2, 2015) 10. 3 Confidentiality and Assignment of Inventions Agreement dated as of March 22, 2005 between XBiotech and John Simard (incorporated by reference to Exhibit 10. 3 to the Company's Registration Statement on Form S-1 filed with the SEC on February 2, 2015) 10. 4 XBiotech 2005 Incentive Stock Option Plan (Restated) (incorporated by reference to Exhibit 4. 4 to the Company's Registration Statement on Form S-8 filed with the SEC on October 19, 2015) 10. 5 Form of indemnification agreement between XBiotech and each director of XBiotech (incorporated by reference to Exhibit 10. 5 to the Company's Registration Statement on Form S-1 filed with the SEC on February 2, 2015) 10. 6 Licensing Agreement dated January 16, 2015 between XBiotech USA, Inc. and Lonza Sales AG (portions of this exhibit have been omitted pursuant to a request for confidential treatment under Rule 406 of the Securities Act. incorporated by reference to Exhibit 10. 9 to the Company's Registration Statement on Form S-1 / A filed with the SEC on March 10, 2015) 10. 7 Research and Collaboration Agreement dated December 15, 2014

by and between XBiotech USA, Inc. and the South Texas Blood & Tissue Center (portions of this exhibit have been omitted pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, incorporated by reference to Exhibit 10. 10 to the Company's Registration Statement on Form S- 1 / A filed with the SEC on March 10, 2015) 10. 8 XBiotech Inc. 2015 Equity Incentive Plan (incorporated by reference to Exhibit 10. 11 to the Company's Registration Statement on Form S- 1 / A filed with the SEC on March 10, 2015) 10. 9 Form of Incentive Share Option Agreement under the 2015 Equity Incentive Plan (incorporated by reference to Exhibit 10. 9 to the Annual Report on Form 10- K filed with the SEC on March 15, 2023) 10. 10 Form of Nonqualified Share Option Agreement under the 2015 Equity Incentive Plan (incorporated by reference to Exhibit 10. 10 to the Annual Report on Form 10- K filed with the SEC on March 15, 2023) 10. 11 Second Amendment to the XBiotech Inc. 2015 Equity Incentive Plan (incorporated by reference to Annex A to the Registrant's Definitive Proxy Statement on Schedule 14A filed on April 29, 2020) 10. 12 Third Amendment to the XBiotech Inc. 2015 Equity Incentive Plan (incorporated by reference to Annex B to the Registrant's Definitive Proxy Statement on Schedule 14A filed on April 29, 2020) 10. 13 \*Board Member Agreement, dated as of February 27, 2018, by and between XBiotech Inc. and Jan- Paul Waldin. (incorporated by reference to Exhibit 10. 13 to the Annual Report on Form 10- K filed with the SEC on March 15, 2023) 10. 14 \*Board Member Agreement, dated as of March 20, 2018, by and between XBiotech Inc. and Donald H. MacAdam. (incorporated by reference to Exhibit 10. 14 to the Annual Report on Form 10- K filed with the SEC on March 15, 2023) 10. 15 Board Member Agreement, dated as of July 10, 2019, by and between XBiotech Inc. and Peter Libby (incorporated by reference to Exhibit 10. 1 to the Registrant's Current Report on Form 8- K filed on July 16, 2019) 10. 16 † IP Non- Assertion and License Agreement, dated as of December 30, 2019, between XBiotech Inc. and Janssen Biotech, Inc. (incorporated by reference to Exhibit 10. 1 to the Registrant's Current Report on Form 8- K filed on December 30, 2019) 10. 17 † Clinical Manufacturing Agreement, dated as of December 30, 2019, between XBiotech Inc. and Janssen Biotech, Inc. (incorporated by reference to Exhibit 10. 2-14 to the Registrant's Current Report on Form 8-10 - K filed on July-March 16, 2019-2020) 10. 18 † Transition Services Agreement, dated as of December 30, 2019, between XBiotech Inc. and Janssen Biotech, Inc. (incorporated by reference to Exhibit 10. 3-15 to the Registrant's Current Report on Form 8-10 - K filed on July-March 16, 2019-2020) 10. 19 † \* XBiotech Inc. Insider Trading Policy 97 \* XBiotech Inc. Clawback Policy 21. 1 \* List of subsidiaries 23. 1 \* Consent of Independent Registered Public Accounting Firm, Whitley Penn LLP 31. 1 \* Certification of the Principal Executive Officer Required Under Rules 13a- 14 (a) and 15d- 14 (a) of the Securities Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes- Oxley Act of 2002 31. 2 \* Certification of the Principal Financial Officer Required Under Rules 13a- 14 (a) and 15d- 14 (a) of the Securities Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes- Oxley Act of 2002 32. 1 \* \* Certification of Chief Executive Officer pursuant to 18 U. S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002 32. 2 \* \* Certification of Chief Financial Officer pursuant to 18 U. S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002 XBiotech Inc. Clawback Policy-101 \* The following financial statements from the XBiotech Inc. Annual Report on Form 10- K for the year ended December 31, 2023-2024, formatted in Inline Extensive Business Reporting Language (XBRL): (i) consolidated balance sheets, (ii) consolidated statements of operations, (iii) consolidated statements of comprehensive loss, (iv) consolidated statements of shareholders' equity; (v) consolidated statements of cash flows and (vi) notes to consolidated financial statements (detail tagged). 104 \* Cover Page Interactive Data File (embedded within the inline iXBRL document and contained in Exhibit 101). † Certain identified information has been excluded from this exhibit because the Company does not believe it is material and is the type that the Company customarily treats as private and confidential. Redacted information is indicated by [ \* \* \* \* \* ]. The Company hereby agrees to furnish a copy of any omitted schedule or attachment to the Securities and Exchange Commission upon request. Indicates management contract or compensatory plan \* Filed herewith \* \* Exhibits 32. 1 and 32. 2 shall not be deemed " filed " for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that Section. Such exhibits shall not be deemed incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934. ITEM 16. FORM 10 – K SUMMARY SUMMARY Not Not applicable. SIGNATURES Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March 15-18, 2024-2025. XBIOTECH INC., / s / JOHN SIMARD Name: John Simard Title: President and Chief Executive Officer (Principal Executive Officer) Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated. Signature and Title Date / s / JOHN SIMARD SIMARD March 15, 2024 John Simard, Chief Executive Officer (Principal Executive Officer) and Director Director March 18, 2025 / s / ANGELA HU HU March 15, 2024 Angela Hu, Principal Financial Officer and Principal Accounting Officer Officer March 18, 2025 / s / W. THORPE MCKENZIE March 15, 2024 W. Thorpe McKenzie, Director Director March 18, 2025 / s / JAN- PAUL WALDIN March 15, 2024 Jan- Paul Waldin Jan- Paul Waldin, Director Director March 18, 2025 / s / DONALD MACADAM March 15, 2024 Donald MacAdam, Director / s / PETER LIBBY March 15, 2024 Peter Libby Peter Libby, Director March 18, 2025 / s / TAK W. MAK Tak W. Mak, Director March 18, 2025 Exhibit 4. 1 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes the common shares, no par value, of XBiotech Inc. (the " Company, " " we, " " our, " " us, " and " our " ), which are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. The following description is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our Articles, which are incorporated by reference as an exhibit to the Annual Report on Form 10- K of which this Exhibit 4. 1 is a part. We encourage you to read our Articles and the applicable provisions of the British Columbia Business Corporations Act ( " BCBCA " ) for additional information. Authorized and Outstanding Stock Our authorized share capital as described in our Articles consists of an unlimited number of common shares and preferred shares without par value. As of December 31, 2024, 30, 487, 731 shares of the Company's common shares were outstanding. No preferred shares are outstanding. Common Shares Voting Rights. Holders of common shares are entitled to one vote in respect of each common share held at any meeting of the Company. Except as otherwise provided with respect to any particular series of preferred shares and except as otherwise required by law, the registered holders of preferred shares shall not be entitled as a class to receive notice of or to attend to vote at any meetings of the Company. Under our Articles, the holders of our common shares will be entitled to one vote for each common share held on all matters submitted to a vote of the shareholders, including the election of directors. Our Articles do not provide for cumulative voting rights. Because of this, the holders of a plurality of our common shares entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. Dividend Rights. Subject to the BCBCA, and subject to the prior rights of any holders of preferred shares, the holders of the common shares in the absolute discretion of the directors, shall be entitled to receive, and the Company shall pay thereon, out of moneys of the Company properly applicable to the payment of dividends, when declared by the directors, only such dividends as may be declared from time to time in respect of the common shares. The preferred shares are entitled to preference over the common shares with respect to the payment

of dividends. With the exception of the dividend paid in 2021, we have not paid any dividends since our incorporation. At the discretion of our board of directors, we will consider paying dividends in future as our operational circumstances may permit having regard to, among other things, our earnings, cash flow and financial requirements.

**Liquidation Rights.** Subject to the prior payment to the holders of the preferred shares described below, in the event of the liquidation, dissolution or winding-up of the Company or other distribution of the assets of the Company among its shareholders, the holders of the shares of our common shares shall be entitled to share pro rata in the distribution of the balance of the assets. The preferred shares shall be entitled to a preference over the common shares with respect to the distribution of assets of the Company, whether voluntary or involuntary, or in the event of any other distribution of assets of the Company among its shareholders for the purpose of winding up its affairs; and the preferred stock may be given such other preference not inconsistent with our Articles.

**Other Rights.** Our common shares have no preemptive rights, no conversion rights, no redemption or sinking fund provisions, and are not liable for further call or assessment.

**Listing.** Our common shares currently trade on the Nasdaq Global Select Market under the symbol “XBIT.”

**Anti-Takeover Provisions Certain Takeover Bid Requirements.** Unless such offer constitutes an exempt transaction, an offer made by a person, an “offeror”, to acquire outstanding shares of a Canadian entity that, when aggregated with the offeror’s holdings (and those of persons or companies acting jointly with the offeror), would constitute 20 % or more of the outstanding shares in a class, would be subject to the take-over provisions of Canadian securities laws. The foregoing is a limited and general summary of certain aspects of applicable securities law in the provinces and territories of Canada, all in effect as of the date hereof. In addition to those takeover bid requirements noted above, the acquisition of our shares may trigger the application of statutory regimes including among others, the Investment Canada Act (Canada) and the Competition Act (Canada). Limitations on the ability to acquire and hold our common shares may be imposed by the Competition Act (Canada). This legislation permits the Commissioner of Competition, or the Commissioner, to review any acquisition of control over or of a significant interest in us. This legislation grants the Commissioner jurisdiction, for up to one year, after any such acquisition, to challenge this type of acquisition before the Canadian Competition Tribunal on the basis that it would, or would be likely to, substantially prevent or lessen competition in any market in Canada. This legislation also requires any person who intends to acquire our common shares to file a pre-closing notification with the Canadian Competition Bureau if certain financial thresholds are exceeded and if that person (and their affiliates) would hold more than 20 % of our common shares. If a person (and its affiliates) already owns 20 % or more of our common shares, a notification must be filed when the acquisition of additional shares would bring that person’s holdings to over 50 %. Where a notification is required, the legislation prohibits completion of the acquisition until the expiration of a statutory waiting period, unless the Commissioner provides written notice that she does not intend to challenge the acquisition. The Investment Canada Act requires any person that is a “non-Canadian” (as defined in the Investment Canada Act) who acquires control of an existing Canadian business, where the acquisition of control is not a reviewable transaction, to file a notification with Industry Canada. The Investment Canada Act generally prohibits the implementation of a reviewable transaction unless, after review, the relevant minister is satisfied that the investment is likely to be of net benefit to Canada. Under the Investment Canada Act, the acquisition of control of us (either through the acquisition of our common shares or all or substantially all our assets) by a non-Canadian who is a World Trade Organization member country investor, including a US investor, would be reviewable only if our enterprise value was equal to or greater than a specified amount. Currently, the specified amount for is CAD \$ 600 million, but will eventually increase to CAD \$ 1.0 billion. We believe that we are not a cultural business for Investment Canada Act purposes and that the lower threshold for reviews of acquisitions of such businesses does not apply. The threshold amount is subject to an annual adjustment on the basis of a prescribed formula in the Investment Canada Act to reflect changes in Canadian gross domestic product. The acquisition of a majority of the voting interests of an entity is deemed to be acquisition of control of that entity. The acquisition of less than a majority but one-third or more of the voting shares of a corporation or an equivalent undivided ownership interest in the voting shares of a corporation is presumed to be an acquisition of control of that corporation unless it can be established that, on the acquisition, the corporation is not controlled in fact by the acquirer through the ownership of voting shares. The acquisition of less than one-third of the voting shares of a corporation is deemed not to be an acquisition of control of that corporation. Under the new national security regime in the Investment Canada Act, review on a discretionary basis may also be undertaken by the federal government in respect of a much broader range of investments by a non-Canadian to “acquire, in whole or in part, or to establish an entity carrying on all or any part of its operations in Canada.” The relevant test is whether such an investment by a non-Canadian could be “injurious to national security.” The Minister of Industry has broad discretion to determine whether an investor is a non-Canadian and may be subject to national security review. Review on national security grounds is at the discretion of the federal government and may occur on a pre- or post-closing basis, subject to certain limitation provisions. The government has the power in a national security review to direct that the investment not be implemented, to direct that the investor provide undertakings or the investor implement the investment on prescribed terms or conditions and to order the investor to divest itself of the investment. There is no law, governmental decree or regulation in Canada that restricts the export or import of capital or which would affect the remittance of dividends or other payments by us to non-Canadian holders of our common shares or preferred shares, other than withholding tax requirements. Our Articles do not contain any change of control limitations with respect to a merger, acquisition or corporate restructuring that involves us. This summary is not a comprehensive description of relevant or applicable considerations regarding such requirements and, accordingly, is not intended to be, and should not be interpreted as, legal advice to any prospective purchaser and no representation with respect to such requirements to any prospective purchaser is made. Prospective investors should consult their own Canadian legal advisors with respect to any questions regarding securities law in the provinces and territories of Canada.

**Actions Requiring a Special Majority.** Under the BCBCA and our Articles, certain corporate actions require the approval of a special majority of shareholders, meaning holders of shares representing not less than 66 2/3 % of those votes cast in respect of a shareholder vote addressing such matter. Subject to the BCBCA, those items requiring the approval of a special majority generally relate to fundamental changes with respect to our business, and include among others, resolutions: (i) to alter its articles or authorized share structure; (ii) to remove a director before the expiry of his or her term; and (iii) to provide for a sale, lease or exchange of all or substantially all of the Company’s property.

**Shareholder Proposals.** Under the BCBCA, shareholders may make proposals for matters to be considered at the annual general meeting of shareholders. Such proposals must be sent to us in advance of any proposed meeting by delivering a timely written notice in proper form to our registered office in accordance with the requirements of the BCBCA. The notice must include information on the business the shareholder intends to bring before the meeting.

**Advance Notice Provisions.** Our Articles contain provisions (the “Advance Notice Provisions”) which provide that advance notice to the Company must be made and the

procedures set out in the Articles must be followed for persons to be eligible for election to the our board of directors. Nomination of persons for election to the board of directors may only be made at an annual meeting of shareholders or at a special meeting of shareholders called for any purpose which includes the election of directors. Among other things, the Advance Notice Provisions fix a deadline by which holders of record of common shares must submit director nominations to us prior to any annual or special meeting of shareholders and set forth the specific information that a shareholder must include in the written notice to the Company for an effective nomination to occur. No person will be eligible for election as a director of the Company unless nominated in accordance with the provisions of the Advance Notice Provisions. In the case of an annual meeting of shareholders, notice to us must be made not less than 30 or more than 65 days prior to the date of the annual meeting; provided, however, that if the annual meeting is to be held on a date that is less than 50 days after the date on which the first public announcement of the date of the annual meeting was made, notice may be made not later than the close of business on the 10th day following such public announcement. In the case of a special meeting of shareholders (which is not also an annual meeting), notice to us must be made not later than the close of business on the 15th day following the day on which the first public announcement of the date of the special meeting was made. The board of directors may, in its sole discretion, waive any requirement of the Advance Notice Provisions.

**Limitation of Liability and Indemnification** We are subject to the provisions of Part 5, Division 5 of the BCBCA. Under Section 160 of the BCBCA, we may, subject to Section 163 of the BCBCA: (1) indemnify an individual who: (a) is or was a director or officer of the Company; (b) is or was a director or officer of another corporation (i) at a time when such corporation is or was an affiliate of the Company; or (ii) at the Company's request, or (c) at the Company's request, is or was, or holds or held a position equivalent to that of, a director or officer of a partnership, trust, joint venture or other unincorporated entity, and including, subject to certain limited exceptions, the heirs and personal or other legal representatives of that individual (collectively, an "eligible party"), against all eligible penalties to which the eligible party is or may be liable; and (2) after final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by an eligible party in respect of that proceeding, where: (a) "eligible penalty" means a judgment, penalty or fine awarded or imposed in, or an amount paid in settlement of, and eligible proceeding. (b) "eligible proceeding" means a proceeding in which an eligible party or any of the heirs and personal or other legal representatives of the eligible party, by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, the Company or an associated corporation (i) is or may be joined as a party, or (ii) is or may be liable for or in respect of a judgment, penalty or fine in, or expenses related to, the proceeding. (c) "proceeding" includes any legal proceeding or investigative action, whether current, threatened, pending or completed. Under Section 161 of the BCBCA, and subject to Section 163 of the BCBCA, we must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by an eligible party in respect of that proceeding if the eligible party (i) has not been reimbursed for those expenses, and (ii) is wholly successful, on the merits or otherwise, in the outcome of the proceeding or is substantially successful on the merits in the outcome of the proceeding. Under Section 162 of the BCBCA, and subject to Section 163 of the BCBCA, we may pay, as they are incurred in advance of the final disposition of an eligible proceeding, the expenses actually and reasonably incurred by an eligible party in respect of the proceeding, provided that the Company must not make such payments unless we first receive from the eligible party a written undertaking that, if it is ultimately determined that the payment of expenses is prohibited under Section 163 of the BCBCA, the eligible party will repay the amounts advanced. Under Section 163 of the BCBCA, we must not indemnify an eligible party against eligible penalties to which the eligible party is or may be liable or pay the expenses of an eligible party in respect of that proceeding under Sections 160, 161 or 162 of the BCBCA, as the case may be, if any of the following circumstances apply: • if the indemnity or payment is made under an earlier agreement to indemnify or pay expenses and, at the time that the agreement to indemnify or pay expenses was made, the Company was prohibited from giving the indemnity or paying the expenses by the Company's memorandum or Articles; • if the indemnity or payment is made otherwise than under an earlier agreement to indemnify or pay expenses and, at the time that the indemnity or payment is made, the Company is prohibited from giving the indemnity or paying the expenses by the Company's memorandum or Articles; • if, in relation to the subject matter of the eligible proceeding, the eligible party did not act honestly and in good faith with a view to the best interests of the Company or the associated corporation, as the case may be; or • in the case of an eligible proceeding other than a civil proceeding, if the eligible party did not have reasonable grounds for believing that the eligible party's conduct in respect of which the proceeding was brought was lawful. If an eligible proceeding is brought against an eligible party by or on behalf of the Company or by or on behalf of an associated corporation, we must not either indemnify the eligible party against eligible penalties to which the eligible party is or may be liable, or pay the expenses of the eligible party under Sections 160, 161 or 162 of the BCBCA, as the case may be, in respect of the proceeding. Under Section 164 of the BCBCA, and despite any other provision of Part 5, Division 5 of the BCBCA and whether or not payment of expenses or indemnification has been sought, authorized or declined under Part 5, Division 5 of the BCBCA, on application of the Company or an eligible party, the Supreme Court of British Columbia may do one or more of the following: • order us to indemnify an eligible party against any liability incurred by the eligible party in respect of an eligible proceeding; • order us to pay some or all of the expenses incurred by an eligible party in respect of an eligible proceeding; • order the enforcement of, or payment under, an agreement of indemnification entered into by us; • order us to pay some or all of the expenses actually and reasonably incurred by any person in obtaining an order under Section 164 of the BCBCA; or • make any other order the court considers appropriate. Section 165 of the BCBCA provides that we may purchase and maintain insurance for the benefit of an eligible party or the heirs and personal or other legal representatives of the eligible party against any liability that may be incurred by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, the Company or an associated corporation. Under our Articles, and subject to the BCBCA, we must indemnify an eligible party and his or her heirs and legal personal representatives against all eligible penalties to which such person is or may be liable, and we must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by such person in respect of that proceeding. Each eligible party is deemed to have contracted with the Company on the terms of the indemnity contained in the Articles. Under our Articles, and subject to the BCBCA, we may agree to indemnify and may indemnify any person (including an eligible party) against eligible penalties and pay expenses incurred in connection with the performance of services by that person for us. Under our Articles, and subject to the BCBCA, we may advance expenses to an eligible party. Pursuant to our Articles, the failure of an eligible party to comply with the BCBCA or the Articles does not, of itself, invalidate any indemnity to which he or she is entitled under the Articles. Under our Articles, we may purchase and maintain insurance for the benefit of an eligible person (or his or her heirs or legal personal representatives) against any liability incurred by him or her as a director, officer or person who holds or held such equivalent position. Transfer Agent and Registrar

The Transfer Agent and Registrar for shares of our common shares is American Stock Transfer & Trust Company, LLC ("AST"). The address for AST is 6201 15th Avenue, Brooklyn, New York 11219 and its telephone number is (718) 921-8206. Exhibit 10.19 XBIOTECH INC. INSIDER TRADING POLICY. I. PURPOSE XBiotech Inc. and its subsidiaries (the "Company") has adopted this Insider Trading Policy (this "Policy") to help its directors, officers and employees comply with insider trading laws and to prevent even the appearance of improper insider trading. II. SCOPE A. This Policy applies to all directors, officers and employees of the Company, as well as their respective family members and others in their households (collectively referred to as "Insiders"), and any other individuals that Angela Hu, Director of Finance (the "Compliance Officer") may designate as Insiders because they have access to material nonpublic information concerning the Company. This Policy also applies to any entities that Insiders control, including corporations, trusts or partnerships. B. Except as set forth explicitly below, this Policy applies to any and all transactions in the Company's securities, including transactions in common stock, options, preferred stock, and any other type of securities that the Company may issue, as well as to derivative securities relating to any of the Company's securities, whether or not issued by the Company. III. SPECIFIC GUIDANCE A. Generally Prohibited Activities. 1. Trading in Company Securities. a. No Insider may buy, sell or otherwise trade in Company securities while aware of material nonpublic information concerning the Company. b. No Insider may buy, sell or otherwise trade in Company securities during any special trading blackout period applicable to such Insider as designated by the Compliance Officer. 2. Tipping. Providing material nonpublic information to another person who may trade or advise others to trade on the basis of that information is known as "tipping" and is illegal. Therefore, no Insider may "tip" or provide material nonpublic information concerning the Company to any person other than a director, officer or employee of the Company, unless required as part of that Insider's regular duties for the Company and authorized by the Compliance Officer. 3. Trading in Securities of Other Companies. No Insider may, while in possession of material nonpublic information about any other public company gained in the course of employment with the Company, (a) trade in the securities of the other public company, (b) "tip" or disclose such material nonpublic information concerning that company to anyone, or (c) give trading advice of any kind to anyone concerning the other public company. B. Additional Restrictions Applicable to Section 16 Individuals and Key Employees. 1. No Section 16 Individual or Key Employee listed on Exhibit A may trade in Company securities outside of the Company trading window described in Section V. B below. 2. No Section 16 Individual may trade in Company securities unless the trade(s) have been approved by the Compliance Officer in accordance with the procedures set forth in Section V. C. 1 below. C. Exceptions. The prohibited activities above do not apply to: 1. Exercises of stock options or similar equity awards or the surrender of shares to the Company in payment of the stock option exercise price or in satisfaction of any tax withholding obligations, provided that any securities acquired pursuant to such exercise may not be sold while the Insider is in possession of material nonpublic information or subject to a special trading blackout or, with respect to Section 16 Individuals and Key Employees, while the Company's trading window is closed. 2. Acquisitions or dispositions of Company securities under the Company's 401(k) plan or any other individual account that are made pursuant to standing instructions entered into while the Insider is not in possession of material nonpublic information or otherwise subject to a special trading blackout and, with respect to Section 16 Individuals and Key Employees, while the Company's trading window is open. 3. Purchases or sales made pursuant to a Rule 10b5-1 plan that is adopted and operated in compliance with the terms of this Policy (see Section VII). IV. DETERMINING WHETHER INFORMATION IS MATERIAL AND NONPUBLIC A. Definition of "Material" Information. 1. There is no bright line test for determining whether particular information is material. Such a determination depends on the facts and circumstances unique to each situation, and cannot be made solely based on the potential financial impact of the information. 2. In general, information about the Company should be considered "material" if: • A reasonable investor would consider the information significant when deciding whether to buy or sell Company securities; or • The information, if disclosed, could be viewed by a reasonable investor as having significantly altered the total mix of information available in the marketplace about the Company. Put simply, if the information could reasonably be expected to affect the price of the Company's stock, it should be considered material. 3. It is important to remember that whether information is material will be viewed by enforcement authorities with the benefit of hindsight. In other words, if the price of the Company's stock changed as a result of the information having been made public, it will likely be considered material by enforcement authorities. 4. While it is not possible to identify every type of information that could be deemed "material," the following matters ordinarily should be considered material: • significant changes in the Company's prospects, whether positive or negative (e.g., news regarding approval of a drug candidate by the FDA, results of clinical trials or FDA regulatory actions); • major discoveries or significant changes or developments in products or product lines, research or technologies; • significant developments regarding product and research development; • significant litigation or government agency investigations; • financial performance, especially quarterly and year-end earnings or significant changes in financial performance or liquidity; • major changes in management; • development of a significant new product or process; • proposals, plans or agreements, even if preliminary in nature, involving mergers, acquisitions, divestitures, strategic alliances, joint ventures, licensing arrangements, or purchases or sales of substantial assets; • the contents of forthcoming publications that may affect the market price of Company securities; and • offerings of Company securities. B. Definition of "Nonpublic" Information. Information is "nonpublic" if it has not been disseminated to investors through a widely circulated news or wire service (such as Dow Jones, Bloomberg, PR Newswire, etc.) or through a public filing with the Securities and Exchange Commission (the "SEC"). For the purposes of this Policy, information will be not considered public until after the close of trading on the second full trading day following the Company's widespread public release of the information. C. Consult the Compliance Officer for Guidance. Any Insider who is unsure whether the information that he or she possesses is material or nonpublic should consult the Compliance Officer for guidance before trading in any Company securities. D. Post Termination Transactions This Policy continues to apply to transactions in Company securities even after the termination of services to the Company. If an individual is in possession of material non-public information when his or her service terminates, that individual may not trade in the Company Securities until that information has become public or is no longer material. V. ADDITIONAL PROVISIONS FOR SECTION 16 INDIVIDUALS AND KEY EMPLOYEES A. Definitions of Section 16 Individuals and Key Employees. 1. "Section 16 Individual" – Each member of the Company's Board of Directors ("Board"), those executive officers of the Company designated by the Board as "Section 16 officers" of the Company and their respective family members and others in their households. A list of the Section 16 Individuals is contained on Appendix A, which may be supplemented or amended from time to time by the Compliance Officer. 2. "Key Employees" – Certain individuals listed are designated as Key Employees because of their position with the Company and their possible access to material nonpublic information. A list of the Key Employees is contained on Appendix A, which may be supplemented or amended from time to time by the Compliance Officer. B. The Trading

Window. Section 16 Individuals and Key Employees may buy, sell or trade in Company securities only while the Company's trading window is open. In general, the Company's trading window opens after the close of trading on the second full trading day following the earlier of the Company's filing its Form 10-Q or Form 10-K or the Company's public announcement of quarterly earnings, and remains open through the last trading day of the third calendar month of the then-current fiscal quarter (the "Open Window"). In addition, the Company, through the Compliance Officer, may authorize longer or additional trading windows in which buying, selling or otherwise effecting transactions in the Company's securities shall be permitted pursuant to this Policy as if it were the "Open Window." Similarly, the Company, through the Compliance Officer, may impose special black-out periods during which certain persons will be prohibited from buying, selling or otherwise effecting transactions in any stock or other securities of the Company or derivative securities thereof, even through the trading windows would otherwise be open. If a special black-out period is imposed, the Company will notify affected individuals, who should not engage in any transaction involving the purchase or sale of the Company's securities during the blackout period and should not disclose to others the fact of such suspension of trading. It should be noted that even during the Open Window, any Section 16 Individual or Key Employee who is in possession of material nonpublic information regarding the Company shall not engage in any transaction in the Company's securities until the close of trading on the second full trading day following the Company's widespread public release of the material information.

C. Procedures for approving trades by Section 16 Individuals

1. Section 16 Individual Trades. No Section 16 Individual may trade in Company securities until: a. the individual has notified the Compliance Officer in writing, at least three business days prior to the proposed trade (s), of the amount and nature of the proposed trade (s), and b. the individual has certified to the Compliance Officer in writing, no more than three business days prior to the proposed trade (s), that he or she is not aware of material nonpublic information regarding the Company. The notice and certification required by this Section V. C. 1 shall be given using the form attached hereto as Exhibit B. Beginning on the day that is the fourth business day following the date of such notice, and for four additional business days thereafter, provided that the facts referred to in the certification remain correct, the Section 16 Individual may execute the trade set forth in such notice. Once the approval period identified in the notice has expired, a new notice and certification pursuant to this Section V. C. 1 must be given in order for the Section 16 Individual to trade in Company securities.

2. No Obligation to Approve Trades. The existence of the foregoing approval procedures does not in any way obligate the Compliance Officer (or, in the case of any trade by the Compliance Officer, the Chief Executive Officer or the Chief Financial Officer of the Company) to approve any trades requested by Section 16 Individuals or the Compliance Officer.

D. Prohibited Transactions.

1. Section 16 Individuals who purchase Company securities may not sell any Company securities of the same class for at least six months after the purchase.

2. Section 16 Individuals may not sell the Company's securities short.

3. Section 16 Individuals may not buy or sell puts or calls or other derivative securities on the Company's securities.

4. Section 16 Individuals may not hold Company securities in a margin account or pledge Company securities as collateral for a loan.

5. Section 16 Individuals may not enter into hedging or monetization transactions or similar arrangements with respect to Company securities.

VI. COMPLIANCE OFFICER

The Company has designated Angela Hu, Director of Finance, as the individual responsible for ensuring compliance with this Policy (the "Compliance Officer"). The duties of the Compliance Officer include the following:

A. Administering this Policy and monitoring and enforcing compliance with all Policy provisions and procedures.

B. Responding to all inquiries relating to this Policy.

C. Reviewing and either approving or denying all proposed trades by Section 16 Individuals in accordance with the procedures set forth in Section V. C. 1 above.

D. After discussing with the blackout assessment team, designating and announcing special trading blackout periods during which certain Insiders may not trade in Company securities.

E. Providing copies of this Policy and other appropriate materials to all new Insiders.

F. Administering, monitoring and enforcing compliance with all federal and state insider trading laws and regulations.

G. Assisting in the preparation and filing of all required SEC reports relating to insider trading in Company securities.

H. Revising the Policy as necessary to reflect changes in federal or state insider trading laws and regulations, or as otherwise deemed necessary or appropriate. The Compliance Officer may designate one or more individuals who may perform the Compliance Officer's duties in the event that the Compliance Officer is unable or unavailable to perform such duties.

VII. RULE 10b5-1 TRADING PLANS

A. General Information. Under Rule 10b5-1 of the Securities Exchange Act of 1934, an individual has an affirmative defense against an allegation of insider trading if he or she demonstrates that the purchase, sale or trade in question took place pursuant to a binding contract, specific instruction or written plan that was put into place before he or she became aware of material nonpublic information. Such contracts, irrevocable instructions and plans are commonly referred to as Rule 10b5-1 plans. Rule 10b5-1 plans have the obvious advantage of protecting against insider trading liability. However, they also require advance commitments regarding the amounts, prices and timing of purchases or sales of Company securities and thus limit flexibility and discretion. In addition, once a Rule 10b5-1 plan has been adopted, it is generally not permissible to amend or modify such plan. Accordingly, while some individuals may find Rule 10b5-1 plans attractive, they may not be suitable for all Insiders.

B. Specific Requirements.

1. Pre-Approval. For a Rule 10b5-1 plan to serve as an adequate defense against an allegation of insider trading, a number of legal requirements must be satisfied. Accordingly, anyone wishing to establish a Rule 10b5-1 plan must first receive approval from the Compliance Officer or his or her designee. Section 16 Individuals wanting to establish a Rule 10b5-1 plan must also satisfy the notification and certification requirements set forth in Section V. C. 1 above.

2. Material Nonpublic Information and Special Blackouts. An individual desiring to enter into a Rule 10b5-1 plan must enter into the plan at a time when he or she is not aware of any material nonpublic information about the Company or otherwise subject to a special trading blackout.

3. Trading Window. Section 16 Individuals and Key Employees may only establish a Rule 10b5-1 plan when the Company's trading window is open.

4. 30-Day Waiting Period. To avoid even the appearance of impropriety, the Company requires a waiting period of 30 days between the date the Rule 10b5-1 plan is adopted and the date of the first possible transaction under the plan.

VIII. POTENTIAL PENALTIES AND DISCIPLINARY SANCTIONS

A. Civil and Criminal Penalties. The consequences of prohibited insider trading or tipping can be severe. Persons violating insider trading or tipping rules may be required to disgorge the profit made or the loss avoided by the trading, pay the loss suffered by the person who purchased securities from or sold securities to the Insider or tippee, pay significant civil and / or criminal penalties, and serve a lengthy jail term. The Company in such circumstances may also be required to pay major civil or criminal penalties.

B. Company Discipline. Violation of this Policy or federal or state insider trading or tipping laws by any Insider may, in the case of a director, subject the director to removal proceedings and, in the case of an officer or employee, subject the officer or employee to disciplinary action by the Company up to and including termination for cause.

C. Reporting of Violations. Any Insider who violates this Policy or any federal or state law governing insider trading or tipping, or knows of any such violation by any other Insider, must report the violation immediately to the Compliance Officer. Upon determining that any such violation has occurred, the

Compliance Officer, in consultation with the Company's Disclosure Committee and, where appropriate, the Chair of the Audit Committee of the Board, will determine whether the Company should release any material nonpublic information, and, when required by applicable law, shall cause the Company to report the violation to the SEC or other appropriate governmental authority. IX. MISCELLANEOUS This Policy will be delivered to all directors, officers, employees and designated outsiders upon its adoption by the Company and to all new directors, officers, employees and designated outsiders at the start of their employment or relationship with the Company. Upon first receiving a copy of this Policy or any revised versions, each Section 16 Individual and Key Employee must sign an acknowledgment that he or she has received a copy of this Policy and agrees to comply with the terms. ACKNOWLEDGMENT AND CERTIFICATION The undersigned does hereby acknowledge receipt of the Company's Insider Trading Policy. The undersigned has read and understands such Insider Trading Policy and agrees to be governed by such Insider Trading Policy at all times in connection with the purchase and sale of securities and the confidentiality of non-public information. (Signature) Date (Print Name) EXHIBIT A John Simard, CEO and President Sushma Shivaswamy, Chief Scientific Officer Norma I. Gonzalez Qian Wu Michael C. Cavalier Triveni H. Pallapotu EXHIBIT B XBIOTECH INC. INSIDER TRADING POLICY Notice and Certification for Section 16 Individuals and Key Employees To the Compliance Officer: I hereby notify you of my intent to trade in securities of XBiotech Inc. (the "Company"). The amount and nature of the proposed trade is as follows:  Exercise stock options granted under the 2005 Incentive Stock Option Plan or the 2015 Equity Incentive Plan on;  Sell in the open market shares of Company Common Stock currently held at (example: Fidelity; another broker; in certificated form);  Purchase in the open market shares of Company Common Stock;  Gift shares of Company Common Stock to;  Adopt a Rule 10b5-1 plan to sell shares granted on;  Other (explain) I understand that I am not authorized to trade in Company Securities or adopt a Rule 10b5-1 plan in reliance upon this Notice and Certification until (insert the date that is four business days after the date hereof), and that such authorization will continue until (insert the date that is eight business days after the date hereof). I understand that if I have not completed my proposed trade or adopted my Rule 10b5-1 plan by the last date of the authorization period set forth in the immediately preceding sentence, I must submit a new Notice and Certification in order to trade in Company securities or adopt a plan. I hereby certify that I am not aware of material nonpublic information concerning the Company. Date: Signature: Print Name: To be completed by Compliance Officer Approved: Approved: Date: Exhibit 21. 1

EXHIBIT 21. 1 LIST OF SUBSIDIARIES  
SUBSIDIARIES Name Name Country XBiotech USA, Inc. United States (Delaware) Exhibit XBiotech Germany GmbH Germany Exhibit 23. 1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form S-8 (File Nos. 333-207476 and 333-249288) of our report dated March 15-18, 2024-2025 relating to the consolidated financial statements of XBiotech Inc. and subsidiaries appearing in this Annual Report on Form 10-K of XBiotech Inc. and subsidiaries for the year ended December 31, 2023-2024. Exhibit 31. 1 CERTIFICATIONS I, John Simard, certify that: 1. I have reviewed this annual report on Form 10-K of XBiotech Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (e) and 15d-15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15 (f) and 15d-15 (f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: March 15-18, 2024-2025 / s / John Simard John Simard Chief Executive Officer and President (Principal Executive Officer) Exhibit 31. 2 I, Angela Hu, certify that: Date: March 15-18, 2024-2025 / s / Angela Hu Angela Hu Director of Finance (Principal Financial Officer) Exhibit 32. 1 CERTIFICATION PURSUANT TO 18 U. S. C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES- OXLEY ACT OF 2002 In connection with the Annual Report of XBiotech Inc. on Form 10-K for the period ended December 31, 2023-2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, John Simard, Chief Executive Officer and President of the Company, certify, pursuant to 18 U. S. C. § 1350, as adopted pursuant to § 906 of the Sarbanes- Oxley Act of 2002, that to the best of my knowledge: (1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of XBiotech Inc. / s / JOHN SIMARD John Simard John Simard Chief Executive Officer and President (Principal Executive Officer) Date: March 15-18, 2024-2025 Exhibit 32. 2 In connection with the Annual Report of XBiotech Inc. on Form 10-K for the period ended December 31, 2023-2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Angela Hu, Principal Financial Officer and Principal Accounting Officer of the Company, certify, pursuant to 18 U. S. C. § 1350, as adopted pursuant to § 906 of the Sarbanes- Oxley Act of 2002, that to the best of my knowledge: (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of XBiotech Inc. / s / Angela Hu Angela Hu Director of Finance (Principal Financial Officer) Date: March 15-18, 2024-2025 EXHIBIT 2025 Exhibit 97 XBIOTECH INC. CLAWBACK POLICY Definitions For purposes of this policy Policy, the following definitions shall apply: • "Accounting Restatement" means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an

error in previously issued financial statements that is material to the previously issued financial statements or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. • “ Erroneously Awarded Compensation ” means the amount of Incentive- Based Compensation Received by an Executive Officer that exceeds the amount of Incentive- Based Compensation that otherwise would have been Received had it been determined based on the restated amounts, which amount must be computed without regard to any taxes paid by such Executive Officer. • “ Executive Officer ” means the Company’ s president, chief executive officer, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice- president of the issuer in charge of a principal business unit, division or function, any other officer who performs a policy- making function, or any other person who performs similar policy- making functions for the issuer. Executive Officers for purposes of this policy includes, at a minimum, such executive officers identified as such in the Company’ s Annual Report on Form 10- K. • “ Financial Reporting Measure ” are measures that are determined and presented in accordance with the accounting principles used in preparing the Company’ s financial statements, and any measures that are derived wholly or in part from such measures. Stock price and total shareholder return are also Financial Reporting Measures. A Financial Reporting Measure need not be presented within the financial statements or included in a filing with the U. S. Securities and Exchange Commission. • “ Incentive- Based Compensation ” means any compensation that is granted, earned or vested based wholly or in part upon the attainment of any Financial Reporting Measure. • “ Received ” with respect to Incentive- Based Compensation means the fiscal period during which the Financial Reporting Measure specified in the Incentive- Based Compensation award is attained, even if the payment or grant of the Incentive- Based Compensation occurs after the end of that period. • “ Recovery Period ” means the three (3) completed fiscal years immediately preceding the date that the Company is required to prepare an Accounting Restatement, which date is the earlier to occur of (a) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement or (b) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement. In addition to these last three (3) completed fiscal years, the Recovery Period also applies to any transition period (that results from a change in the Company’ s fiscal year) within or immediately following those three (3) completed fiscal years. However, a transition period between the last day of the Company’ s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine (9) to twelve (12) months would be deemed a completed fiscal year.

**Notwithstanding anything to the contrary in this paragraph, the Recovery Period is limited to Incentive- Based Compensation received on or after October 2, 2023.**

Policy Statement In the event the Company is required to prepare an Accounting Restatement, then the Company will recover reasonably promptly the amount of Erroneously Awarded Compensation that is Received by any current or former Executive Officer during the Recovery Period. Additionally, the Board, in its sole discretion and subject to applicable law, may seek to **pursue additional remedies permitted recover Incentive- Based Compensation or discretionary compensation Received by law against** any current or former Executive Officer **during the Recovery Period** in the event that such Executive Officer willfully engaged in conduct which **contributed materially to the Accounting Restatement and** is demonstrably or materially injurious to the Company, monetarily or otherwise, **subject to any defenses the Executive Officer may have.** ~~Exceptions-~~ The Company will not be required to enforce this **policy Policy** to the extent that the Compensation Committee (the “ Committee ”) of the Board determines that (i) recovery would be impracticable and (ii) one of the conditions of (A), (B), or (C) are satisfied: (A) The direct expense paid to a third party to assist in enforcing this **policy Policy** would exceed the amount to be recovered; provided, before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement, the Company has made a reasonable attempt to recover such amounts, documented such reasonable attempt (s) to recover, and provided that documentation to NASDAQ. (B) Recovery would violate home country law where that law was adopted prior to November 28, 2022; provided, that before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of home country law, the Company must obtain an opinion of home country counsel, acceptable to NASDAQ, that recovery would result in such a violation, and must provide such opinion to NASDAQ. (C) Recovery would likely cause an otherwise tax- qualified retirement plan, under which benefits are broadly available to the Company’ s employees, to fail to meet the requirements of the Internal Revenue Code of 1986, as amended. Prohibition on Indemnity or Reimbursement The Company is prohibited from indemnifying any current or former Executive Officer against the loss of any Erroneously Awarded Compensation or paying or reimbursing such Executive Officers for insurance premiums to recover losses incurred under this **policy Policy . This Policy supersedes any prior policies of the Company pertaining to recoupment of Incentive- Based Compensation awards.**

v3. 25 24-0. 1Document And Entity Information- USD (\$) 12 Months Ended Dec. 31, 2023-2024 Mar. 45-18, 2024-2025 Jun. 30, 2023-2024 Document-2024 Document Information [ Line Items ] Document Type 10- K Document Annual Report true Document Period End Date Dec. 31, 2023-2024 Document Transition Report false Entity File Number 001- 37437 Entity Registrant Name XBIOTECH INC. Entity Incorporation, State or Country Code A1 Entity Address, Address Line One 5217 Winnebago Ln Entity Address, City or Town Austin Entity Address, State or Province TX Entity Address, Postal Zip Code City Area Code Local Phone Number 386- 2900 Title of 12 (b) Security Common Stock, no par value Trading Symbol XBIT Security Exchange Name NASDAQ Entity Well- known Seasoned Issuer No Entity Voluntary Filers No Entity Current Reporting Status Yes Entity Interactive Data Current Yes Entity Filer Category Non- accelerated Filer Entity Small Business true Entity Emerging Growth Company false ICFR Auditor Attestation Flag false Document Financial Statement Error Correction [ Flag ] false Entity Shell Company false Entity Public Float \$ 140-121, 476-869, 818-Entity-724Entity Common Stock, Shares Outstanding (in shares) 30, 450-487, 881-731 Auditor Firm ID Auditor Name Whitley Penn LLP Auditor Location Austin, Texas Entity Central Index Key Current Fiscal Year End Date-- 12- 31 Document Fiscal Year Focus Document Fiscal Period Focus FY Amendment Flag false X- Definition Boolean flag that is true when the XBRL content amends previously- filed or accepted submission. ReferencesNo definition available. Details Name: dei\_ AmendmentFlag Namespace Prefix: dei\_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX- Definition PCAOB issued Audit Firm Identifier ReferencesReference 1: http: // www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 10- K- Number 249- Section 310Reference 2: http: // www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection fReference 3: http: // www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection fDetails Name: dei\_ AuditorFirmId Namespace Prefix: dei\_ Data Type: dei: nonemptySequenceNumberItemType Balance Type: na Period Type: durationX- ReferencesReference 1: http: // www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 10- K- Number 249- Section 310Reference 2: http: // www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection fReference 3: http: // www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection fDetails Name: dei\_ AuditorLocation Namespace Prefix: dei\_ Data Type: dei: internationalNameItemType Balance Type: na Period Type: durationX- ReferencesReference 1: http: // www. xbrl. org / 2003 / role / presentationRef- Publisher SEC- Name Form 10- K- Number 249- Section 310Reference 2: http: // www. xbrl. org / 2003 / role /

presentationRef- Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection fReference 3: [http://www.xbrl.org/2003/role/presentationRef- Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection fDetails](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection fDetails) Name: dei\_AuditorName  
Namespace Prefix: dei\_ Data Type: dei: internationalNameItemType Balance Type: na Period Type: durationX- DefinitionArea code of city  
ReferencesNo definition available. Details Name: dei\_CityAreaCode Namespace Prefix: dei\_ Data Type: xbrli: normalizedStringItemType  
Balance Type: na Period Type: durationX- DefinitionEnd date of current fiscal year in the format-- MM- DD. ReferencesNo definition  
available. Details Name: dei\_CurrentFiscalYearEndDate Namespace Prefix: dei\_ Data Type: xbrli: gMonthDayItemType Balance Type: na  
Period Type: durationX- DefinitionBoolean flag that is true only for a form used as an annual report. ReferencesReference 1: [http://www.xbrl.org/2003/role/presentationRef- Publisher SEC- Name Form 10- K- Number 249- Section 310Reference 2](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 10- K- Number 249- Section 310Reference 2): [http://www.xbrl.org/2003/role/presentationRef- Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection fReference 3](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection fReference 3): [http://www.xbrl.org/2003/role/presentationRef- Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection fDetails](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection fDetails) Name:  
dei\_DocumentAnnualReport Namespace Prefix: dei\_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX-  
DefinitionIndicates whether any of the financial statement period in the filing include a restatement due to error correction.  
ReferencesReference 1: [http://www.xbrl.org/2003/role/presentationRef- Publisher SEC- Name Regulation S- K- Number 229- Section 402- Subsection wReference 2](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Regulation S- K- Number 229- Section 402- Subsection wReference 2): [http://www.xbrl.org/2003/role/presentationRef- Publisher SEC- Name Form 10- K- Number 249- Section 310Reference 3](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 10- K- Number 249- Section 310Reference 3): [http://www.xbrl.org/2003/role/presentationRef- Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection fReference 4](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection fReference 4): [http://www.xbrl.org/2003/role/presentationRef- Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection fDetails](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection fDetails) Name: dei\_DocumentFinStmtErrorCorrectionFlag Namespace Prefix: dei\_ Data Type: xbrli:  
booleanItemType Balance Type: na Period Type: durationX- DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd  
quarter 10- Q or 10- QT statements have value Q1, Q2, and Q3 respectively, with 10- K, 10- KT or other fiscal year statements having FY.  
ReferencesNo definition available. Details Name: dei\_DocumentFiscalPeriodFocus Namespace Prefix: dei\_ Data Type: dei:  
fiscalPeriodItemType Balance Type: na Period Type: durationX- DefinitionThis is focus fiscal year of the document report in YYYY  
format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal  
year focus. Example: 2006. ReferencesNo definition available. Details Name: dei\_DocumentFiscalYearFocus Namespace Prefix: dei\_ Data  
Type: xbrli: gYearItemType Balance Type: na Period Type: durationX- DefinitionLine items represent financial concepts included in a  
table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.  
ReferencesNo definition available. Details Name: dei\_DocumentInformationLineItems Namespace Prefix: dei\_ Data Type: xbrli:  
stringItemType Balance Type: na Period Type: durationX- DefinitionFor the EDGAR submission types of Form 8- K: the date of the report,  
the date of the earliest event reported; for the EDGAR submission types of Form N- 1A: the filing date; for all other submission types: the  
end of the reporting or transition period. The format of the date is YYYY- MM- DD. ReferencesNo definition available. Details Name:  
dei\_DocumentPeriodEndDate Namespace Prefix: dei\_ Data Type: xbrli: dateTimeItemType Balance Type: na Period Type: durationX-  
DefinitionBoolean flag that is true only for a form used as a transition report. ReferencesReference 1: [http://www.xbrl.org/2003/role/presentationRef- Publisher SEC- Name Forms 10- K, 10- Q, 20- F- Number 240- Section 13- Subsection a- 1](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Forms 10- K, 10- Q, 20- F- Number 240- Section 13- Subsection a- 1) Details Name:  
dei\_DocumentTransitionReport Namespace Prefix: dei\_ Data Type: xbrli: booleanItemType Balance Type: na Period Type: durationX-  
DefinitionThe type of document being provided (such as 10- K, 10- Q, 485BPOS, etc). The document type is limited to the same value as  
the supporting SEC submission type, or the word 'Other'. ReferencesNo definition available. Details Name: dei\_DocumentType Namespace  
Prefix: dei\_ Data Type: dei: submissionTypeItemType Balance Type: na Period Type: durationX- DefinitionAddress Line 1 such as Attn,  
Building Name, Street Name ReferencesNo definition available. Details Name: dei\_EntityAddressAddressLine1 Namespace Prefix: dei\_  
Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type: durationX- DefinitionName of the City or Town ReferencesNo  
definition available. Details Name: dei\_EntityAddressCityOrTown Namespace Prefix: dei\_ Data Type: xbrli: normalizedStringItemType  
Balance Type: na Period Type: durationX- DefinitionCode for the postal or zip code ReferencesNo definition available. Details Name:  
dei\_EntityAddressPostalZipCode Namespace Prefix: dei\_ Data Type: xbrli: normalizedStringItemType Balance Type: na Period Type:  
durationX- DefinitionName of the state or province. ReferencesNo definition available. Details Name: dei\_EntityAddressStateOrProvince  
Namespace Prefix: dei\_ Data Type: dei: stateOrProvinceItemType Balance Type: na Period Type: durationX- DefinitionA unique 10- digit  
SEC- issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. ReferencesReference 1:  
[http://www.xbrl.org/2003/role/presentationRef- Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2)  
Details Name: dei\_EntityCentralIndexKey Namespace Prefix: dei\_ Data Type: dei: centralIndexKeyItemType Balance Type: na Period  
Type: durationX- DefinitionIndicate number of shares or other units outstanding of each of registrant' s classes of capital or common stock  
or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/  
interest by adding class of stock items such as Common Class A [ Member ], Common Class B [ Member ] or Partnership Interest [ Member  
] onto the Instrument [ Domain ] of the Entity Listings, Instrument. ReferencesNo definition available. Details Name:  
dei\_EntityCommonStockSharesOutstanding Namespace Prefix: dei\_ Data Type: xbrli: sharesItemType Balance Type: na Period Type:  
instantX- DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15 (d) of the  
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such  
reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant' s  
current or most recent filing containing the related disclosure. ReferencesNo definition available. Details Name:  
dei\_EntityCurrentReportingStatus Namespace Prefix: dei\_ Data Type: dei: yesNoItemType Balance Type: na Period Type: durationX-  
DefinitionIndicate if registrant meets the emerging growth company criteria. ReferencesReference 1: [http://www.xbrl.org/2003/role/presentationRef- Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2) Details Name:  
dei\_EntityEmergingGrowthCompany Namespace Prefix: dei\_ Data Type: xbrli: booleanItemType Balance Type: na Period Type:  
durationX- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1- 3 digits, the sequence  
number may contain 1- 8 digits, the optional suffix may contain 1- 4 characters, and the fields are separated with a hyphen. ReferencesNo  
definition available. Details Name: dei\_EntityFileNumber Namespace Prefix: dei\_ Data Type: dei: fileNumberItemType Balance Type: na  
Period Type: durationX- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-  
accelerated Filer. Definitions of these categories are stated in Rule 12b- 2 of the Exchange Act. This information should be based on the  
registrant' s current or most recent filing containing the related disclosure. ReferencesReference 1: [http://www.xbrl.org/2003/role/presentationRef- Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2) Details Name: dei\_EntityFilerCategory  
Namespace Prefix: dei\_ Data Type: dei: filerCategoryItemType Balance Type: na Period Type: durationX- DefinitionTwo- character  
EDGAR code representing the state or country of incorporation. ReferencesNo definition available. Details Name:  
dei\_EntityIncorporationStateCountryCode Namespace Prefix: dei\_ Data Type: dei: edgarStateCountryItemType Balance Type: na Period

Type: durationX- Definition Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S- T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ReferencesReference 1: [http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Regulation S- T- Number 232- Section 405 Details Name: dei\\_EntityInteractiveDataCurrent Namespace Prefix: dei\\_ Data Type: dei: yesNoItem Type Balance Type: na Period Type: durationX- Definition](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Regulation S- T- Number 232- Section 405 Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei: yesNoItem Type Balance Type: na Period Type: durationX- Definition)The aggregate market value of the voting and non- voting common equity held by non- affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter. ReferencesNo definition available. Details Name: dei\_EntityPublicFloat Namespace Prefix: dei\_ Data Type: xbrli: monetaryItem Type Balance Type: credit Period Type: instantX- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. ReferencesReference 1: [http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei\\_EntityRegistrantName Namespace Prefix: dei\\_ Data Type: xbrli: normalizedStringItem Type Balance Type: na Period Type: durationX- Definition](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli: normalizedStringItem Type Balance Type: na Period Type: durationX- Definition) Boolean flag that is true when the registrant is a shell company as defined in Rule 12b- 2 of the Exchange Act. ReferencesReference 1: [http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei\\_EntityShellCompany Namespace Prefix: dei\\_ Data Type: xbrli: booleanItem Type Balance Type: na Period Type: durationX- Definition](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli: booleanItem Type Balance Type: na Period Type: durationX- Definition) Indicates that the company is a Smaller Reporting Company (SRC). ReferencesReference 1: [http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei\\_EntitySmallBusiness Namespace Prefix: dei\\_ Data Type: xbrli: booleanItem Type Balance Type: na Period Type: durationX- Definition](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b- 2 Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli: booleanItem Type Balance Type: na Period Type: durationX- Definition) Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15 (d) of the Act. ReferencesNo definition available. Details Name: dei\_EntityVoluntary Filers Namespace Prefix: dei\_ Data Type: dei: yesNoItem Type Balance Type: na Period Type: durationX- DefinitionIndicate 'Yes' or 'No' if the registrant is a well- known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10- K, 10- Q, 8- K, 20- F, 6- K, 10- K / A, 10- Q / A, 20- F / A, 6- K / A, N- CSR, N- Q, N- 1A. ReferencesReference 1: [http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Securities Act- Number 230- Section 405 Details Name: dei\\_EntityWellKnownSeasonedIssuer Namespace Prefix: dei\\_ Data Type: dei: yesNoItem Type Balance Type: na Period Type: durationX- References](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Securities Act- Number 230- Section 405 Details Name: dei_EntityWellKnownSeasonedIssuer Namespace Prefix: dei_ Data Type: dei: yesNoItem Type Balance Type: na Period Type: durationX- References)Reference 1: [http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 10- K- Number 249- Section 310 Reference 2: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection f Reference 3: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection f Details Name: dei\\_IcfrAuditorAttestationFlag Namespace Prefix: dei\\_ Data Type: xbrli: booleanItem Type Balance Type: na Period Type: durationX- Definition](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 10- K- Number 249- Section 310 Reference 2: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 20- F- Number 249- Section 220- Subsection f Reference 3: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 40- F- Number 249- Section 240- Subsection f Details Name: dei_IcfrAuditorAttestationFlag Namespace Prefix: dei_ Data Type: xbrli: booleanItem Type Balance Type: na Period Type: durationX- Definition) Local phone number for entity. ReferencesNo definition available. Details Name: dei\_LocalPhoneNumber Namespace Prefix: dei\_ Data Type: xbrli: normalizedStringItem Type Balance Type: na Period Type: durationX- DefinitionTitle of a 12 (b) registered security. ReferencesReference 1: [http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b Details Name: dei\\_Security12bTitle Namespace Prefix: dei\\_ Data Type: dei: securityTitleItem Type Balance Type: na Period Type: durationX- Definition](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection b Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei: securityTitleItem Type Balance Type: na Period Type: durationX- Definition) Name of the Exchange on which a security is registered. ReferencesReference 1: [http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection d1- 1 Details Name: dei\\_SecurityExchangeName Namespace Prefix: dei\\_ Data Type: dei: edgarExchangeCodeItem Type Balance Type: na Period Type: durationX- Definition](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Exchange Act- Number 240- Section 12- Subsection d1- 1 Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei: edgarExchangeCodeItem Type Balance Type: na Period Type: durationX- Definition) Trading symbol of an instrument as listed on an exchange. ReferencesNo definition available. Details Name: dei\_TradingSymbol Namespace Prefix: dei\_ Data Type: dei: tradingSymbolItem Type Balance Type: na Period Type: durationConsolidated Balance Sheets- USD (\$) \$ in Thousands Dec. 31, 2023-2024 Dec. 31, 2022Cash-2023Cash and cash equivalents \$ 172, 677 \$ 200, 023 \$ 157, 306Interest bearing time deposit 60, 172Accrued-2023Accrued interest receivable-2023Income 1, 216Income tax receivablePrepaid expenses and other current assetsTotal-2023Total current assets 174, 567 201, 718219, 843Property-- 718Property and equipment, net 24, 89726 526 24, 260Total-2023Total assets 199, 093 226, 615246, 103Accounts-2023Accounts payable 2, 516223 2, 408Accrued-2023Accrued expenses 2, 632 3, 5011, 603Income-2023Income tax payableTotal current liabilities 15, 105 6, 400 4, 066Income-2023Income tax payable 1, 669720 1, 669Total-2023Total liabilities 16, 825 7, 7695, 701Preferred 769Preferred stock, no par value, unlimited shares authorized, no shares outstandingCommon stock, no par value, unlimited shares authorized, both 30, 439487 275 731 and 30, 436, 964 shares issued and outstanding at December 31, 2022-2024 and December 31, 2021-2023 , respectively 273, 105 271, 452267, 325Accumulated-2023Accumulated other comprehensive income (Accumulated-2023Accumulated deficit (90, 837 ) retained earnings (52, 306 )(27, 749) Total shareholders' equity 182, 268 218, 846240, 402Total-2023Total liabilities and shareholders' equity 199, 093 226, 615Related Party [ Member ] Convertible loan 10, 000Nonrelated Party [ Member ] Convertible loan \$ 250 226; 615 \$ 0X 246, 103X- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). ReferencesReference 1: <http://www.fasb.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic 852-210> - SubTopic 10- Name Accounting Standards Codification- Section 55- S99 - Paragraph 1- Subparagraph (SX 210- 10- 5- 02 (19) (a)) - Publisher FASB- URI https://asc.fasb.org/#1943274/2147481372-2147480566/210-10-S99-1Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification- Topic 210-SubTopic 10-Section S99-55- Paragraph 1- Subparagraph \(SX 210- 10- 5- 02- 19\(a\)\)](http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification- Topic 210-SubTopic 10-Section S99-55- Paragraph 1- Subparagraph (SX 210- 10- 5- 02- 19(a))) - Publisher FASB- URI https://asc.fasb.org/#1943274/2147480566-2147481372/852-210-10-10-55-10 S99-1Details Name: us- gaap\_ AccountsPayableCurrent Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItem Type Balance Type: credit Period Type: instantX- DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph \(SX 210. 5- 02 \(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (20))) - Publisher FASB- URI https://asc.fasb.org/#1943274/2147480566/210-10-S99-1Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph \(SX 210. 9- 03 \(15\) \(1\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942- SubTopic 210- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 9- 03 (15) (1))) - Publisher FASB- URI https://asc.fasb.org/#1943274/2147479853-2147478546/942-210-S99-1Details Name: us- gaap\_ AccruedIncomeTaxesCurrent Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItem Type Balance Type: credit Period Type: instantX- DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph \(SX 210. 5- 02 \(24\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (24))) - Publisher FASB- URI https://asc.fasb.org/#1943274/2147480566/210-10-S99-



Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 7-5- 03-02 ( 9 a)(12))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147479440-2147480566/944-210-10- S99- 1Reference 9: http://www.xbrl.org/2003/role/disclosureRef- Topic 280-470- SubTopic 10- Name Accounting Standards Codification- Section 50-S99- Paragraph 22-1A- Subparagraph (SX 210. 13- 01 (a) (4) (i))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482810-2147480097/280-470-10-50-S99-22Reference-1AReference 10: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef- Topic 946-470- SubTopic 210-10- Name Accounting Standards Codification- Section S99- Paragraph 1-1A- Subparagraph (SX 210. 6-13- 04-01 ( 8-a) (4) (ii))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147479617-2147480097/946-470-210-10- S99- 1Reference-1AReference 11: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef- Topic 210-470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1-1A- Subparagraph (SX 210. 5-13- 02-01 ( 18-a) (4) (iii))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480566-2147480097/210-470-10- S99- 1Reference-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13- 01 (a) (4) ( i-iii) (A))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480097/470-10- S99- 1AReference 13: http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13- 01 (a) (4) ( ii-iv))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480097/470-10- S99- 1AReference 14: http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A- Subparagraph (SX 210. 13- 01 (a) ( 5-4) (iii))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480097/470-10- S99- 1AReference 15: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A-1B- Subparagraph (SX 210. 13- 01-02 (a) (4) ( i-iii) (A))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480097/470-10- S99- 1AReference-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A-1B- Subparagraph (SX 210. 13- 01-02 (a) (4) ( iv-iii) (A))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480097/470-10- S99- 1AReference-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1A-1B- Subparagraph (SX 210. 13- 01-02 (a) ( 5-4) (iii) (B))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480097/470-10- S99- 1AReference-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210. 13- 02 (a) (4) ( i-iv))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480097/470-10- S99- 1BReference 19: http://www.xbrl.org/2003/role/disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210. 13- 02 (a) ( 5-4) (iii) (A))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480097/470-10- S99- 1BReference 20: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef- Topic 470-852- SubTopic 10- Name Accounting Standards Codification- Section S99-50- Paragraph 1B-7- Subparagraph (SX 210. 13- 02 (a) (4) (iii) (B))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480097/470-...../asc.fasb.org/#1943274/2147481404/852-10-50-7 Details Name: us- gaap\_ AssetsCurrent Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (1))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480566/210-10- S99- 1Reference 2: http://www.xbrl.org/2003/role/exampleRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 1- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147483467/210-10-45-1Reference 3: http://asc.fasb.org/us- gaap/role/ref/legacyRef- Name Accounting Standards Codification- Topic 230- SubTopic 10- Section 45- Paragraph 4- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-4 Details Name: us- gaap\_ CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. ReferencesReference 1: http://www.fasb. xbrl.org/2003-us- gaap/role/exampleRef-ref/legacyRef- Topic 852-210- SubTopic 10- Name Accounting Standards Codification- Section 55-S99- Paragraph 1- Subparagraph (SX 210. 5- 02 (29))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147481372-2147480566/210-10- S99- 1Reference 2: http://www.xbrl.org/2003/role/exampleRef- Topic 852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef- Topic 944- SubTopic 210-10- Name Accounting Standards Codification- Section S99-55- Paragraph 1- Subparagraph (SX 210. 10- 7- 03 (a) (22))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147479440-2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef- Topic 944- SubTopic 210- S99- 1Reference 3: http://asc.fasb.org/us- gaap/role/ref/legacyRef- Topic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5-7- 02-03 ( 29-a) (22))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480566-2147478777/944-210-10- S99- 1 Details Name: us- gaap\_ CommonStockValue Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionThe portion DefinitionAmount, after deferred tax asset, of deferred tax liability attributable the carrying value of long- term convertible debt as of the balance sheet date that is scheduled to taxable differences be repaid with within jurisdictional netting one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity' s common stock, at the option of the issuer or the holder. ReferencesReference 1: http://www.fasb. xbrl.org/2003-us- gaap/role/disclosureRef-ref/legacyRef- Topic 944-210- SubTopic 210-10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 7-5- 03-02 ( 19 a)(15)(b)(2))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147479440-2147480566/944-210-10- S99- 1Reference 2: http://..... 740-10-45-6 Details Name: us- gaap\_ DeferredIncomeTaxLiabilitiesNet- gaap\_ ConvertibleDebtCurrent Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionCarrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed- upon resolutions of disputes. ReferencesReference 1: http://www.fasb. xbrl.org/2009-us- gaap/role/commonPracticeRef-ref/legacyRef- Topic 942- SubTopic 210- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5-9- 02-03 ( 10 3)(a)(4))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480566-2147478546/

942-210-10-S99-1Reference 2: [http://fasb-www.xbrl.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Topic 942-SubTopic 210-Section S99-Paragraph 1-Subparagraph \(SX 210. 9-5-03-10-02 \(3\) \(a\) \(4\)\)](http://fasb-www.xbrl.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Topic 942-SubTopic 210-Section S99-Paragraph 1-Subparagraph (SX 210. 9-5-03-10-02 (3) (a) (4))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479853-2147480566> 942-210-10-S99-1 Details Name: us-gaap\_IncomeTaxesReceivable Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- Definition Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. References Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 5-02 \(3\) \(a\) \(4\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 5-02 (3) (a) (4))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566/210-10-S99-1> Details Name: us-gaap\_InterestReceivableCurrent Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- Definition Sum Definition Amount of the carrying amounts as of the balance sheet date of all liabilities liability that are recognized - Liabilities are probable future sacrifices of for present obligation requiring transfer or otherwise providing economic benefits - benefit arising from present obligations of an entity to transfer assets or provide services to other others entities in the future. References Reference 1: [http://www.fasb.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 3-1-Subparagraph \(e-SX 210. 5-02 \(22\)\)](http://www.fasb.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 3-1-Subparagraph (e-SX 210. 5-02 (22))) - SubTopic 10-Topic 210- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481203-2147480566/810-10-210-50-10-S99-3> Reference 1 Reference 2: [http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 810-210-SubTopic 10-Name Accounting Standards Codification-Section 45-S99-Paragraph 25-1-Subparagraph \(b-SX 210. 5-02 \(20\)\)](http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 810-210-SubTopic 10-Name Accounting Standards Codification-Section 45-S99-Paragraph 25-1-Subparagraph (b-SX 210. 5-02 (20))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481231-2147480566/810-10-210-45-10-S99-25> Reference 3: [http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 810-210-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 3-1-Subparagraph \(bb-SX 210. 5-02 \(24\)\)](http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 810-210-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 3-1-Subparagraph (bb-SX 210. 5-02 (24))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481203-2147480566/810-10-210-50-10-S99-3> Reference 4: [http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 235-210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 4-5-08-02 \(19 g\)\(1\)\(ii\)\)](http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 235-210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 4-5-08-02 (19 g)(1)(ii))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480678-2147480566/235-210-10-S99-1> Reference 5: [http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 323-210-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 3-1-Subparagraph \(e-SX 210. 5-02 \(25\)\)](http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 323-210-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 3-1-Subparagraph (e-SX 210. 5-02 (25))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481687-2147480566/323-10-210-50-10-S99-3> Reference 6: [http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 825-210-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 28-1-Subparagraph \(f-SX 210. 5-02 \(26\)\)](http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 825-210-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 28-1-Subparagraph (f-SX 210. 5-02 (26))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482907-2147480566/825-10-210-50-10-S99-28> Reference 7: [http://www.fasb.xbrl.org/2003-us-gaap/role/exampleRef/ref/legacyRef-Topic 946-210-SubTopic 830-10-Name Accounting Standards Codification-Section 55-S99-Paragraph 12-1-Subparagraph \(SX 210. 5-02 \(23\)\)](http://www.fasb.xbrl.org/2003-us-gaap/role/exampleRef/ref/legacyRef-Topic 946-210-SubTopic 830-10-Name Accounting Standards Codification-Section 55-S99-Paragraph 12-1-Subparagraph (SX 210. 5-02 (23))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480167-2147480566/946-210-830-10-55-S99-12> Reference 8: [http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210. 6-5-04-02 \(14-21\)\)](http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic 946-210-SubTopic 210-10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210. 6-5-04-02 (14-21))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479617-2147480566/946-210-10-10-S99-1> Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-810-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1A-3-Subparagraph \(c-SX 210. 13-01 \(a\) \(4\) \(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-810-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1A-3-Subparagraph (c-SX 210. 13-01 (a) (4) (i))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147481203/470-10-810-S99-10-50-1A> Reference 3 Reference 10: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 470-810-SubTopic 10-Name Accounting Standards Codification-Section S99-45-Paragraph 1A-25-Subparagraph \(b-SX 210. 13-01 \(a\) \(4\) \(ii\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 470-810-SubTopic 10-Name Accounting Standards Codification-Section S99-45-Paragraph 1A-25-Subparagraph (b-SX 210. 13-01 (a) (4) (ii))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147481231/470-10-810-S99-10-45-1A> Reference 25 Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-810-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1A-3-Subparagraph \(bb-SX 210. 13-01 \(a\) \(4\) \(iii\) \(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-810-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1A-3-Subparagraph (bb-SX 210. 13-01 (a) (4) (iii) (A))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147481203/470-10-810-S99-10-50-1A> Reference 3 Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-1-Subparagraph \(SX 210. 13-01 \(a\) \(4\) \(iv\) \(g\) \(1\) \(ii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-1-Subparagraph (SX 210. 13-01 (a) (4) (iv) (g) (1) (ii))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147480678/470-235-10-S99-1A> Reference 1 Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-323-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1A-3-Subparagraph \(c-SX 210. 13-01 \(a\) \(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-323-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1A-3-Subparagraph (c-SX 210. 13-01 (a) (5))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147481687/470-323-10-S99-50-1A> Reference 3 Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-825-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1B-28-Subparagraph \(f-SX 210. 13-02 \(a\) \(4\) \(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-825-SubTopic 10-Name Accounting Standards Codification-Section S99-50-Paragraph 1B-28-Subparagraph (f-SX 210. 13-02 (a) (4) (i))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147482907/470-825-10-S99-50-1B> Reference 28 Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic 470-946-SubTopic 10-830-Name Accounting Standards Codification-Section S99-55-Paragraph 12-1B-Subparagraph \(SX 210. 13-02 \(a\) \(4\) \(iii\) \(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic 470-946-SubTopic 10-830-Name Accounting Standards Codification-Section S99-55-Paragraph 12-1B-Subparagraph (SX 210. 13-02 (a) (4) (iii) (A))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147479168/470-946-10-830-S99-55-1B> Reference 12 Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-946-SubTopic 10-210-Name Accounting Standards Codification-Section S99-Paragraph 1B-1-Subparagraph \(SX 210. 13-6-02-04 \(14 a\) \(4\) \(iii\) \(B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-946-SubTopic 10-210-Name Accounting Standards Codification-Section S99-Paragraph 1B-1-Subparagraph (SX 210. 13-6-02-04 (14 a) (4) (iii) (B))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147479170/470-946-10-210-S99-1B> Reference 1 Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-1A-Subparagraph \(SX 210. 13-02-01 \(4\) \(iv-i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-1A-Subparagraph (SX 210. 13-02-01 (4) (iv-i))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1B> Reference 1A Reference 18: [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-1A-Subparagraph \(SX 210. 13-02-01 \(a\) \(5-4\) \(ii\)\)](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-1A-Subparagraph (SX 210. 13-02-01 (a) (5-4) (ii))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1B> Reference 1A Reference 19: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 852-470-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 7-1A-Subparagraph \(SX 210. 13-01 \(a\) \(4\) \(iii\) \(A\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 852-470-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 7-1A-Subparagraph (SX 210. 13-01 (a) (4) (iii) (A))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481404-2147480097/852-470-10-50-S99-7> Reference 1A Reference 20: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 852-470-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 7-1A-Subparagraph \(b-SX 210. 13-01 \(a\) \(4\) \(iv\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 852-470-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 7-1A-Subparagraph (b-SX 210. 13-01 (a) (4) (iv))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481404-2147480097/852-470-10-50-S99-7> Reference 1A Reference 21: [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic 280-470-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 30-1A-Subparagraph \(d-SX 210. 13-01 \(a\) \(5\)\)](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic 280-470-SubTopic 10-Name Accounting Standards Codification-Section 50-S99-Paragraph 30-1A-Subparagraph (d-SX 210. 13-01 (a) (5))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147480097/280-470-10-50-S99-30> Reference 1A Reference 22: <http://fasb-www>

[xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic470-SubTopic10](http://www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic470-SubTopic10) - Name Accounting Standards Codification- Topic 210- SubTopic 10- Section S99- Paragraph 1- **1B** - Subparagraph (SX 210. 5-13 - 02 -19-26 (a) (4) (i)) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-2147480097/470-10-S99-1B> Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iii)(A))) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> - Namespace Prefix: us - Publisher FASB- **gaap** - Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX - URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1> - Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions. - References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic852-740> - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 6- **7** - Subparagraph (a) - Publisher FASB- URI <https://asc.fasb.org/1943274/2147481404-2147482685-852-740> - 10- 50- 7- Reference 6: Reference 28- **2** : [http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic852-SubTopic10-NameAccountingStandardsCodification-Topic740-SubTopic10-Section50-Paragraph8-7-Subparagraph\(b\)-PublisherFASB-URI](http://www.xbrl.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic852-SubTopic10-NameAccountingStandardsCodification-Topic740-SubTopic10-Section50-Paragraph8-7-Subparagraph(b)-PublisherFASB-URI) <https://asc.fasb.org/1943274/2147481404-2147482685-852-740> - 10- 50- 7- Reference 29- **8** - Details Name: us - <http://www.xbrl.org/2003/role/exampleRef-gaap-DeferredTaxAssetsUnrealizedCurrencyLosses-Topic280-DetailsName-us-gaap-Liabilities> Namespace Prefix: us- **gaap** - Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- Definition Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. - References Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic852-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph10-PublisherFASB-URI> <https://asc.fasb.org/#1943274/2147481372/852-10-55-10> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.7-03\(a\)\(25\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.7-03(a)(25))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479440-2147478777/944-210-S99-1> Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.4-08\(g\)\(1\)\(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.4-08(g)(1)(ii))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480678/235-10-S99-1> Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic323-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph\(c\)-PublisherFASB-URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic323-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph(c)-PublisherFASB-URI) <https://asc.fasb.org/#1943274/2147481687/323-10-50-3> Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic825-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph28-Subparagraph\(f\)-PublisherFASB-URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic825-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph28-Subparagraph(f)-PublisherFASB-URI) <https://asc.fasb.org/#1943274/2147482907/825-10-50-28> Reference 6: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic942-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.9-03\(23\)\)](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic942-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.9-03(23))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479853-2147478546/942-210-S99-1> Reference 7: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(32\)\)](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(32))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566/210-10-S99-1> - Details Name: us- **gaap** - LiabilitiesAndStockholdersEquity Namespace Prefix: us- **gaap** - Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- Definition Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. - References Reference 1: [http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic810-210-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph3-1-Subparagraph\(e\)-SX210.5-02\(21\)\)](http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic810-210-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph3-1-Subparagraph(e)-SX210.5-02(21))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481203-2147480566/810-10-210-50-10-S99-3> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic810-SubTopic10-NameAccountingStandardsCodification-Section45-50-Paragraph25-3-Subparagraph\(b-c\)-PublisherFASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic810-SubTopic10-NameAccountingStandardsCodification-Section45-50-Paragraph25-3-Subparagraph(b-c)-PublisherFASB-URI) <https://asc.fasb.org/#1943274/2147481231-2147481203/810-10-45-50-25-3> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic810-SubTopic10-NameAccountingStandardsCodification-Section50-45-Paragraph3-25-Subparagraph\(bb-b\)-PublisherFASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic810-SubTopic10-NameAccountingStandardsCodification-Section50-45-Paragraph3-25-Subparagraph(bb-b)-PublisherFASB-URI) <https://asc.fasb.org/#1943274/2147481203-2147481231/810-10-50-45-3> Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic235-810-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-3-Subparagraph\(bb\)-SX210.4-08\(g\)\(1\)\(ii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic235-810-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-3-Subparagraph(bb)-SX210.4-08(g)(1)(ii))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480678-2147481203/810-10-50-3> Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic235-10-S99-1> Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic323-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph3-1-Subparagraph\(e\)-SX210.4-08\(g\)\(1\)\(ii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic323-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph3-1-Subparagraph(e)-SX210.4-08(g)(1)(ii))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481687-2147480678/235-10-S99-1> Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic825-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph28-3-Subparagraph\(fc\)-PublisherFASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic825-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph28-3-Subparagraph(fc)-PublisherFASB-URI) <https://asc.fasb.org/#1943274/2147482907-2147481687/323-10-50-3> Reference 8: [http://www.xbrl.org/2003/role/exampleRef-Topic852-SubTopic10-NameAccountingStandardsCodification-Section55-50-Paragraph10-28-Subparagraph\(f\)-PublisherFASB-URI](http://www.xbrl.org/2003/role/exampleRef-Topic852-SubTopic10-NameAccountingStandardsCodification-Section55-50-Paragraph10-28-Subparagraph(f)-PublisherFASB-URI) <https://asc.fasb.org/#1943274/2147481372-2147482907/825-10-50-28> Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic210-SubTopic10-NameAccountingStandardsCodification-Section45-55-Paragraph5-10-PublisherFASB-URI> <https://asc.fasb.org/#1943274/2147483467-2147481372/852-10-55-10> Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-45-Paragraph5-1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-45-Paragraph5-1A-Subparagraph(SX210.13-01(a)(4)(i))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097-2147483467/470-10-210-S99-10-45-1A> Reference 11: [http://www.xbrl.org/2009-2009/role/disclosureRef-commonPracticeRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iii-ii\)\(A\)\)](http://www.xbrl.org/2009-2009/role/disclosureRef-commonPracticeRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(iii-ii)(A))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1A> Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iv-iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(iv-iii)(A))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1A> Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(5-4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(5-4)(iv))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1A> Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-1A-Subparagraph\(SX210.13-02-01\(a\)\(5-4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-1A-Subparagraph(SX210.13-02-01(a)(5-4)(i))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1B> Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-1A-Subparagraph\(SX210.13-02-01\(a\)\(5-4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-1A-Subparagraph(SX210.13-02-01(a)(5-4)(i))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1B> Reference 15:

role / disclosureRef- Topic 470- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1B- Subparagraph (SX 210. 13- 02 (a) (4) ( **iii** )-(A)-) Publisher FASB- URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference16>: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iii\)\(B-A\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference17](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iii)(B-A))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference17): [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iv-iii\)\(B\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference18](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iv-iii)(B))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference18): [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(5-4\)\(iv\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference19](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(5-4)(iv))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference19): [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic852-470-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph7-1B-Subparagraph\(SX210.13-02\(a\)\(5\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481404-2147480097/852-470-10-50-S99-7Reference1BReference20](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic852-470-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph7-1B-Subparagraph(SX210.13-02(a)(5))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481404-2147480097/852-470-10-50-S99-7Reference1BReference20): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic852-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph7-Subparagraph\(b-a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481404/852-10-50-7Reference21](http://www.xbrl.org/2009/role/commonPracticeRef-Topic852-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph7-Subparagraph(b-a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481404/852-10-50-7Reference21): [http://www.fasb.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic852-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-7-Subparagraph\(b-SX210.5-02-21\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566-2147481404/852-210-10-10-50-7S99-1DetailsName:us-gaap\\_LiabilitiesCurrentNamespacePrefix:us-gaap\\_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:instantX-DefinitionAggregateparorstatedvalueofissuednonredeemablepreferredstock\(orpreferredstockredeemablesolelyattheoptionoftheissuer\).Thisitemincludes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.](http://www.fasb.org/2009-us-gaap/role/ref/legacyRef-commonPracticeRef-Topic852-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-7-Subparagraph(b-SX210.5-02-21)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566-2147481404/852-210-10-10-50-7S99-1DetailsName:us-gaap_LiabilitiesCurrentNamespacePrefix:us-gaap_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:instantX-DefinitionAggregateparorstatedvalueofissuednonredeemablepreferredstock(orpreferredstockredeemablesolelyattheoptionoftheissuer).Thisitemincludes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.) [http://www.fasb.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic852-210-SubTopic10-NameAccountingStandardsCodification-Section55-S99-Paragraph1-Subparagraph\(SX210.5-02\(28\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481372-2147480566/210-10-S99-1Reference2:](http://www.fasb.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic852-210-SubTopic10-NameAccountingStandardsCodification-Section55-S99-Paragraph1-Subparagraph(SX210.5-02(28))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481372-2147480566/210-10-S99-1Reference2:) <http://www.xbrl.org/2003/role/exampleRef-Topic852-10-55-10Reference2:> [http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-55-Paragraph1-Subparagraph\(SX210-10-7-03\(a\)\(21\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479440-2147481372/852-10-55-10Reference3:](http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-55-Paragraph1-Subparagraph(SX210-10-7-03(a)(21))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479440-2147481372/852-10-55-10Reference3:) <http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-S99-1Reference3:> [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-7-02-03\(28a\)\(21\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566-2147478777/944-210-10-S99-1DetailsName:us-gaap\\_PreferredStockValueNamespacePrefix:us-gaap\\_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:instantX-DefinitionAmountofassetrelatedtoconsiderationpaidinadvanceforcosts that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-7-02-03(28a)(21))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566-2147478777/944-210-10-S99-1DetailsName:us-gaap_PreferredStockValueNamespacePrefix:us-gaap_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:instantX-DefinitionAmountofassetrelatedtoconsiderationpaidinadvanceforcosts that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.) [http://www.xbrl.org/2009/role/commonPracticeRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(9\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1DetailsName:us-gaap\\_PrepaidExpenseAndOtherAssetsCurrentNamespacePrefix:us-gaap\\_DataType:xbrli:monetaryItemTypeBalanceType:debitPeriodType:instantX-DefinitionAmountafteraccumulateddepreciation,depletionandamortizationofphysicalassetsusedinthenormalconductofbusiness to produce goods and services and not intended for resale.](http://www.xbrl.org/2009/role/commonPracticeRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(9))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1DetailsName:us-gaap_PrepaidExpenseAndOtherAssetsCurrentNamespacePrefix:us-gaap_DataType:xbrli:monetaryItemTypeBalanceType:debitPeriodType:instantX-DefinitionAmountafteraccumulateddepreciation,depletionandamortizationofphysicalassetsusedinthenormalconductofbusiness to produce goods and services and not intended for resale.) <http://www.fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph1-SubTopic10-Topic360-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482099/360-10-50-1Reference2:> [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic852-842-SubTopic40-20-NameAccountingStandardsCodification-Section55-50-Paragraph10-7A-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481372-2147478964/842-20-50-7AReference3:](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic852-842-SubTopic40-20-NameAccountingStandardsCodification-Section55-50-Paragraph10-7A-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481372-2147478964/842-20-50-7AReference3:) <http://www.xbrl.org/2003/role/exampleRef-Topic852-10-55-10Reference3:> [http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-55-Paragraph1-Subparagraph\(SX210-10-7-03\(a\)\(8\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479440-2147481372/852-10-55-10Reference4:](http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-55-Paragraph1-Subparagraph(SX210-10-7-03(a)(8))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479440-2147481372/852-10-55-10Reference4:) [http://www.xbrl.org/2003/role/disclosureRef-Topic942-SubTopic360-NameAccountingStandardsCodification-Section50-S99-Paragraph1-Subparagraph\(SX210.7-03\(a\)\(8\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480842-2147478777/944-210-S99-1Reference5:](http://www.xbrl.org/2003/role/disclosureRef-Topic942-SubTopic360-NameAccountingStandardsCodification-Section50-S99-Paragraph1-Subparagraph(SX210.7-03(a)(8))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480842-2147478777/944-210-S99-1Reference5:) [http://www.xbrl.org/2003/role/disclosureRef-Topic942-SubTopic360-NameAccountingStandardsCodification-Section50-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147478451/942-360-50-1DetailsName:us-gaap\\_PropertyPlantAndEquipmentNetNamespacePrefix:us-gaap\\_DataType:xbrli:monetaryItemTypeBalanceType:debitPeriodType:instantX-DefinitionAmountofaccumulatedundistributedearnings\(deficit\).](http://www.xbrl.org/2003/role/disclosureRef-Topic942-SubTopic360-NameAccountingStandardsCodification-Section50-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147478451/942-360-50-1DetailsName:us-gaap_PropertyPlantAndEquipmentNetNamespacePrefix:us-gaap_DataType:xbrli:monetaryItemTypeBalanceType:debitPeriodType:instantX-DefinitionAmountofaccumulatedundistributedearnings(deficit).) [http://www.fasb.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic852-210-SubTopic10-NameAccountingStandardsCodification-Section55-S99-Paragraph1-Subparagraph\(SX210.5-02\(30\)\(a\)\(3\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481372-2147480566/210-10-S99-1Reference2:](http://www.fasb.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic852-210-SubTopic10-NameAccountingStandardsCodification-Section55-S99-Paragraph1-Subparagraph(SX210.5-02(30)(a)(3))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481372-2147480566/210-10-S99-1Reference2:) [http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic40-10-NameAccountingStandardsCodification-Section65-55-Paragraph10-2-Subparagraph\(g\)\(2\)\(i\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480016-2147481372/944-852-40-10-65-55-2Reference10Reference3:](http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic40-10-NameAccountingStandardsCodification-Section65-55-Paragraph10-2-Subparagraph(g)(2)(i)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480016-2147481372/944-852-40-10-65-55-2Reference10Reference3:) [http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic40-NameAccountingStandardsCodification-Section65-Paragraph2-Subparagraph\(h-g\)\(2\)\(i\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480016/944-40-65-2Reference4:](http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic40-NameAccountingStandardsCodification-Section65-Paragraph2-Subparagraph(h-g)(2)(i)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480016/944-40-65-2Reference4:) [http://www.xbrl.org/2003/role/disclosureRef-Topic946-944-SubTopic20-40-NameAccountingStandardsCodification-Section50-65-Paragraph11-2-Subparagraph\(h\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480990-2147480016/944-40-65-2Reference5:](http://www.xbrl.org/2003/role/disclosureRef-Topic946-944-SubTopic20-40-NameAccountingStandardsCodification-Section50-65-Paragraph11-2-Subparagraph(h)(2)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480990-2147480016/944-40-65-2Reference5:) [http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-50-Paragraph11-1-Subparagraph\(SX210.7-03\(a\)\(23\)\(a\)\(4\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479440-2147480990/946-20-50-11Reference6:](http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-50-Paragraph11-1-Subparagraph(SX210.7-03(a)(23)(a)(4))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479440-2147480990/946-20-50-11Reference6:) <http://www.xbrl.org/2003/role/disclosureRef-Topic944-210-S99-1Reference6:> [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.6-7-04-03\(17a\)\(23\)\(a\)\(4\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479617-2147478777/946-944-210-S99-1Reference7:](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.6-7-04-03(17a)(23)(a)(4))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479617-2147478777/946-944-210-S99-1Reference7:) <http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic505-946-SubTopic40-210-NameAccountingStandardsCodification-SectionS99-Paragraph1->

Subparagraph (SX 210. 3-6- 04 (17)) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480008-2147479170/505-946-10-210> - S99- 1Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(30\)\(a\)\(3\)-04\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(30)(a)(3)-04)) - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147480566-2147480008/210-505-10-S99-1DetailsName:us-gaap\\_RetainedEarningsAccumulatedDeficitNamespacePrefix:us-gaap\\_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:instantX-DefinitionAmountof.....xbrli:monetaryItemTypeBalanceType:debitPeriodType:instantX-DefinitionAmountofequity\(deficit\)attributabletoparent.Excludes](https://asc.fasb.org/#1943274/2147480566-2147480008/210-505-10-S99-1DetailsName:us-gaap_RetainedEarningsAccumulatedDeficitNamespacePrefix:us-gaap_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:instantX-DefinitionAmountof.....xbrli:monetaryItemTypeBalanceType:debitPeriodType:instantX-DefinitionAmountofequity(deficit)attributabletoparent.Excludes) temporary equity and equity attributable to noncontrolling interest. ReferencesReference 1: [http://www.fasb.xbrl.org/2003-us-gaap/role/exampleRefref/legacyRef-Topic852-210-SubTopic10-NameAccountingStandardsCodification-Section55-S99-Paragraph1-Subparagraph\(SX10-210.5-02\(29\)\)](http://www.fasb.xbrl.org/2003-us-gaap/role/exampleRefref/legacyRef-Topic852-210-SubTopic10-NameAccountingStandardsCodification-Section55-S99-Paragraph1-Subparagraph(SX10-210.5-02(29))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481372-2147480566/852-10-210-55-10-S99-1Reference-1Reference2>: [http://www.fasb.xbrl.org/2003-us-gaap/role/exampleRefref/legacyRef-Topic946-210-SubTopic830-10-NameAccountingStandardsCodification-Section55-S99-Paragraph12-1-Subparagraph\(SX210.5-02\(30\)\)](http://www.fasb.xbrl.org/2003-us-gaap/role/exampleRefref/legacyRef-Topic946-210-SubTopic830-10-NameAccountingStandardsCodification-Section55-S99-Paragraph12-1-Subparagraph(SX210.5-02(30))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480167-2147480566/946-210-830-10-55-S99-12Reference-1Reference3>: [http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRefref/legacyRef-Topic946-210-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.6-5-0402\(19-31\)\)](http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRefref/legacyRef-Topic946-210-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.6-5-0402(19-31))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479617-2147480566/946-210-10-S99-1Reference4>: [http://www.xbrl.org/2003/role/disclosureRefexampleRef-Topic946-852-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-55-Paragraph2-Subparagraph\(SX210-10-6-05\(4\)\)](http://www.xbrl.org/2003/role/disclosureRefexampleRef-Topic946-852-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-55-Paragraph2-Subparagraph(SX210-10-6-05(4))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479617-2147481372/946-852-210-10-S99-55-2Reference-10Reference5>: [http://www.xbrl.org/2009-2003/role/commonPracticeRefexampleRef-Topic946-SubTopic220-830-NameAccountingStandardsCodification-SectionS99-55-Paragraph12-3-Subparagraph\(SX210.6-09\(4\)\(b\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRefexampleRef-Topic946-SubTopic220-830-NameAccountingStandardsCodification-SectionS99-55-Paragraph12-3-Subparagraph(SX210.6-09(4)(b))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483575-2147479168/946-220-830-S99-55-3Reference-12Reference6>: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-1-Subparagraph\(SX210.6-09-04\(6-19\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-1-Subparagraph(SX210.6-09-04(6-19))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483575-2147479170/946-220-210-S99-3Reference-1Reference7>: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-2-Subparagraph\(SX210.6-09-05\(7-4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-2-Subparagraph(SX210.6-09-05(7-4))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483575-2147479170/946-210-S99-2Reference8>: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic946-SubTopic220-S99-3Reference8>: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-3-Subparagraph\(SX210.6-09\(4-08\)\(g\)\(b\)\(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-3-Subparagraph(SX210.6-09(4-08)(g)(b)(ii))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480678-2147479134/235-946-10-220-S99-1Reference3Reference9>: [http://www.xbrl.org/2009-2003/role/commonPracticeRefdisclosureRef-Topic323-946-SubTopic10-220-NameAccountingStandardsCodification-Section50-S99-Paragraph28-3-Subparagraph\(SX210.6-09\(7\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRefdisclosureRef-Topic323-946-SubTopic10-220-NameAccountingStandardsCodification-Section50-S99-Paragraph28-3-Subparagraph(SX210.6-09(7))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482907-2147479134/825-946-10-220-50-S99-28Reference3Reference11>: [http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRefref/legacyRef-Topic210-235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-4-02-08\(29-g\)\(1\)\(ii\)\)](http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRefref/legacyRef-Topic210-235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-4-02-08(29-g)(1)(ii))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-2147480678/210-235-10-S99-1Reference12>: [http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRefref/legacyRef-Topic210-323-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-3-Subparagraph\(SX210.5-02\(31\)\)](http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRefref/legacyRef-Topic210-323-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-3-Subparagraph(SX210.5-02(31))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-2147481687/323-210-10-10-50-S99-1Reference3Reference13>: [http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRefref/legacyRef-Topic210-825-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-28-Subparagraph\(SX210.5-02\(30\)\)](http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRefref/legacyRef-Topic210-825-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-28-Subparagraph(SX210.5-02(30))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480566-2147482907/825-210-10-10-50-S99-1Reference28Reference14>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic310-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph\(SABTopic4.E\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic310-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph(SABTopic4.E)) - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147480418/310-10-S99-2DetailsName:us-gaap\\_StockholdersEquityNamespacePrefix:us-gaap\\_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:instantX-DetailsName:us-gaap\\_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap\\_RelatedPartyMemberNamespacePrefix:Data Type:na Balance Type:Period Type:X-Details Name:us-gaap\\_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap\\_NonrelatedPartyMemberNamespacePrefix:Data Type:na Balance Type:Period Type:instantConsolidated-----Consolidated](https://asc.fasb.org/#1943274/2147480418/310-10-S99-2DetailsName:us-gaap_StockholdersEquityNamespacePrefix:us-gaap_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:instantX-DetailsName:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMemberNamespacePrefix:Data Type:na Balance Type:Period Type:X-Details Name:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMemberNamespacePrefix:Data Type:na Balance Type:Period Type:instantConsolidated-----Consolidated) Balance Sheets (Parentheticals)- \$ / shares \$ / shares in Thousands 12 Months EndedDec. 31, 2023-2024 Dec. 31, 2022Preferred 2023Preferred Stock, No Par Value (in dollars per share) \$ 0 \$ 0Preferred Stock, Shares Authorized, Unlimited [ Fixed List ] Unlimited UnlimitedPreferred Stock, Shares Outstanding (in shares) Common Stock, No Par Value (in dollars per share) \$ 0 \$ 0Common Stock, Shares Authorized, Unlimited [ Fixed List ] Unlimited UnlimitedCommon Stock, Shares, Outstanding (in shares) 30, 487, 731 30, 436, 964Common Stock, Shares, Issued (in shares) 30, 439-487, 275X-731 30, 436, 964X - DefinitionFace amount per share of no-par value common stock. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(29))) - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147480566/210-10-S99-1DetailsName:us-gaap\\_CommonStockNoParValueNamespacePrefix:us-gaap\\_DataType:dtr-types:perShareItemTypeBalanceType:naPeriodType:instantX-DefinitionIndicateswhetherthatthenumberofcommonsharespermittedtobeissuedbyanentity'scharterandbylawsisunlimited.TheacceptableAcceptablevalueisUnlimited](https://asc.fasb.org/#1943274/2147480566/210-10-S99-1DetailsName:us-gaap_CommonStockNoParValueNamespacePrefix:us-gaap_DataType:dtr-types:perShareItemTypeBalanceType:naPeriodType:instantX-DefinitionIndicateswhetherthatthenumberofcommonsharespermittedtobeissuedbyanentity'scharterandbylawsisunlimited.TheacceptableAcceptablevalueisUnlimited)". ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph\(SX210.5-02-\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-Topic210-SubTopic10-SectionS99-Paragraph1-Subparagraph(SX210.5-02-(29))) - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147480566/210-10-S99-1DetailsName:us-gaap\\_CommonStockSharesAuthorizedUnlimitedNamespacePrefix:us-gaap\\_DataType:us-types:authorizedUnlimitedItemTypeBalanceType:naPeriodType:durationX-DefinitionTotalnumberofcommonsharesofanentitythat](https://asc.fasb.org/#1943274/2147480566/210-10-S99-1DetailsName:us-gaap_CommonStockSharesAuthorizedUnlimitedNamespacePrefix:us-gaap_DataType:us-types:authorizedUnlimitedItemTypeBalanceType:naPeriodType:durationX-DefinitionTotalnumberofcommonsharesofanentitythat) have been sold or granted to be purchased shareholders (includes common shares that were issued, repurchased and remain Price Per Share (-in the treasury dollars per share) \$ 3. 8 Maximum [ Member ] Treasury Stock These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held Offered to Be Purchased, Price Per Share (-in the treasury dollars per share) \$ 4 X - DefinitionFace amount per share of no-par value common stock. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(29))) - Publisher FASB- URI [https://asc.fasb.org/#1943274/2147480566/210-10-S99-1DetailsName:us-gaap\\_CommonStockNoParValue](https://asc.fasb.org/#1943274/2147480566/210-10-S99-1DetailsName:us-gaap_CommonStockNoParValue)

**gaap\_CommonStockSharesIssued** Namespace Prefix: us-gaap\_ Data Type: xbrli:dtm-types: perShareItemType sharesItemType Balance Type: na Period Type: instantX - Definition The cash inflow from the additional capital contribution to the entity. References Reference 1- Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10-Topic505-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-2> Reference 2: [http://www.fasb.org/xbrl-org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic946-210-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-Paragraph2-1-Subparagraph\(SX210.6-09-05\(4\)\(b\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479617-2147480566/946-210-10-S99-2](http://www.fasb.org/xbrl-org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic946-210-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-Paragraph2-1-Subparagraph(SX210.6-09-05(4)(b))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479617-2147480566/946-210-10-S99-2) Reference 3: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-2-Subparagraph\(SX210.6-09-05\(4\)\(b\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483575-2147479170/946-220-210-S99-3](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-2-Subparagraph(SX210.6-09-05(4)(b))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483575-2147479170/946-220-210-S99-3) Reference 4: [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic946-SubTopic210-220-NameAccountingStandardsCodification-SectionS99-Paragraph1-3-Subparagraph\(SX210.6-04-09\(16-4\)\(a-b\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479617-2147479134/946-210-220-S99-1](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic946-SubTopic210-220-NameAccountingStandardsCodification-SectionS99-Paragraph1-3-Subparagraph(SX210.6-04-09(16-4)(a-b))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479617-2147479134/946-210-220-S99-1) Reference 5: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-1-Subparagraph\(SX210.6-09-04\(7-16\)\(a\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483575-2147479170/946-210-S99-1](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-1-Subparagraph(SX210.6-09-04(7-16)(a))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483575-2147479170/946-210-S99-1) Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic946-SubTopic220-S99-3> Reference 7: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-3-Subparagraph\(SX210.5-6-02-09\(29-7\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566-2147479134/210-946-10-220-S99-1-3](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-3-Subparagraph(SX210.5-6-02-09(29-7))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566-2147479134/210-946-10-220-S99-1-3) Details Name: us-gaap\_CommonStockSharesOutstanding Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX- Definition Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(28\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(28))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566/210-10-S99-1) Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-13](http://www.xbrl.org/2009/role/commonPracticeRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-13) Details Name: us-gaap\_PREFERREDSTOCKNOPARVALUE Namespace Prefix: us-gaap\_ Data Type: dtm-types: perShareItemType Balance Type: na Period Type: instantX- Definition Indicates whether that the number of nonredeemable preferred shares, or preferred stock redeemable solely at the option of the issuer, permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable "Acceptable" value is "Unlimited". References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02-\(28\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02-(28))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566/210-10-S99-1) Details Name: us-gaap\_PREFERREDSTOCKSHARESAUTHORIZEDUNLIMITED Namespace Prefix: us-gaap\_ Data Type: us-types: authorizedUnlimitedItemType Balance Type: na Period Type: durationX- Definition Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. References Reference 1: [http://www.fasb.org/xbrl-org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic946-210-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-Paragraph2-1-Subparagraph\(SX210.6-5-05-02\(4-28\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479617-2147480566/946-210-10-S99-2](http://www.fasb.org/xbrl-org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic946-210-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-Paragraph2-1-Subparagraph(SX210.6-5-05-02(4-28))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479617-2147480566/946-210-10-S99-2) Reference 2: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-2-Subparagraph\(SX210.6-09-05\(4\)\(b\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483575-2147479170/946-220-210-S99-3](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-2-Subparagraph(SX210.6-09-05(4)(b))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483575-2147479170/946-220-210-S99-3) Reference 3: [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic946-SubTopic210-220-NameAccountingStandardsCodification-SectionS99-Paragraph1-3-Subparagraph\(SX210.6-04-09\(16-4\)\(a-b\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479617-2147479134/946-210-220-S99-1](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic946-SubTopic210-220-NameAccountingStandardsCodification-SectionS99-Paragraph1-3-Subparagraph(SX210.6-04-09(16-4)(a-b))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479617-2147479134/946-210-220-S99-1) Reference 4: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-1-Subparagraph\(SX210.6-09-04\(7-16\)\(a\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483575-2147479170/946-210-S99-1](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-1-Subparagraph(SX210.6-09-04(7-16)(a))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483575-2147479170/946-210-S99-1) Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic946-SubTopic220-S99-3> Reference 6: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-3-Subparagraph\(SX210.5-6-02-09\(28-7\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566-2147479134/210-946-10-220-S99-1-3](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-3-Subparagraph(SX210.5-6-02-09(28-7))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566-2147479134/210-946-10-220-S99-1-3) Details Name: us-gaap\_PREFERREDSTOCKSHARESAUTHORIZEDUNLIMITED Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant Consolidated Statements of Operations- USD (\$) \$ in Thousands 12 Months Ended Dec. 31, 2023 2024 Dec. 31, 2022 Revenue \$ 0 \$ 4, 010 Cost of goods sold Gross margin 3, 359 Research and development \$ 37, 757 \$ 32, 848 31, 544 General 848 General and administrative 4, 662 6 714 4, 305 Total 662 Total operating expenses 37, 510 Loss 510 37, 849 Loss from operations ( 42, 471 ) ( 37, 510 ) ( 34, 490 ) Interest income 40 9, 421 3 812 10, 823 Other 421 Interest expense ( 121 807 ) Foreign Other expense Foreign exchange ( loss ) gain ( 5, 529 ) 1, 893 ( 2, 800 ) Total 893 Total other income ( loss ) 3, 908 13, 197 Income before income taxes ( 38, 563 ) ( 24, 313 ) ( 33, 588 ) Income tax ( expense ) benefit ( 244 ) Net loss \$ ( 38, 531 ) \$ ( 24, 557 ) \$ ( 32, 900 ) Net loss per share — basic (in dollars per share) \$ ( 1.26 ) \$ ( 0.81 ) \$ ( 1.08 ) Shares used to compute basic net loss per share (in shares) 30, 460, 980 30, 438, 459 459 X 30, 439, 275 Net loss per..... Type: debit Period Type: durationX- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-6-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443/250-10-50-3> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph1-5-2-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482635/260-10-55-1> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic815-805-SubTopic40-60-NameAccountingStandardsCodification-Section65-Paragraph1-Subparagraph\(ge\)\(4\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480175-2147476176/815-805-40-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic815-805-SubTopic40-60-NameAccountingStandardsCodification-Section65-Paragraph1-Subparagraph(ge)(4)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480175-2147476176/815-805-40-60-65-1) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic815-740-SubTopic40-323-NameAccountingStandardsCodification-Section65-Paragraph1-2-Subparagraph\(fg\)\(3\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480175-2147478666/815-40-740-323-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic815-740-SubTopic40-323-NameAccountingStandardsCodification-Section65-Paragraph1-2-Subparagraph(fg)(3)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480175-2147478666/815-40-740-323-65-1) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-1-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-1-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443/250-10-50-1) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-260-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph15-1-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic250-260-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph15-1-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443/250-10-50-1)

/ asc. fasb. org / #1943274 / 2147483443-2147482635-250-260-10-50-55-1Reference-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-815-SubTopic 10-40-Name Accounting Standards Codification-Section 50-65-Paragraph 7-1-Subparagraph (a-e) (4)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483443-2147480175/250-815-10-40-50-65-7Reference-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-815-SubTopic 10-40-Name Accounting Standards Codification-Section 45-65-Paragraph 2-1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482689-2147480175/260-815-10-40-45-65-2Reference-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-250-SubTopic 10-Name Accounting Standards Codification-Section 45-50-Paragraph 60B-11-Subparagraph (d-a)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482689-2147483443/260-250-10-45-50-60BReference-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483443/250-10-50-4Reference-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482662-2147483443/260-250-10-50-1Reference-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-2-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482689/260-10-45-10Reference-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-260-SubTopic 10-Name Accounting Standards Codification-Section S99-45-Paragraph 2-60B-Subparagraph (d SX 210.5-03(25))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483621-2147482689/220-260-10-S99-45-2Reference-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-250-SubTopic 220-10-Name Accounting Standards Codification-Section S99-50-Paragraph 4-1-Subparagraph (SX 210.9-04(27))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483586-2147483443/942-250-220-10-S99-50-1Reference-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-260-SubTopic 220-10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-Subparagraph (a SX 210.7-04(23))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483586-2147482662/944-260-220-10-S99-50-1Reference 16: http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-45-Paragraph 52-10-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482635-2147482689/260-10-55-45-52Reference-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-220-SubTopic 10-Name Accounting Standards Codification-Section S99-Accounting Standards Codification-Section 50-Paragraph 1-2-Subparagraph (SX 210.5-03(25))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482900-2147483621/835-220-30-10-50-S99-1Reference-2Reference 2-18: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-942-SubTopic 20-220-Name Accounting Standards Codification-Section 50-S99-Paragraph 1B-1-Subparagraph (a SX 210.9-04(27))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481139-2147478524/470-942-20-220-50-S99-1BReference-1Reference 3-19: http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic 470-944-SubTopic 20-220-Name Accounting Standards Codification-Section 55-S99-Paragraph 69B-1-Subparagraph (SX 210.7-04(23))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481568-2147477250/470-944-220-S99-1Reference 20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic 470-260-SubTopic 20-10-Name Accounting Standards Codification-Section 55-Paragraph 69C-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481568/470-45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482689/260-10-45-7-Details Name: us-gaap\_EarningsPerShareBasic Namespace Prefix: us-gaap\_Data..... Details Name: us-gaap\_EarningsPerShareDiluted Namespace Prefix: us-gaap\_Data Type: dtr-types: perShareItemType Balance Type: na Period Type: durationX-DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(7))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483575-2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 35-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 17-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481839/830-10-45-17-Details Name: us-gaap\_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. ReferencesReference 1: http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic 946-220-SubTopic 220-10-Name Accounting Standards Codification-Section S99-Paragraph 1-2-Subparagraph (SX 210.6-5-07-03(42)(a))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483575-2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-1-Subparagraph (SX 210.5-6-03-407(2)(a))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483621-2147479134/946-220-10-S99-2-1-Details Name: us-gaap\_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionAggregate revenue..... xbrli:monetaryItemType Balance Type: credit Period Type: durationX-DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. ReferencesReference 1: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 944-280-SubTopic 220-10-Name Accounting Standards Codification-Section S99-50-Paragraph 22-1-Subparagraph (SX 210.7-04(11))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147483586-2147482810/944-280-220-10-S99-50-1Reference-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-55-Paragraph 22-48-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482810-2147482785/280-10-50-55-22Reference-48Reference 3: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-32-Subparagraph (b-f)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482810/280-10-50-30Reference-32Reference 4: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-30-Subparagraph (fb)-Publisher FASB-URI https://asc.fasb.org/#

1943274 / 2147482810 / 280-10-50-32Reference 30Reference 5: <http://www.xbrl.org/2003-2009/role/exampleRef>  
**commonPracticeRef** - Topic 280-270 - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 31-1-  
**Subparagraph (i)** - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147482964/280-270-10-50-31Reference-1Reference> 6: <http://www.xbrl.org/2003-2009/role/disclosureRef>**commonPracticeRef** - Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 32- Subparagraph (e-ee) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810/280-10-50-32Reference> 7: <http://www.fasb.org/xbrl.org/2003-us-gaap/role/disclosureRef>**ref/otherTransitionRef** - Topic 942-280 - SubTopic 235-10 - Name Accounting Standards Codification- Section S99-50 - Paragraph 1-32 - Subparagraph (c SX 210.9-05 (b) (2))- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479557-2147482810/942-280-235-10-S99-50-1Reference>  
**32Reference** 8: <http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef>**disclosureRef** - Topic 944- SubTopic 220 - Name Accounting Standards Codification- Section 25-S99 - Paragraph 1- SubTopic-Subparagraph (SX 20-210.7 - Topic 940-04 (11)) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481913-2147477250/940-944-20-220-25-S99-1Reference> 9: <http://fasb-www.xbrl.org/2003-us-gaap/role/exampleRef>**ref/legacyRef** - Topic 220-280 - SubTopic 10- Name Accounting Standards Codification- Section S99-50 - Paragraph 31-2 - Subparagraph (SX 210.5-03 (10))- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483621-2147482810/220-280-10-S99-50-2Reference>  
**31Reference** 10: <http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef>**ref/legacyRef** - Topic 942- SubTopic 220-235 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210.9-04-05 (15-b) (2))- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483589-2147477314> <https://asc.fasb.org/#1943274/2147481568/470-20-235-55-S99-69CReference>**1Reference** 5-11: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 220- SubTopic 10- Name Accounting Standards Codification- Topic 835- SubTopic 30- Section 45-S99 - Paragraph 2 - Subparagraph (SX 210.5-03 (10))- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482925-2147483621/835-220-30-10-45-S99-2Reference> 6-12: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 942- SubTopic 220- Name Accounting Standards Codification- Topic 835- SubTopic 30- Section 55-S99 - Paragraph 8-1- Subparagraph (SX 210.9-04 (15)) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482949-2147478524/835-30-55-8DetailsName> / 942-220- S99- 1 Details Name: us-gaap\_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 250-270 - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 8-1- Subparagraph (i) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483443-2147482964/250-270-10-50-8Reference>  
**1Reference** 2: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 250-280 - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 9-32- Subparagraph (ee) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483443-2147482810/250-280-10-50-9Reference>  
**32Reference** 3: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 10-12 - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482685/740-10-50-10Reference>  
**12Reference** 4: <http://www.xbrl.org/2003/role/disclosureRef>**exampleRef** - Topic 740- SubTopic 10- Name Accounting Standards Codification- Section S99-55 - Paragraph 231-1-Subparagraph (SAB TOPIC 6.1.7) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479360-2147482663/740-10-S99-55-1Reference>  
**231Reference** 5: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 280-250 - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 9-22- Subparagraph (h) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147483443/280-250-10-50-22Reference>  
**9Reference** 6: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 944-740 - SubTopic 220-10 - Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210-SAB Topic 6.1.7 -04 (9))- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483586-2147479360/944-740-220-10-S99-1Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 250- SubTopic 10 - Name Accounting Standards Codification- Section 45-50 - Paragraph 2-8 - Publisher FASB Subparagraph (a)- SubTopic URI <https://asc.fasb.org/1943274/2147483443/20-250-10-50-8Reference> 8: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 740- SubTopic 10 Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482659/740-20-45-2Reference>  
**8Reference** 8: <http://www.xbrl.org/2003/role/disclosureRef> - Name Accounting Standards Codification- Section 50- Paragraph 1-10 - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482900-2147482685/835-740-30-10-50-1Reference>  
**10Reference** 2-9: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470-280 - SubTopic 20-10 - Name Accounting Standards Codification- Section 50- Paragraph 1B-22 - Subparagraph (a-h) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481139-2147482810/470-280-20-10-50-1BReference>  
**22Reference** 3-10: <http://www.xbrl.org/2003/role/exampleRef>**disclosureRef** - Topic 470-944 - SubTopic 20-220 - Name Accounting Standards Codification - Section S99- Paragraph 1- Subparagraph (SX 210.50-7 - Paragraph 1-04 (9)) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482900-2147477250/835-944-30-220-50-S99-1Reference> 2-11: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470- SubTopic 20- Name Accounting Standards Codification- Section 50-45 - Paragraph 1B-2 - Subparagraph (a) - SubTopic 20- Topic 740 - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481139-2147482659/470-740-20-50-45-1BReference>  
**2Reference** 3-12: <http://www.xbrl.org/2003/role/disclosureRef>**exampleRef** - Topic 470- SubTopic 20- Name Accounting Standards Codification- Section 55-S99 - Paragraph 69B-1 - Subparagraph (SX 210.4-08 (h)) - SubTopic 10- Topic 235- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480678/235-10-S99-1DetailsName> : us-gaap\_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit DefinitionFace Period Type: durationX- DefinitionAmount of interest income (par expense) classified as nonoperating amount of debt instrument at time of issuance. ReferencesReference 1: <http://www.xbrl.org/2003-2009/role/disclosureRef>**commonPracticeRef** - Topic 835-220 - SubTopic 30-10 - Name Accounting Standards Codification- Section 50-S99 - Paragraph 1-2- Subparagraph (SX 210.5-03) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482900-2147483621/835-220-30-10-50-S99-1Reference>  
**2Reference** 2: <http://www.xbrl.org/2003-2009/role/disclosureRef>**commonPracticeRef** - Topic 470-280 - SubTopic 20-10 - Name Accounting Standards Codification- Section 50- Paragraph 22-1B- Subparagraph (a)- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481139-2147482810/470-20-280-10-50-1BReference>  
**22Reference** 3: <http://www.xbrl.org/2003/role/exampleRef> - Topic 470-280 - SubTopic 20-10 - Name Accounting Standards Codification- Section 55- Paragraph 69B-48 - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481568-2147482785/470-20-280-10-55-69BReference> 4-48 Details Name: <http://www.us-gaap.org/2003/role/exampleRef> - Topic 470- SubTopic 20- Name Accounting Standards Codification- Period Type: durationX- DefinitionAmount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 220- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 2- Subparagraph (SX 210.5-03 -(8)) - Publisher FASB-

URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference2>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph\(SX210.5-03-\(7\)\(a\)-\(b\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph(SX210.5-03-(7)(a)-(b)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference3>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph\(SX210.5-03\(7\)\(b\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483621/220-10-S99-2DetailsName:us-gaap\\_InvestmentIncomeNetNamespacePrefix:us-gaap\\_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:durationX-DefinitionTheportionofprofitorlossfortheperiod,netofincometaxes,whichisattributabletotheparent](http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph(SX210.5-03(7)(b))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483621/220-10-S99-2DetailsName:us-gaap_InvestmentIncomeNetNamespacePrefix:us-gaap_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:durationX-DefinitionTheportionofprofitorlossfortheperiod,netofincometaxes,whichisattributabletotheparent)

ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic235-250-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph61-Subparagraph\(SX210.4-08\(g\)\(1\)\(ii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic235-250-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph61-Subparagraph(SX210.4-08(g)(1)(ii)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147480678-2147483443/235-250-10-S99-50-1Reference6Reference2>: [http://www.xbrl.org/2003/role/disclosureRef-Topic323-250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph93-Subparagraph\(e\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481687-2147483443/323-250-10-50-3Reference9Reference3](http://www.xbrl.org/2003/role/disclosureRef-Topic323-250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph93-Subparagraph(e)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481687-2147483443/323-250-10-50-3Reference9Reference3): [http://www.xbrl.org/2003/role/disclosureRef-Topic825-805-SubTopic10-NameAccountingStandardsCodification-Section50-65-Paragraph28-1-Subparagraph\(fg\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482907-2147476176/825-805-10-60-50-65-28Reference1Reference4](http://www.xbrl.org/2003/role/disclosureRef-Topic825-805-SubTopic10-NameAccountingStandardsCodification-Section50-65-Paragraph28-1-Subparagraph(fg)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482907-2147476176/825-805-10-60-50-65-28Reference1Reference4): [http://www.xbrl.org/2003/role/disclosureRef-Topic220-740-SubTopic10-323-NameAccountingStandardsCodification-Section50-65-Paragraph6-2-Subparagraph\(g\)\(3\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482765-2147478666/740-323-65-2Reference5](http://www.xbrl.org/2003/role/disclosureRef-Topic220-740-SubTopic10-323-NameAccountingStandardsCodification-Section50-65-Paragraph6-2-Subparagraph(g)(3)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482765-2147478666/740-323-65-2Reference5): <http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-10-50-6Reference5>: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph3-2-Subparagraph\(SX210.5-03\(20\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph3-2-Subparagraph(SX210.5-03(20)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147483443-2147483621/250-220-10-50-S99-3Reference2Reference6>: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-235-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph1-Subparagraph\(b\)SX210.4-08\(2-g\)\(1\)\(ii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic250-235-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph1-Subparagraph(b)SX210.4-08(2-g)(1)(ii)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147483443-2147480678/250-235-10-50-S99-1Reference7>: [http://www.xbrl.org/2003/role/disclosureRef-Topic815-323-SubTopic10-NameAccountingStandardsCodification-Section65-50-Paragraph1-3-Subparagraph\(fc\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480175-2147481687/815-323-40-10-65-50-1Reference1Reference8](http://www.xbrl.org/2003/role/disclosureRef-Topic815-323-SubTopic10-NameAccountingStandardsCodification-Section65-50-Paragraph1-3-Subparagraph(fc)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480175-2147481687/815-323-40-10-65-50-1Reference1Reference8): [http://www.xbrl.org/2003/role/disclosureRef-Topic250-825-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph8-28-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443-2147482907/250-825-10-50-8Reference28Reference9](http://www.xbrl.org/2003/role/disclosureRef-Topic250-825-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph8-28-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443-2147482907/250-825-10-50-8Reference28Reference9): <http://www.xbrl.org/2003/role/disclosureRef-Topic250-220-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph9-6-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443-2147482765/250-220-10-50-9Reference6Reference10>: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-1-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-1Reference3Reference11](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-1-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-1Reference3Reference11): [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-1-Subparagraph\(b\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-1Reference1Reference12](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-1-Subparagraph(b)(2)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-1Reference1Reference12): [http://www.xbrl.org/2003/role/disclosureRef-Topic250-815-SubTopic10-40-NameAccountingStandardsCodification-Section50-65-Paragraph4-1-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443-2147480175/815-40-65-1Reference13](http://www.xbrl.org/2003/role/disclosureRef-Topic250-815-SubTopic10-40-NameAccountingStandardsCodification-Section50-65-Paragraph4-1-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443-2147480175/815-40-65-1Reference13): <http://www.xbrl.org/2003/role/exampleRef-Topic946-SubTopic830-10-NameAccountingStandardsCodification-Section55-50-Paragraph10-8-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480167-2147483443/946-250-830-10-55-50-10Reference8Reference14>: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-250-SubTopic220-10-NameAccountingStandardsCodification-Section45-50-Paragraph7-11-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483581-2147483443/946-250-220-10-45-50-7Reference11Reference15](http://www.xbrl.org/2003/role/disclosureRef-Topic946-250-SubTopic220-10-NameAccountingStandardsCodification-Section45-50-Paragraph7-11-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483581-2147483443/946-250-220-10-45-50-7Reference11Reference15): [http://www.xbrl.org/2003/role/disclosureRef-Topic944-250-SubTopic220-10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-11-Subparagraph\(b\)SX210.7-04\(18\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483586-2147483443/944-250-220-10-S99-50-1Reference11Reference16](http://www.xbrl.org/2003/role/disclosureRef-Topic944-250-SubTopic220-10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-11-Subparagraph(b)SX210.7-04(18))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483586-2147483443/944-250-220-10-S99-50-1Reference11Reference16): <http://www.xbrl.org/2003/role/disclosureRef-Topic280-250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22-4-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810-2147483443/280-250-10-50-22Reference4Reference17>: [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic946-SubTopic220-830-NameAccountingStandardsCodification-SectionS99-55-Paragraph1-Subparagraph\(SX210-10-6-07\(9\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575-2147479168/946-220-830-S99-55-1Reference10Reference18](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic946-SubTopic220-830-NameAccountingStandardsCodification-SectionS99-55-Paragraph1-Subparagraph(SX210-10-6-07(9))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575-2147479168/946-220-830-S99-55-1Reference10Reference18): [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-45-Paragraph7-3-Subparagraph\(SX210-6-09\(1\)\(d\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575-2147479105/946-220-S99-45-3Reference7Reference19](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-45-Paragraph7-3-Subparagraph(SX210-6-09(1)(d))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483575-2147479105/946-220-S99-45-3Reference7Reference19): [http://www.xbrl.org/2003/role/disclosureRef-Topic470-944-SubTopic10-220-NameAccountingStandardsCodification-SectionS99-Paragraph1A-1-Subparagraph\(SX210.13-7-01-04\(18\)a\(4\)\(i\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097-2147477250/470-944-10-220-S99-1Reference1Reference20](http://www.xbrl.org/2003/role/disclosureRef-Topic470-944-SubTopic10-220-NameAccountingStandardsCodification-SectionS99-Paragraph1A-1-Subparagraph(SX210.13-7-01-04(18)a(4)(i))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097-2147477250/470-944-10-220-S99-1Reference1Reference20): [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic470-946-SubTopic10-220-NameAccountingStandardsCodification-SectionS99-Paragraph1A-1-Subparagraph\(SX210.13-6-01-07\(9\)a\(4\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097-2147479134/470-946-10-220-S99-1Reference1Reference21](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic470-946-SubTopic10-220-NameAccountingStandardsCodification-SectionS99-Paragraph1A-1-Subparagraph(SX210.13-6-01-07(9)a(4)(ii))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097-2147479134/470-946-10-220-S99-1Reference1Reference21): [http://www.xbrl.org/2003/role/disclosureRef-Topic470-946-SubTopic10-220-NameAccountingStandardsCodification-SectionS99-Paragraph1A-3-Subparagraph\(SX210.13-6-01-09\(a-1\)\(d4\)\(iii\)\(A\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097-2147479134/470-946-10-220-S99-1Reference3Reference22](http://www.xbrl.org/2003/role/disclosureRef-Topic470-946-SubTopic10-220-NameAccountingStandardsCodification-SectionS99-Paragraph1A-3-Subparagraph(SX210.13-6-01-09(a-1)(d4)(iii)(A))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097-2147479134/470-946-10-220-S99-1Reference3Reference22): [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iv-i\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference23](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(iv-i))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference23): [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(5-4\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference24](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(5-4)(ii))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference24): [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-1A-Subparagraph\(SX210.13-02-01\(a\)\(4\)\(i-iii\)\(A\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference1AReference25](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-1A-Subparagraph(SX210.13-02-01(a)(4)(i-iii)(A))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference1AReference25): [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-1A-Subparagraph\(SX210.13-02-01\(a\)\(4\)\(iv-iii\)\(A\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference1AReference26](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-1A-Subparagraph(SX210.13-02-01(a)(4)(iv-iii)(A))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference1AReference26): [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-1A-Subparagraph\(SX210.13-02-01\(a\)\(5-4\)\(iii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-1A-Subparagraph(SX210.13-02-01(a)(5-4)(iii)))

(B)- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1BReference-1AReference> 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iv-i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iv-i)))- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1BReference28>: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(5-4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(5-4)(iii)(A)))- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480097/470-10-S99-1BReference29>: [http://www.xbrl.org/2003/role/disclosureRef-Topic280-470-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph30-1B-Subparagraph\(b-SX210.13-02\(a\)\(4\)\(iii\)\(B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic280-470-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph30-1B-Subparagraph(b-SX210.13-02(a)(4)(iii)(B)))- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147480097/280-470-10-50-S99-30Reference-1BReference30>: [http://www.xbrl.org/2003/role/disclosureRef-Topic280-470-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph32-1B-Subparagraph\(f-SX210.13-02\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic280-470-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph32-1B-Subparagraph(f-SX210.13-02(a)(4)(iv)))- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147480097/280-470-10-50-S99-32Reference-1BReference31>: [http://www.xbrl.org/2003/role/disclosureRef-Topic260-470-SubTopic10-NameAccountingStandardsCodification-Section45-S99-Paragraph60B-1B-Subparagraph\(SX210.13-02\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic260-470-SubTopic10-NameAccountingStandardsCodification-Section45-S99-Paragraph60B-1B-Subparagraph(SX210.13-02(a)(5)))- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482689-2147480097/470-10-S99-1BReference32>: <http://www.xbrl.org/2003/role/disclosureRef-Topic260-45-60BReference32>: [http://www.xbrl.org/2003/role/exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-45-Paragraph31-60B-Subparagraph\(a\)](http://www.xbrl.org/2003/role/exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-45-Paragraph31-60B-Subparagraph(a))- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482810-2147482689/280-260-10-50-45-31Reference-60BReference33>: [http://www.xbrl.org/2003/role/disclosureRef-Topic280-205-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph7-32-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810-2147483499-205-280-20-10-50-32Reference-7Reference34](http://www.xbrl.org/2003/role/disclosureRef-Topic280-205-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph7-32-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810-2147483499-205-280-20-10-50-32Reference-7Reference34): <http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic205-230-SubTopic20-10-NameAccountingStandardsCodification-Section50-45-Paragraph7-28>- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483499-2147482740/205-20-230-50-10-45-7Reference-28Reference35>: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic230-220-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph28-1A-Subparagraph\(a\)](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic230-220-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph28-1A-Subparagraph(a))- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482740-2147482790/230-220-10-45-28Reference-1AReference36>: [http://www.xbrl.org/2003/role/disclosureRef-Topic220-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph1A-1B-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482790/220-10-45-1AReference-1BReference37](http://www.xbrl.org/2003/role/disclosureRef-Topic220-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph1A-1B-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482790/220-10-45-1AReference-1BReference37): [http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic942-SubTopic220-SubTopic10-NameAccountingStandardsCodification-Section45-S99-Paragraph1B-1-Subparagraph\(a-SX210.9-04\(22\)\)](http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic942-SubTopic220-SubTopic10-NameAccountingStandardsCodification-Section45-S99-Paragraph1B-1-Subparagraph(a-SX210.9-04(22)))- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147478524-2147482790/220-10-45-942-220-S99-1> Details Name: us-gaap\_NetIncomeLoss Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph\(SX210.5-03-\(7\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph(SX210.5-03-(7)))- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483621/220-10-S99-2> Details Name: us-gaap\_NonoperatingIncomeExpense Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. ReferencesNo definition available. Details Name: us-gaap\_OperatingExpenses Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe net result for the period of deducting operating expenses from operating revenues. ReferencesReference 1: <http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810/280-10-50-22Reference2>: [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph30-32-Subparagraph\(b-f\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810/280-10-50-30Reference-32Reference3](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph30-32-Subparagraph(b-f)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810/280-10-50-30Reference-32Reference3): [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-270-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-30-Subparagraph\(f-b\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810/280-10-50-32Reference-30Reference4](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-270-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-30-Subparagraph(f-b)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810/280-10-50-32Reference-30Reference4): [http://www.xbrl.org/2003-2009/role/exampleRef-commonPracticeRef-Topic280-270-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph31-1-Subparagraph\(i\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810-2147482964/280-270-10-50-31Reference-1Reference5](http://www.xbrl.org/2003-2009/role/exampleRef-commonPracticeRef-Topic280-270-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph31-1-Subparagraph(i)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810-2147482964/280-270-10-50-31Reference-1Reference5): [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph\(e-ee\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810/280-10-50-32Reference6](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph(e-ee)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810/280-10-50-32Reference6): [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-10-50-32Reference7](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-10-50-32Reference7): <http://www.xbrl.org/2003/role/exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph31-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-10-50-31> Details Name: us-gaap\_OperatingIncomeLoss Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of income (expense) related to nonoperating activities, classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph\(SX210.5-03-\(9\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph(SX210.5-03-(9)))- Publisher FASB- URI <https://asc.fasb.org/#1943274/2147483621/220-10-S99-2> Details Name: us-gaap\_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects. Includes, including the but is not limited to, costs- cost for of developing computer software up product to the point be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than time of achieving technological feasibility, and costs allocated in accounting for a business combination to or joint venture formation or both. Excludes write- down of intangible asset acquired in -process projects deemed to have no alternative future business combination or from joint venture formation or both, use used in research and development activity. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic730-280-SubTopic10-NameAccountingStandards>

Codification- Section 50-55- Paragraph 1-48- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482916-2147482785/730-280-10-50-55-1Reference 48Reference 2: http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic 912-985-SubTopic 730-20-Name Accounting Standards Codification- Section 25-50- Paragraph 1-2- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482517-2147481283/912-985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 730-SubTopic 10-25-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification- Topic 985-SubTopic 20-Section 50- Paragraph 1- Publisher FASB- URI https://asc.fasb.org/#1943274/2147481283-2147482916/985-730-20-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 912-SubTopic 730-Name Accounting Standards Codification- Section 25- Paragraph 1- Publisher FASB- URI https://asc.fasb.org/1943274/2147479532/912-730-25-1-Details Name: us-gaap\_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount,..... xbrli:sharesItemType Balance Type: na Period Type: durationX- DefinitionNumber of [ basic ] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification- Section 50- Paragraph 1- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification- Section 45- Paragraph 10- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482689/260-10-45-10-Details Name: us-gaap\_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap\_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationConsolidated Statements of Comprehensive Loss- USD (\$) \$ in Thousands 12 Months EndedDec. 31, 2023-2024Dec. 31, 2022Net 2023Net loss \$ ( 38, 531 ) \$ ( 24, 557 ) \$ ( 32, 900 ) Realized comprehensive income (0) 1, 567 Foreign --- Foreign currency translation adjustment (252) Reclassification of deferred tax assets (574) Comprehensive loss \$ ( 38, 531 ) \$ ( 25, 383 ) \$ ( 34, 045 ) X- DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification- Section S99- Paragraph 2- Subparagraph (SX 210. 5- 03 (24))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 9- 04 (26))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147483589-2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 7- 04 (22))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147483586-2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification- Section 45- Paragraph 1A- Subparagraph (c)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification- Section 45- Paragraph 1B- Subparagraph (b)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/us-gaap/role/ref/legacyRef-disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 7- 04 (20))- Publisher FASB- URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification- Topic 220- SubTopic 10- Section 45- Paragraph 5- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482790/220-10-45-5-Details Name: us-gaap\_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-250-SubTopic 10-Name Accounting Standards Codification- Section S99-50- Paragraph 6-1-Subparagraph (SX 210. 4-08 (g) (1) (ii))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480678-2147483443/235-250-10-S99-50-1Reference 6Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 323-250-SubTopic 10-Name Accounting Standards Codification- Section 50- Paragraph 9-3-Subparagraph (c)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147481687-2147483443/323-250-10-50-3Reference 9Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 825-805-SubTopic 10-60-Name Accounting Standards Codification- Section 50-65- Paragraph 28-1- Subparagraph ( f g )- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482907-2147476176/825-805-10-60-50-65-28Reference 1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-740-SubTopic 10-323-Name Accounting Standards Codification- Section 50-65- Paragraph 6-2- Subparagraph (g) (3)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482765-2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification- Section 50-S99- Paragraph 3-2- Subparagraph (SX 210. 5- 03 (20))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147483443-2147483621/250-220-10-50-S99-3Reference 2Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-235-SubTopic 10-Name Accounting Standards Codification- Section 50-S99- Paragraph 1- Subparagraph ( b ) SX 210. 4-08 ( 2 g ) ( 1 ) ( ii ) )- Publisher FASB- URI https://asc.fasb.org/#1943274/2147483443-2147480678/250-235-10-50-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-323-SubTopic 40-10-Name Accounting Standards Codification- Section 65-50- Paragraph 1-3- Subparagraph ( f c )- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480175-2147481687/815-323-40-10-65-50-1Reference 3Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-825-SubTopic 10-Name Accounting Standards Codification- Section 50- Paragraph 8-28- Subparagraph (f)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147483443-2147482907/250-825-10-50-8Reference 28Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-220-SubTopic 10-Name Accounting Standards Codification- Section 50- Paragraph 9-6- Publisher FASB- URI https://asc.fasb.org/#1943274/2147483443-2147482765/250-220-10-50-9Reference 6Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification- Section 50- Paragraph 3-11- Subparagraph (a)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147483443/250-10-50-11Reference 3Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification- Section 50- Paragraph 11-1- Subparagraph (b) (2)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147483443/250-10-50-11Reference 11Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-815-SubTopic 40-40-Name Accounting Standards Codification- Section 50-65- Paragraph 4-1- Subparagraph (f)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147483443-2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-40-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-10-Name Accounting Standards Codification- Section 55-50- Paragraph 10-8- Publisher

FASB- URI <https://asc.fasb.org/1943274/2147480167-2147483443/946-250-830-10-55-50-10Reference-8Reference> 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-250-SubTopic-220-10-Name-Accounting-Standards-Codification-Section-45-50-Paragraph-7-11-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483581-2147483443/946-250-220-10-45-50-7Reference-11Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-250-SubTopic-220-10-Name-Accounting-Standards-Codification-Section-45-50-Paragraph-7-11-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483581-2147483443/946-250-220-10-45-50-7Reference-11Reference) 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-250-SubTopic-220-10-Name-Accounting-Standards-Codification-Section-S99-50-Paragraph-1-11-Subparagraph-\(b\)-SX-210-7-04-\(18\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483586-2147483443/944-250-220-10-S99-50-1Reference-11Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-250-SubTopic-220-10-Name-Accounting-Standards-Codification-Section-S99-50-Paragraph-1-11-Subparagraph-(b)-SX-210-7-04-(18)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483586-2147483443/944-250-220-10-S99-50-1Reference-11Reference) 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic-280-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-4-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810-2147483443/280-250-10-50-22Reference-4Reference> 17: [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic-946-SubTopic-220-830-Name-Accounting-Standards-Codification-Section-S99-55-Paragraph-1-Subparagraph-\(SX-210-10-6-07-\(9\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575-2147479168/946-220-830-S99-55-1Reference-10Reference](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic-946-SubTopic-220-830-Name-Accounting-Standards-Codification-Section-S99-55-Paragraph-1-Subparagraph-(SX-210-10-6-07-(9))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575-2147479168/946-220-830-S99-55-1Reference-10Reference) 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-45-Paragraph-7-3-Subparagraph-\(SX-210-6-09-\(1\)-\(d\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575-2147479105/946-220-S99-45-3Reference-7Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-45-Paragraph-7-3-Subparagraph-(SX-210-6-09-(1)-(d))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483575-2147479105/946-220-S99-45-3Reference-7Reference) 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-944-SubTopic-10-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-1-Subparagraph-\(SX-210-13-7-01-04-18-a\)-\(4\)-\(i\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097-2147477250/470-944-10-220-S99-1AReference-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-944-SubTopic-10-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-1-Subparagraph-(SX-210-13-7-01-04-18-a)-(4)-(i))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097-2147477250/470-944-10-220-S99-1AReference-1Reference) 20: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic-470-946-SubTopic-10-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-1-Subparagraph-\(SX-210-13-6-01-07-9-a\)-\(4\)-\(ii\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097-2147479134/470-946-10-220-S99-1AReference-1Reference](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic-470-946-SubTopic-10-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-1-Subparagraph-(SX-210-13-6-01-07-9-a)-(4)-(ii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097-2147479134/470-946-10-220-S99-1AReference-1Reference) 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-946-SubTopic-10-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-3-Subparagraph-\(SX-210-13-6-01-09-\(a-1\)-\(d-4\)-\(iii\)-\(A\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097-2147479134/470-946-10-220-S99-1AReference-3Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-946-SubTopic-10-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-3-Subparagraph-(SX-210-13-6-01-09-(a-1)-(d-4)-(iii)-(A))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097-2147479134/470-946-10-220-S99-1AReference-3Reference) 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(4\)-\(iv-i\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference-23](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(iv-i))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference-23) 23: [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01-\(a\)-\(5-4\)-\(ii\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference-24](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(5-4)-(ii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference-24) 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-1A-Subparagraph-\(SX-210-13-02-01-\(a\)-\(4\)-\(i-iii\)-\(A\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference-1AReference](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-1A-Subparagraph-(SX-210-13-02-01-(a)-(4)-(i-iii)-(A))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference-1AReference) 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-1A-Subparagraph-\(SX-210-13-02-01-\(a\)-\(4\)-\(iv-iii\)-\(A\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference-1AReference](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-1A-Subparagraph-(SX-210-13-02-01-(a)-(4)-(iv-iii)-(A))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference-1AReference) 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-1A-Subparagraph-\(SX-210-13-02-01-\(a\)-\(5-4\)-\(iii\)-\(B\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference-1AReference](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-1A-Subparagraph-(SX-210-13-02-01-(a)-(5-4)-(iii)-(B))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference-1AReference) 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(4\)-\(iv-i\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference-28](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iv-i))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference-28) 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(5-4\)-\(iii\)-\(A\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference-29](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(5-4)-(iii)-(A))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference-29) 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-30-1B-Subparagraph-\(b\)-SX-210-13-02-\(a\)-\(4\)-\(iii\)-\(B\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810-2147480097/280-470-10-50-S99-30Reference-1BReference](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-30-1B-Subparagraph-(b)-SX-210-13-02-(a)-(4)-(iii)-(B))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810-2147480097/280-470-10-50-S99-30Reference-1BReference) 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-32-1B-Subparagraph-\(f\)-SX-210-13-02-\(a\)-\(4\)-\(iv\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810-2147480097/280-470-10-50-S99-32Reference-1BReference](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-32-1B-Subparagraph-(f)-SX-210-13-02-(a)-(4)-(iv))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810-2147480097/280-470-10-50-S99-32Reference-1BReference) 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-S99-Paragraph-60B-1B-Subparagraph-\(SX-210-13-02-\(a\)-\(5\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689-2147480097/470-10-S99-1BReference-32](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-S99-Paragraph-60B-1B-Subparagraph-(SX-210-13-02-(a)-(5))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689-2147480097/470-10-S99-1BReference-32) 32: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-10-45-60BReference-32> 33: [http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-45-Paragraph-31-60B-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810-2147482689/280-260-10-50-45-31Reference-60BReference](http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-45-Paragraph-31-60B-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810-2147482689/280-260-10-50-45-31Reference-60BReference) 34: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-205-SubTopic-10-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-32-Subparagraph-\(e\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810-2147483499/205-280-20-10-50-32Reference-7Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-205-SubTopic-10-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-32-Subparagraph-(e)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810-2147483499/205-280-20-10-50-32Reference-7Reference) 35: <http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic-205-230-SubTopic-20-10-Name-Accounting-Standards-Codification-Section-50-45-Paragraph-7-28-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483499-2147482740/205-20-230-50-10-45-7Reference-28Reference> 36: [http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic-230-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-1A-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740-2147482790/230-220-10-45-28Reference-1AReference](http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic-230-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-1A-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740-2147482790/230-220-10-45-28Reference-1AReference) 37: [http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic-942-SubTopic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-S99-Paragraph-1B-1-Subparagraph-\(a\)-SX-210-9-04-\(22\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478524-2147482790/220-10-45-11Reference-3](http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic-942-SubTopic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-S99-Paragraph-1B-1-Subparagraph-(a)-SX-210-9-04-(22))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478524-2147482790/220-10-45-11Reference-3) 38: [http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic-830-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-9-10A-Subparagraph-\(c\)-](http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic-830-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-9-10A-Subparagraph-(c)-)

Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481839-2147482790/830-220-10-45-9>Reference 10Reference 4: [http://www.fasb.xbrl.org/2003/us-gaap/role/disclosureRef/ref/legacyRef-Topic830-220-SubTopic20-10-NameAccountingStandardsCodification-Section35-45-Paragraph3-10A-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482014-2147482790/830-20-220-35-10-45-3](http://www.fasb.xbrl.org/2003/us-gaap/role/disclosureRef/ref/legacyRef-Topic830-220-SubTopic20-10-NameAccountingStandardsCodification-Section35-45-Paragraph3-10A-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482014-2147482790/830-20-220-35-10-45-3)Reference 10Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic830-SubTopic30-10-NameAccountingStandardsCodification-Section45-Paragraph42-9-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139-2147481839/470-830-20-10-50-45-1>Reference 9Reference 3-6 :<http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic470-830-SubTopic20-NameAccountingStandardsCodification-Section55-35-Paragraph69B-3-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481568-2147482014/470-830-20-55-35-69>Reference 3Reference 4-7 :<http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic470-830-SubTopic20-30-NameAccountingStandardsCodification-Section55-45-Paragraph69C-12-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481694/830-30-45-12> Details Name: us-gaap\_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount after..... xbrli:monetaryItemType Balance Type: debit Period Type: durationX- DefinitionRepresents reclassification of deferred tax assets, net of tax. ReferencesNo definition available. Details Name: xbit\_OtherComprehensiveIncomeLossReclassificationOfDeferredTaxAssetsNetOfTax Namespace Prefix: xbit\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationConsolidated Statements of Shareholders' Equity- USD (\$) shares in Thousands, \$ in Thousands Common Stock Including Additional Paid in Capital [ Member ] AOCI Attributable to Parent [ Member ] Retained Earnings [ Member ] Common Stock Outstanding [ Member ] TotalBalance (in shares) at Dec. 31, 2021-2022 30, 439 Balance at Dec. 31, 2021-2022 \$ 262,267, 263,325 \$ 826,1,971 \$ 5-(27, +51-749) \$ 269,240, 385Net 402Net loss (32,24, 900-557) (32,24, 900-557) Tender offer (in shares) (4) Tender offer (14) (14) Tender offer Foreign currency translation adjustment Realized comprehensive income 1, 567 1, 567Realized comprehensive income (1, 567) (1, 567) Share-based compensation expense 5, 062 5, 062Reclassification of deferred tax assets Share-based compensation expense \$ 5, 062 5, 062Balance (in shares) at Dec. 31, 2022 30, 439 Balance at Dec. 31, 2022 \$ 267, 325 (27, 749) 240, 402Net loss (24, 557) (24, 557) Foreign currency translation adjustment (252) (252) Realized comprehensive income (0) Realized comprehensive income Share-based compensation expense 3, 262 3, 262Tender offer (in shares) (4) Tender offer (14) (14) Tender offer-Reclassification of deferred tax assets \$ 574 (574) (574) Issuance of common stock under stock option plan (in shares) Issuance of common stock under stock option plan \$ 5 Share-based compensation expense 3, 262 3, 262Share-based compensation expense \$ 3, 262 3, 262Balance (in shares) at Dec. 31, 2023 30, 436 Balance at Dec. 31, 2023 \$ 271, 152 (52, 306) 218, 846Net loss \$ 0 (38, 531) (38, 531) Foreign currency translation adjustment Reclassification of deferred tax assets (0) Issuance of common stock under stock option plan (in shares) Issuance of common stock under stock option plan \$ 200 Share-based compensation expense 1, 753 1, 753Share-based compensation expense \$ 1, 753 1, 753Balance (in shares) at Dec. 31, 2024 30, 487 Balance at Dec. 31, 2024 \$ 273, 105 \$ 0 \$ (52-90, 306-837) \$ 218-182, 846X-268X - DefinitionAmount of increase to additional paid- in capital (APIC) for recognition of cost for award under share- based payment arrangement. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section35-Paragraph2-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480483/718-10-35-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic718-SubTopic20-Section55-Paragraph13-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481089/718-20-55-13>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic718-SubTopic20-Section55-Paragraph12-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481089/718-20-55-12> Details Name: us-gaap\_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic235-250-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph6-1-Subparagraph\(SX210.4-08\(e\)\(1\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480678-2147483443/235-250-10-S99-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic235-250-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph6-1-Subparagraph(SX210.4-08(e)(1)(ii))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480678-2147483443/235-250-10-S99-50-1)Reference 6Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic323-250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph9-3-Subparagraph\(e\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481687-2147483443/323-250-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic323-250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph9-3-Subparagraph(e)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481687-2147483443/323-250-10-50-3)Reference 9Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic825-805-SubTopic40-60-NameAccountingStandardsCodification-Section50-65-Paragraph28-1-Subparagraph\(fg\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482907-2147476176/825-805-40-60-50-65-28](http://www.xbrl.org/2003/role/disclosureRef-Topic825-805-SubTopic40-60-NameAccountingStandardsCodification-Section50-65-Paragraph28-1-Subparagraph(fg)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482907-2147476176/825-805-40-60-50-65-28)Reference 1Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic220-740-SubTopic40-323-NameAccountingStandardsCodification-Section50-65-Paragraph6-2-Subparagraph\(g\)\(3\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482765-2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic220-740-SubTopic40-323-NameAccountingStandardsCodification-Section50-65-Paragraph6-2-Subparagraph(g)(3)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482765-2147478666/740-323-65-2)Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-10-50-6>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph3-2-Subparagraph\(SX210.5-03\(20\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443-2147483621/250-220-10-50-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph3-2-Subparagraph(SX210.5-03(20))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443-2147483621/250-220-10-50-S99-3)Reference 2Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-235-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph1-Subparagraph\(b\)-SX210.4-08\(2g\)\(1\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443-2147480678/250-235-10-50-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic250-235-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph1-Subparagraph(b)-SX210.4-08(2g)(1)(ii))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443-2147480678/250-235-10-50-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic815-323-SubTopic40-10-NameAccountingStandardsCodification-Section65-50-Paragraph1-3-Subparagraph\(fc\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480175-2147481687/815-323-40-10-65-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic815-323-SubTopic40-10-NameAccountingStandardsCodification-Section65-50-Paragraph1-3-Subparagraph(fc)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480175-2147481687/815-323-40-10-65-50-1)Reference 3Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-825-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph8-28-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443-2147482907/250-825-10-50-8](http://www.xbrl.org/2003/role/disclosureRef-Topic250-825-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph8-28-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443-2147482907/250-825-10-50-8)Reference 8Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic250-220-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph9-6-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443-2147482765/250-220-10-50-9>Reference 6Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-11-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-11-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443/250-10-50-11)Reference 3Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph11-1-Subparagraph\(b\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph11-1-Subparagraph(b)(2)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443/250-10-50-11)Reference 1Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-815-SubTopic40-40-NameAccountingStandardsCodification-Section50-65-Paragraph4-1-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443-2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic250-815-SubTopic40-40-NameAccountingStandardsCodification-Section50-65-Paragraph4-1-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483443-2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef-Topic250-10-50-4>Reference 13: <http://www.xbrl.org/2003/role/exampleRef-Topic946-SubTopic830-10-Name>



Standards Codification- Section 45- Paragraph 9-10A- Subparagraph (c) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481839-2147482790/830-220> - 10- 45- 9Reference-10AReference 4: <http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef> - Topic 830-220 - SubTopic 20-10 - Name Accounting Standards Codification- Section 35-45 - Paragraph 3-10A- Subparagraph (b) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482014-2147482790/830-20-220-35-10-45-3Reference-10AReference> 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic830-SubTopic30-10-NameAccountingStandardsCodification-Section45-Paragraph12-9-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139-2147481839/470-830-20-10-50-45-1BReference9Reference3-6>:<http://www.xbrl.org/2003/role/exampleRefdisclosureRef-Topic470-830-SubTopic20-NameAccountingStandardsCodification-Section55-35-Paragraph69B-3-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481568-2147482014/470-830-20-55-35-69BReference3Reference4-7>:<http://www.xbrl.org/2003/role/exampleRefdisclosureRef-Topic470-830-SubTopic20-30-NameAccountingStandardsCodification-Section55-45-Paragraph69C-12> - Publisher FASB- URI <https://asc.fasb.org/1943274/2147481694/830-30-45-12> Details Name: us-gaap\_ OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount after..... xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. ReferencesNo definition available. Details Name: us-gaap\_SharesOutstanding Namespace Prefix: us-gaap\_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: instantX- DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10-Topic505-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-2Reference2>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(28\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566/210-10-S99-1Reference3](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(28))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566/210-10-S99-1Reference3): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic505-210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.3-5-04-02\(29\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480008-2147480566/505-210-10-S99-1Reference4](http://fasb.org/us-gaap/role/ref/legacyRef-Topic505-210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.3-5-04-02(29))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480008-2147480566/505-210-10-S99-1Reference4): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-3-04-02\(29\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566-2147480008/210-505-10-S99-1DetailsName:us-gaap\\_StockIssuedDuringPeriodSharesShareBasedCompensationNamespacePrefix:us-gaap\\_DataType:xbrli:sharesItemTypeBalanceType:naPeriodType:durationX-DefinitionValue,afterforfeiture,ofsharesissuedundershare-basedpaymentarrangement.Excludesemployeestockownershipplan\(ESOP\).ReferencesReference1:](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-3-04-02(29))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566-2147480008/210-505-10-S99-1DetailsName:us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationNamespacePrefix:us-gaap_DataType:xbrli:sharesItemTypeBalanceType:naPeriodType:durationX-DefinitionValue,afterforfeiture,ofsharesissuedundershare-basedpaymentarrangement.Excludesemployeestockownershipplan(ESOP).ReferencesReference1:) [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(28\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566/210-10-S99-1Reference2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(28))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566/210-10-S99-1Reference2): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic505-210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.3-5-04-02\(29\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480008-2147480566/505-210-10-S99-1Reference3](http://fasb.org/us-gaap/role/ref/legacyRef-Topic505-210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.3-5-04-02(29))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480008-2147480566/505-210-10-S99-1Reference3): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-3-04-02\(29\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566-2147480008/210-505-10-S99-1Reference4](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-3-04-02(29))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566-2147480008/210-505-10-S99-1Reference4): [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic718-SubTopic10-Section50-Paragraph2-Subparagraph\(d\)\(1\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480429/718-10-50-2DetailsName:us-gaap\\_StockIssuedDuringPeriodValueShareBasedCompensationNamespacePrefix:us-gaap\\_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:durationX-DefinitionAmountofequity\(deficit\)attributabletoparent.Excludestemporaryequityandequityattributabletononcontrollinginterest.ReferencesReference1:](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic718-SubTopic10-Section50-Paragraph2-Subparagraph(d)(1)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480429/718-10-50-2DetailsName:us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationNamespacePrefix:us-gaap_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:durationX-DefinitionAmountofequity(deficit)attributabletoparent.Excludestemporaryequityandequityattributabletononcontrollinginterest.ReferencesReference1:) [http://www.fasb.xbrl.org/2003-us-gaap/role/exampleRef/ref/legacyRef-Topic852-210-SubTopic10-NameAccountingStandardsCodification-Section55-S99-Paragraph1-Subparagraph\(SX10-210.5-02\(29\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481372-2147480566/852-10-210-55-10-S99-10Reference-1Reference2](http://www.fasb.xbrl.org/2003-us-gaap/role/exampleRef/ref/legacyRef-Topic852-210-SubTopic10-NameAccountingStandardsCodification-Section55-S99-Paragraph1-Subparagraph(SX10-210.5-02(29))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481372-2147480566/852-10-210-55-10-S99-10Reference-1Reference2): [http://www.fasb.xbrl.org/2003-us-gaap/role/exampleRef/ref/legacyRef-Topic946-210-SubTopic830-10-NameAccountingStandardsCodification-Section55-S99-Paragraph12-1-Subparagraph\(SX210.5-02\(30\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480167-2147480566/946-210-830-10-55-S99-12Reference-1Reference3](http://www.fasb.xbrl.org/2003-us-gaap/role/exampleRef/ref/legacyRef-Topic946-210-SubTopic830-10-NameAccountingStandardsCodification-Section55-S99-Paragraph12-1-Subparagraph(SX210.5-02(30))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480167-2147480566/946-210-830-10-55-S99-12Reference-1Reference3): [http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic946-210-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.6-5-04-02\(19-31\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479617-2147480566/946-210-10-S99-1Reference4](http://www.fasb.xbrl.org/2003-us-gaap/role/disclosureRef/ref/legacyRef-Topic946-210-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.6-5-04-02(19-31))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479617-2147480566/946-210-10-S99-1Reference4): [http://www.xbrl.org/2003/role/disclosureRefexampleRef-Topic946-852-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-55-Paragraph2-Subparagraph\(SX210-10-6-05\(4\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479617-2147481372/946-852-210-10-S99-55-2Reference-10Reference5](http://www.xbrl.org/2003/role/disclosureRefexampleRef-Topic946-852-SubTopic210-10-NameAccountingStandardsCodification-SectionS99-55-Paragraph2-Subparagraph(SX210-10-6-05(4))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479617-2147481372/946-852-210-10-S99-55-2Reference-10Reference5): [http://www.xbrl.org/2009-2003/role/commonPracticeRefexampleRef-Topic946-SubTopic220-830-NameAccountingStandardsCodification-SectionS99-55-Paragraph12-3-Subparagraph\(SX210.6-09\(4\)\(b\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483575-2147479168/946-220-830-S99-55-3Reference-12Reference6](http://www.xbrl.org/2009-2003/role/commonPracticeRefexampleRef-Topic946-SubTopic220-830-NameAccountingStandardsCodification-SectionS99-55-Paragraph12-3-Subparagraph(SX210.6-09(4)(b))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483575-2147479168/946-220-830-S99-55-3Reference-12Reference6): [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-1-Subparagraph\(SX210.6-09-04\(6-19\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483575-2147479170/946-220-210-S99-3Reference-1Reference7](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-1-Subparagraph(SX210.6-09-04(6-19))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483575-2147479170/946-220-210-S99-3Reference-1Reference7): [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-2-Subparagraph\(SX210.6-09-05\(7-4\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483575-2147479170/946-210-S99-2Reference8:](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-210-NameAccountingStandardsCodification-SectionS99-Paragraph3-2-Subparagraph(SX210.6-09-05(7-4))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483575-2147479170/946-210-S99-2Reference8:) <http://www.xbrl.org/2009/role/commonPracticeRef-Topic946-SubTopic220-S99-3Reference8:> [http://www.xbrl.org/2009/role/commonPracticeRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-3-Subparagraph\(SX210.6-09\(4-08\)\(g\)\(b\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480678-2147479134/235-946-10-220-S99-1Reference3Reference9](http://www.xbrl.org/2009/role/commonPracticeRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-3-Subparagraph(SX210.6-09(4-08)(g)(b)(ii))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480678-2147479134/235-946-10-220-S99-1Reference3Reference9): [http://www.xbrl.org/2009-2003/role/commonPracticeRefdisclosureRef-Topic323-946-SubTopic10-220-NameAccountingStandardsCodification-Section50-S99-Paragraph3-Subparagraph\(e-SX210.6-09\(6\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481687-2147479134/323-946-10-220-50-S99-3Reference10:](http://www.xbrl.org/2009-2003/role/commonPracticeRefdisclosureRef-Topic323-946-SubTopic10-220-NameAccountingStandardsCodification-Section50-S99-Paragraph3-Subparagraph(e-SX210.6-09(6))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481687-2147479134/323-946-10-220-50-S99-3Reference10:) [http://www.xbrl.org/2009-2003/role/commonPracticeRefdisclosureRef-Topic825-946-SubTopic10-220-NameAccountingStandardsCodification-Section50-S99-Paragraph28-3-Subparagraph\(f-SX210.6-09\(7\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482907-2147479134/825-946-10-220-50-S99-28Reference3Reference11:](http://www.xbrl.org/2009-2003/role/commonPracticeRefdisclosureRef-Topic825-946-SubTopic10-220-NameAccountingStandardsCodification-Section50-S99-Paragraph28-3-Subparagraph(f-SX210.6-09(7))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482907-2147479134/825-946-10-220-50-S99-28Reference3Reference11:) [http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-Topic210-235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-4-02-08\(29g\)\(1\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566-2147480678/210-235-10-S99-1Reference12:](http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-Topic210-235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-4-02-08(29g)(1)(ii))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480566-2147480678/210-235-10-S99-1Reference12:) <http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef->

Topic 210-323 - SubTopic 10- Name Accounting Standards Codification- Section S99-50 - Paragraph 1-3 - Subparagraph (c) SX 210-5-02 (31)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480566-2147481687/323-210-10-10-50-S99-1Reference 3Reference 13: http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef- Topic 210-825 - SubTopic 10- Name Accounting Standards Codification- Section S99-50 - Paragraph 1-28 - Subparagraph (f) SX 210-5-02(30)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480566-2147482907/825-210-10-10-50-S99-1Reference 28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef- Topic 310- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 2- Subparagraph (SAB Topic 4. E)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480418/310-10-S99-2 Details Name: us-gaap\_StockholdersEquity Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionNumber of shares that have been repurchased during the period and are being held in treasury. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Section 50- Paragraph 2- SubTopic 10- Topic 505- Publisher FASB- URI https://asc.fasb.org/#1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef- Topic 505-210 - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 3-5-04-02(29))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480008-2147480566/505-210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef- Topic 210-505 - SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 5-3-04-02(29))- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480566-2147480008/210-505 - 10-S99-1 Details Name: us-gaap\_TreasuryStockSharesAcquired Namespace Prefix: us-gaap\_ Data Type: xbrli: sharesItemType Balance Type: na Period Type: durationX- DefinitionEquity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Section 50- Paragraph 2- SubTopic 10- Topic 505- Publisher FASB- URI https://asc.fasb.org/#1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef- Topic 505- SubTopic 10- Name Accounting Standards Codification- Section S99- Paragraph 1- Subparagraph (SX 210. 3-04)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Topic 505- SubTopic 30- Section 45- Paragraph 1- Publisher FASB- URI https://asc.fasb.org/#1943274/2147481549/505-30-45-1 Details Name: us-gaap\_TreasuryStockValueAcquiredParValueMethod Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionRepresents reclassification of deferred tax assets, net of tax. ReferencesNo definition available. Details Name: xbit\_OtherComprehensiveIncomeLossReclassificationOfDeferredTaxAssetsNetOfTax Namespace Prefix: xbit\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationConsolidated Statements of Cash Flows- USD (\$) \$ in Thousands 12 Months Ended Dec. 31, 2023-2024 Dec. 31, 2022Net 2023Net loss \$ (38,531) \$ (24,557) \$(32,900) Depreciation 1,744-2,745 1,614Foreign exchange loss 5,529 (1,893) 2,800Share-based compensation expense 1,753 3,262-5,062Income tax receivable 8-(83) 556Accrued interest receivablePrepaid receivable (1,216) Prepaid expenses and other current assets (271) (160) Accounts payableAccrued payable (364) Accrued expenses (877) 1,895Income tax payableDeferred payable (24) Deferred tax liability (59)-(815) Net cash (used in) provided by operating activities (30,963) (18,725) (14,824) Purchase of property and equipment (1,304) (362) (585) Proceeds from maturity (purchases of) interest bearing time deposits (61,859) 63,307Proceeds from maturity (purchases of) interest bearing time deposits (61,859) (63,307) Net cash used in investing activities (1,304) 61,497Cash 497(63,892) Cash paid in tender offer (0) Issuance of common stock under stock option planNet cash used in financing activities 10,450 (9) Effect of foreign exchange rate on cash and cash equivalents (5,529) (46) (961) Net change in cash and cash equivalents (27,346) 42,717Cash 717(79,677) Cash and cash equivalents, beginning of period 200,023 157,306Cash 306236,983Cash and cash equivalents, end of period 172,677 200,023-157,306Purchases of property and equipment in accounts payable payableCash paid for interestCash paid for income taxesRelated Party [ Member ] Proceeds from convertible loan 10,000Nonrelated Party [ Member ] Proceeds from convertible loan \$ 19-250 \$ 18X-0X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Topic 230- SubTopic 10- Section 50- Paragraph 4- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Topic 230- SubTopic 10- Section 50- Paragraph 3- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Topic 230- SubTopic 10- Section 50- Paragraph 5- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482913/230-10-50-5 Details Name: us-gaap\_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 8- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 24- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Topic 230- SubTopic 10- Section 45- Paragraph 4- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-4 Details Name: us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef- Topic 230- SubTopic 10- Name Accounting Standards Codification- Section 45- Paragraph 24- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef- Name Accounting Standards Codification- Section 45- Paragraph 1- SubTopic 230- Topic 830- Publisher FASB- URI https://asc.fasb.org/#1943274/2147481877-2147477401/830-230-45-1 Details Name: us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non- production related depreciation. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(b\)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(b)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482740/230-10-45-28)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic360-SubTopic10-Section50-Paragraph1-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic360-SubTopic10-Section50-Paragraph1-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482099/360-10-50-1) Details Name: us- gaap\_ Depreciation Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic830-SubTopic230-NameAccountingStandardsCodification-Section45-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481877-2147477401> 830- 230- 45- 1 Details Name: us- gaap\_ EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount, before tax, of realized gain (loss) from foreign currency transaction. ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic946-SubTopic830-NameAccountingStandardsCodification-Section55-Paragraph10-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480167-2147479168/> 946- 830- 55- 10Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-Section45-Paragraph6-Subparagraph\(a\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483581-2147479105/](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-Section45-Paragraph6-Subparagraph(a)(2)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483581-2147479105/) 946- 220- 45- 6Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.6-07\(7\)\(a\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483575-2147479134/](http://www.xbrl.org/2009/role/commonPracticeRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.6-07(7)(a))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483575-2147479134/) 946- 220- S99- 1Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic830-SubTopic20-NameAccountingStandardsCodification-Section45-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481956/830-20-45-1>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic830-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481926/830-20-50-1> Details Name: us- gaap\_ ForeignCurrencyTransactionGainLossRealized **Namespace Prefix:us- gaap\_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instantX- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions. ReferencesReference 1:**<http://www.xbrl.org/2003-2009/role/disclosureRefcommonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph23-6-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482685/740-10-50-23>**Reference 3:**<http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482685/740-10-50-22>**Reference 4:**<http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic230-740-SubTopic10-Section50-Paragraph2-8-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482913-2147482685/230-740-10-50-8> **Details Name:us- gaap\_ DeferredTaxAssetsUnrealizedCurrencyLosses** Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity' s business. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(a\)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482740/230-10-45-28) Details Name: us- gaap\_ IncreaseDecreaseInAccountsPayable Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe increase (decrease) during the period in the amount due for taxes based on the reporting entity' s earnings or attributable to the entity' s income earning process (business presence) within a given jurisdiction. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(a\)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482740/230-10-45-28) Details Name: us- gaap\_ IncreaseDecreaseInAccruedIncomeTaxesPayable Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe increase (decrease) during the reporting period in the amount due from borrowers for interest payments. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(a\)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482740/230-10-45-28) Details Name: us- gaap\_ IncreaseDecreaseInAccruedInterestReceivableNet Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(a\)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482740/230-10-45-28) Details Name: us- gaap\_ IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(a\)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482740/230-10-45-28) Details Name: us- gaap\_ IncreaseDecreaseInIncomeTaxesReceivable Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(a\)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482740/230-10-45-28) Details Name: us- gaap\_ IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets **DefinitionFace (par) amount** **Namespace Prefix:us- gaap\_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:durationX- DefinitionAmount of cash paid for interest,excluding capitalized interest,classified as operating activity.Includes,but is not limited to,payment to settle zero- coupon bond for accreted interest of debt discount and debt instrument at time with insignificant coupon interest rate in relation to effective interest rate of issuance-borrowing attributable to accreted interest of debt discount .**

ReferencesReference 1:[http://www.xbrl.org/2003/role/disclosureRef-Topic 835-230-SubTopic 30-10-Name Accounting Standards Codification-Section 50-45-Paragraph 1-17-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482900-2147482740/835-30-230-50-10-45-1Reference-17Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 835-230-SubTopic 30-10-Name Accounting Standards Codification-Section 50-45-Paragraph 1-17-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482900-2147482740/835-30-230-50-10-45-1Reference-17Reference) 2:[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-230-SubTopic 20-10-Name Accounting Standards Codification-Section 50-45-Paragraph 1B-25-Subparagraph \(a-e\)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481139-2147482740/470-20-230-50-10-45-1BReference-25Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-230-SubTopic 20-10-Name Accounting Standards Codification-Section 50-45-Paragraph 1B-25-Subparagraph (a-e)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481139-2147482740/470-20-230-50-10-45-1BReference-25Reference) 3:<http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic 470-230-SubTopic 20-10-Name Accounting Standards Codification-Section 55-50-Paragraph 69B-2-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481568-2147482913/470-20-230-55-10-50-69BReference-4> 4:<http://www.xbrl.org/2003/role/exampleRef-2-Details-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 69C-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481568/470-20-55-69CReference-5> 5:

FASB- URI <https://asc.fasb.org/1943274/2147482810-2147483443-280-250-10-50-22Reference-4Reference> 17: [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic946-SubTopic220-830-NameAccountingStandardsCodification-SectionS99-55-Paragraph1-Subparagraph\(SX210-10-6-07\(9\)\)](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic946-SubTopic220-830-NameAccountingStandardsCodification-SectionS99-55-Paragraph1-Subparagraph(SX210-10-6-07(9)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147483575-2147479168/946-220-830-S99-55-1Reference-10Reference> 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-45-Paragraph7-3-Subparagraph\(SX210-6-09\(1\)\(d\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-45-Paragraph7-3-Subparagraph(SX210-6-09(1)(d)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147483575-2147479105/946-220-S99-45-3Reference-7Reference> 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-944-SubTopic10-220-NameAccountingStandardsCodification-SectionS99-Paragraph1A-1-Subparagraph\(SX210-13-7-01-04\(18a\)\(4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-944-SubTopic10-220-NameAccountingStandardsCodification-SectionS99-Paragraph1A-1-Subparagraph(SX210-13-7-01-04(18a)(4)(i)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147480097-2147477250/470-944-10-220-S99-1AReference-1Reference> 20: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic470-946-SubTopic10-220-NameAccountingStandardsCodification-SectionS99-Paragraph1A-1-Subparagraph\(SX210-13-6-01-07\(9a\)\(4\)\(ii\)\)](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic470-946-SubTopic10-220-NameAccountingStandardsCodification-SectionS99-Paragraph1A-1-Subparagraph(SX210-13-6-01-07(9a)(4)(ii)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147480097-2147479134/470-946-10-220-S99-1AReference-1Reference> 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-946-SubTopic10-220-NameAccountingStandardsCodification-SectionS99-Paragraph1A-3-Subparagraph\(SX210-13-6-01-09\(a-1\)\(d4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-946-SubTopic10-220-NameAccountingStandardsCodification-SectionS99-Paragraph1A-3-Subparagraph(SX210-13-6-01-09(a-1)(d4)(iii)(A)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147480097-2147479134/470-946-10-220-S99-1AReference-3Reference> 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iv-i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(iv-i)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference-23>: [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(5-4\)\(ii\)\)](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(5-4)(ii)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference-24>: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-1A-Subparagraph\(SX210.13-02-01\(a\)\(4\)\(i-iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-1A-Subparagraph(SX210.13-02-01(a)(4)(i-iii)(A)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference-1AReference> 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-1A-Subparagraph\(SX210.13-02-01\(a\)\(4\)\(iv-iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-1A-Subparagraph(SX210.13-02-01(a)(4)(iv-iii)(A)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference-1AReference> 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-1A-Subparagraph\(SX210.13-02-01\(a\)\(5-4\)\(iii\)\(B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-1A-Subparagraph(SX210.13-02-01(a)(5-4)(iii)(B)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference-1AReference> 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iv-i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iv-i)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference-28>: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(5-4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(5-4)(iii)(A)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference-29>: [http://www.xbrl.org/2003/role/disclosureRef-Topic280-470-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph30-1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iii\)\(B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic280-470-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph30-1B-Subparagraph(SX210.13-02(a)(4)(iii)(B)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147482810-2147480097-280-470-10-50-S99-30Reference-1BReference> 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic280-470-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph32-1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic280-470-SubTopic10-NameAccountingStandardsCodification-Section50-S99-Paragraph32-1B-Subparagraph(SX210.13-02(a)(4)(iv)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147482810-2147480097-280-470-10-50-S99-32Reference-1BReference> 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic260-470-SubTopic10-NameAccountingStandardsCodification-Section45-S99-Paragraph60B-1B-Subparagraph\(SX210.13-02\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic260-470-SubTopic10-NameAccountingStandardsCodification-Section45-S99-Paragraph60B-1B-Subparagraph(SX210.13-02(a)(5)))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147482689-2147480097/470-10-S99-1BReference-32>: [http://www.xbrl.org/2003/role/exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-45-Paragraph31-60B-Subparagraph\(a\)](http://www.xbrl.org/2003/role/exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-45-Paragraph31-60B-Subparagraph(a))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147482810-2147482689/280-260-10-50-45-31Reference-60BReference> 33: [http://www.xbrl.org/2003/role/disclosureRef-Topic280-205-SubTopic10-20-NameAccountingStandardsCodification-Section50-Paragraph7-32-Subparagraph\(c\)](http://www.xbrl.org/2003/role/disclosureRef-Topic280-205-SubTopic10-20-NameAccountingStandardsCodification-Section50-Paragraph7-32-Subparagraph(c))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147482810-2147483499/205-280-20-10-50-32Reference-7Reference> 34: <http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic205-230-SubTopic20-10-NameAccountingStandardsCodification-Section50-45-Paragraph7-28>- Publisher FASB- URI <https://asc.fasb.org/1943274/2147483499-2147482740/205-20-230-50-10-45-7Reference-28Reference> 35: [http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic230-220-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph28-1A-Subparagraph\(a\)](http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic230-220-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph28-1A-Subparagraph(a))- Publisher FASB- URI <https://asc.fasb.org/1943274/2147482740-2147482790/230-220-10-45-28Reference-1AReference> 36: [http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic942-SubTopic220-SubTopic10-NameAccountingStandardsCodification-Section45-S99-Paragraph1B-1-Subparagraph\(a-SX210.9-04\(22\)\)](http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic942-SubTopic220-SubTopic10-NameAccountingStandardsCodification-Section45-S99-Paragraph1B-1-Subparagraph(a-SX210.9-04(22)))- Publisher FASB- URI [https://asc.fasb.org/1943274/2147478524-2147482790/220-10-45-220-10-45-220-S99-1-DetailsName:us-gaap\\_NetIncomeLossNamespacePrefix:us-gaap\\_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:durationX-DefinitionThecashoutflowtoacquirecommonstockduringthepreferencereference1](https://asc.fasb.org/1943274/2147478524-2147482790/220-10-45-220-10-45-220-S99-1-DetailsName:us-gaap_NetIncomeLossNamespacePrefix:us-gaap_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:durationX-DefinitionThecashoutflowtoacquirecommonstockduringthepreferencereference1): [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Topic230-SubTopic10-Section45-Paragraph15-Subparagraph\(a\)](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Topic230-SubTopic10-Section45-Paragraph15-Subparagraph(a))- Publisher FASB- URI [https://asc.fasb.org/1943274/2147482740/230-10-45-15-DetailsName:us-gaap\\_PaymentsForRepurchaseOfCommonStockNamespacePrefix:us-gaap\\_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:durationX-DefinitionThecashoutflowassociatedwiththeacquisitionoflong-lived,physicalassetsthatareusedinthenormalconductofbusiness toproducegoodsandservicesandnotintendedforresale;includescashoutflowst topayforconstructionofself-constructedassets](https://asc.fasb.org/1943274/2147482740/230-10-45-15-DetailsName:us-gaap_PaymentsForRepurchaseOfCommonStockNamespacePrefix:us-gaap_DataType:xbrli:monetaryItemTypeBalanceType:creditPeriodType:durationX-DefinitionThecashoutflowassociatedwiththeacquisitionoflong-lived,physicalassetsthatareusedinthenormalconductofbusiness toproducegoodsandservicesandnotintendedforresale;includescashoutflowst topayforconstructionofself-constructedassets). Referencereference1: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph13-Subparagraph\(c\)](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph13-Subparagraph(c))- Publisher FASB- URI [https://asc.fasb.org/1943274/2147482740/230-10-45-13-DetailsName:us-gaap\\_PaymentsToAcquirePropertyPlantAndEquipmentNamespacePrefix:us-gaap\\_DataType:xbrli:monetaryItemTypeBalanceType:credit10-S99-1-DetailsName:us-gaap\\_CommonStockNoParValueNamespacePrefix:us-gaap\\_DataType:durationX-DefinitionThecashinflowfromtheadditionalcapitalcontributiontoissuanceofalong-termdebtinstrumentwhichcanbeexchangedforaspecifiedamountofanothersecurity,typicallytheentity'scommonstock,attheoptionoftheissuerortholder](https://asc.fasb.org/1943274/2147482740/230-10-45-13-DetailsName:us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentNamespacePrefix:us-gaap_DataType:xbrli:monetaryItemTypeBalanceType:credit10-S99-1-DetailsName:us-gaap_CommonStockNoParValueNamespacePrefix:us-gaap_DataType:durationX-DefinitionThecashinflowfromtheadditionalcapitalcontributiontoissuanceofalong-termdebtinstrumentwhichcanbeexchangedforaspecifiedamountofanothersecurity,typicallytheentity'scommonstock,attheoptionoftheissuerortholder). Referencereference1: [http://www.fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic230-SubTopic10-Section45-Paragraph14-Subparagraph\(a-b\)-SubTopic10-Topic230](http://www.fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic230-SubTopic10-Section45-Paragraph14-Subparagraph(a-b)-SubTopic10-Topic230)- Publisher FASB- URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14>

Details Name: us-gaap\_ProceedsFromIssuanceOfCommonStock gaap\_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Definition Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph14-Subparagraph\(a\)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph14-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-14) Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2A-Subparagraph\(a\)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2A](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2A-Subparagraph(a)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2A) Details Name: us-gaap\_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Definition Amount of noncash expense for share-based payment arrangement. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(a\)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482740/230-10-45-28) Details Name: us-gaap\_ShareBasedCompensation Namespace Prefix: us-gaap\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Definition The increase (decrease) during the reporting period in deferred tax liability. References No definition available. Details Name: xbit\_IncreaseDecreaseInDeferredTaxLiability Namespace Prefix: xbit\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Definition The amount of cash inflows from the maturity of interest bearing time deposits. References No definition available. Details Name: xbit\_ProceedsFromMaturityOfInterestBearingTimeDeposits Namespace Prefix: xbit\_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Details Name: us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis = us-gaap\_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_RelatedPartyTransactionsByRelatedPartyAxis = us-gaap\_NonrelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: Insider Trading Arrangements 12 Months Ended Dec. 31, 2024 Dec. 31, 2023 Trading Arrangements, by Individual [ Table ] Material Terms of Trading Arrangement [ Text Block ] ITEM 9B. OTHER INFORMATION None. Rule 10b5-1 Arrangement Adopted [ Flag ] false Non-Rule 10b5-1 Arrangement Adopted [ Flag ] false Rule 10b5-1 Arrangement Terminated [ Flag ] false Non-Rule 10b5-1 Arrangement Terminated [ Flag ] false X- References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameRegulationS-K-Number229-Section408-Subsectiona-Paragraph1> Details Name: ecd\_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd\_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationX- References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameRegulationS-K-Number229-Section408-Subsectiona-Paragraph1> Details Name: ecd\_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd\_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX- References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameRegulationS-K-Number229-Section408-Subsectiona-Paragraph1> Details Name: ecd\_NonRule10b51ArrTrmtdFlag Namespace Prefix: ecd\_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX- References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameRegulationS-K-Number229-Section408-Subsectiona-Paragraph1> Details Name: ecd\_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd\_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX- References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameRegulationS-K-Number229-Section408-Subsectiona-Paragraph1> Details Name: ecd\_TradingArrByIndTable Namespace Prefix: ecd\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration Cybersecurity Risk Management and Strategy Disclosure 12 Months Ended Dec. 31, 2024 Cybersecurity Risk Management, Strategy, and Governance [ Line Items ] Cybersecurity Risk Management Processes Integrated [ Flag ] true Cybersecurity Risk Management Processes Integrated [ Text Block ] We employ processes and tools for assessing, identifying, and managing material risks from cybersecurity threats. These processes and tools are intended to help protect our information assets from internal and external threats and protect the integrity and confidentiality of our data. Our processes and tools include procedural and technical safeguards, response plans, and reviews of our policies. We employ experienced information technology personnel to deploy and oversee these safeguards and to consult with members of our senior management team, including our Chief Executive Officer and our Principal Financial Officer and Principal Accounting Officer, regarding cybersecurity matters when appropriate. Our Audit Committee is provided an opportunity during each quarterly meeting to inquire regarding material cybersecurity threats, deficiencies, and other issues in discussion with members of management. We provide all employees and consultants with cybersecurity and prevention training. Cybersecurity Risk Management Third Party Engaged [ Flag ] false Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [ Flag ] false Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [ Text Block ] As of the date of this Annual Report, we are not aware of any risks from cybersecurity threats, including because of any previous cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. Cybersecurity Risk Management Positions or Committees Responsible [ Flag ] true Cybersecurity Risk Management Positions or Committees Responsible Report to Board [ Flag ] true X- References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameRegulationS-K-Section106-Subsectionc-Paragraph2-Subparagraphi> Reference 2: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm20-F-Section16K-Subsectionc-Paragraph2-Subparagraphi> Details Name: cyd\_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag Namespace Prefix: cyd\_ Data Type: i:booleanItemType Balance Type: na Period Type: durationX- References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameRegulationS-K-Section106-Subsectionc-Paragraph2-Subparagraphiii> Reference 2: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm20-F-Section16K-Subsectionc-Paragraph2-Subparagraphiii> Details Name: cyd\_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag Namespace Prefix: cyd\_ Data Type: i:booleanItemType Balance Type: na Period Type: durationX- References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameRegulationS-K-Section106-Subsectionb-Paragraph1-Subparagraphi> Reference 2: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm20-F-Section16K-Subsectionb-Paragraph1-Subparagraphi> Details Name: cyd\_CybersecurityRiskManagementProcessesIntegratedFlag Namespace Prefix: cyd\_ Data Type: i:booleanItemType Balance Type: na Period Type: durationX- References Reference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameRegulationS-K-Section106-Subsectionb-Paragraph1-Subparagraphi>

Subparagraph iReference 2: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 20- F- Section 16K- Subsection b- Paragraph 1- Subparagraph i> Details Name: cyd\_CybersecurityRiskManagementProcessesIntegratedTextBlock Namespace Prefix: cyd\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Regulation S- K- Section 106>Reference 2: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 20- F- Section 16K> Details Name: cyd\_CybersecurityRiskManagementStrategyAndGovernanceLineItems Namespace Prefix: cyd\_ Data Type: i: stringItemType Balance Type: na Period Type: durationX- ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Regulation S- K- Section 106- Subsection b- Paragraph 1- Subparagraph ii>Reference 2: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 20- F- Section 16K- Subsection b- Paragraph 1- Subparagraph ii> Details Name: cyd\_CybersecurityRiskManagementThirdPartyEngagedFlag Namespace Prefix: cyd\_ Data Type: i: booleanItemType Balance Type: na Period Type: durationX- ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Regulation S- K- Section 106- Subsection b- Paragraph 2>Reference 2: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 20- F- Section 16K- Subsection b- Paragraph 2> Details Name: cyd\_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag Namespace Prefix: cyd\_ Data Type: i: booleanItemType Balance Type: na Period Type: durationX- ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Regulation S- K- Section 106- Subsection b- Paragraph 2>Reference 2: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC- Name Form 20- F- Section 16K- Subsection b- Paragraph 2> Details Name: cyd\_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock Namespace Prefix: cyd\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationNote 1- Organization 12 Months Ended Dec. 31, 2023-2024 Notes to Financial Statements Organization, Consolidation and Presentation of Financial Statements Disclosure [ Text Block ] 1. Organization XBiotech Inc. (“XBiotech” or the “Company”) was incorporated in Canada on March 22, 2005. The Company’s headquarters are located in Austin, Texas. XBiotech USA, Inc., a wholly- owned subsidiary of the Company, was incorporated in Delaware, United States in November 2007. XBiotech Germany GmbH, a wholly- owned subsidiary of the Company, was incorporated in Germany in January 2014. XBiotech Germany GmbH was dissolved in February 2023. Since its inception, XBiotech has focused on advancing technology to rapidly identify and clone antibodies from individuals that have resistance to disease. At the heart of the Company is a proprietary technical knowhow to translate natural human immunity into therapeutic product candidates. The Company has in its pipeline both anti- infective and anti- inflammatory candidate therapeutics derived from this technology. An area of medical focus for XBiotech are therapies that block a potent substance naturally produced by body, known as interleukin- 1 alpha (IL- 1a), that mediates tissue breakdown, angiogenesis, the formation of blood clots and inflammation. IL- 1a is a protein that is on or in cells of the body and is involved in the body’s response to injury or trauma. In almost all chronic and in some acute injury scenarios (such as stroke or heart attack), IL- 1a may mediate harmful disease- related activity. At the end of 2019, XBiotech sold a True Human™ antibody that blocked IL- 1a activity for \$ 750 million in cash and up to \$ 600 million in potential milestone payments (the “Janssen Transaction”). **The potential milestone payments are contingent upon achieving. On February 2, 2022, XBiotech announced an addendum to the required commercialization authorization for a product intended 2019 Janssen Manufacturing Agreement. XBiotech continued to manufacture Bemekimab for use in any non- dermatological indication by Janssen in its clinical trials through November within twelve years. As of December 31, 2022-2024, none of the milestone payments have been earned.** As part of the Janssen Transaction, XBiotech maintained the right to develop new antibodies that block IL- 1a and develop these therapeutics in all areas of medicine except dermatology. Moreover, **Janssen agreed that they would assert all patents they acquired by Janssen relating to IL- 1a would be asserted for the benefit of XBiotech to protect its-our future IL- 1a related therapies in all non- dermatological indications. Consequently, XBiotech is pursuing using its the development of other True Human™ antibodies targeting IL- 1a for areas of medicine outside of dermatology. The Company’s True Human™ antibody discovery technology has been used to identify and develop new IL- 1a targeting product candidates and has already brought one such candidate into a clinical studies in oncology and rheumatology; and another unique anti- IL- 1a antibody into a Phase I study in neurology . While the Company previously was focused on a single True Human™ antibody targeting IL- 1a, it is now developing more than one product candidate that targets IL- 1a to be used in different areas of medicine.** The Company is subject to a number of risks common to companies in clinical stage of development. Principal among these risks are the uncertainties of technological innovations, dependence on key individuals, development of the same or similar technological innovations by the Company’s competitors and protection of proprietary technology. The Company’s ability to fund its planned clinical operations, including completion of its planned trials, is expected to depend on the amount and timing of cash receipts from future collaboration or product sales and / or financing transactions. The Company believes that its cash and cash equivalents of \$ 200-172. 0-7 million at December 31, 2023-2024, will enable the Company to achieve several major inflection points, including completion of clinical studies with lead product candidates. The Company expects to have sufficient cash through at least 12 months from the date of this report. X- ReferencesNo definition available. Details Name: us- gaap\_ DisclosureTextBlockAbstract Namespace Prefix: us- gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef- Topic 946- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 1- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480424/946-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef- Topic 946- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480424/946-10-50-2>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef- Topic 810- Name Accounting Standards Codification- Publisher FASB- URI https://asc.fasb.org/#810/tableOfContent>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef- Topic 205- Name Accounting Standards Codification- Publisher FASB- URI https://asc.fasb.org/#205/tableOfContent> Details Name: us- gaap\_ OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us- gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationNote 2- Significant Accounting Policies 12 Months Ended Dec. 31, 2023-2024 Notes to Financial Statements Significant Accounting Policies [ Text Block ] 2. Significant Accounting Policies Basis of Presentation These consolidated financial statements have been prepared in conformity with U. S. Generally Accepted Accounting Principles (“US GAAP”). In the opinion of management, the accompanying consolidated financial statements reflect all adjustments (consisting only of normal recurring items) considered necessary to present fairly the Company’s financial position at December 31, 2024 and 2023 and 2022, the results of its operations and comprehensive loss for the years ended December 31, 2024, and 2023, and 2022, and the cash flows for the years ended December 31, 2024, and 2023, and 2022. Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly- owned subsidiaries. All significant intercompany transactions have been eliminated upon

consolidation. Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the U. S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.

**Revenue** Revenue from the Janssen Agreements The Company recognized revenues from its Janssen Agreements as follows: The Company entered into its clinical manufacturing and clinical trial services arrangements in connection with its sale of certain intellectual property on December 30, 2019. These contracts commenced January 1, 2020. The Company executed an addendum related to manufacturing agreement, which generated revenue through November 2022. While these agreements are not considered contracts with a customer based on the terms thereof, the Company has applied the revenue recognition guidance by analogy. XBiotech is still in the research and development phase. The eventual output of the Company's intended ordinary activities will be the licensing of intellectual property and / or sale of commercialized compounds for use in pharmaceutical treatment of disease, not the performance of manufacturing of development stage compounds or clinical trials for others. Although Janssen was not a customer, as these services are not the output of XBiotech's ordinary activities, the Company evaluated the terms of the agreements and analogized to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers ("ASC 606") for clinical manufacturing and clinical trial services revenue recognition. Under ASC 606, an entity recognizes revenue when (or as) its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606 (or for those analogized to it), the Company performs the following five steps: (i) identify the contract (s) with a customer ; (ii) identify the performance obligations in the contract ; (iii) determine the transaction price ; (iv) allocate the transaction price to the performance obligations in the contract ; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts (including by analogy) when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the counterparty. At contract inception, once the contract is determined to be within the scope of or analogized to ASC 606, the Company assesses the goods or services promised within each contract and determine those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Manufacturing Revenue The Company had a Clinical Manufacturing Agreement that it accounted for by analogy to ASC 606. In 2022 the Company executed a new manufacturing agreement with a Janssen related company. The agreement generated \$ 4. 0 million in revenue through termination in November 2022.

**Research and Development Costs** All research and development costs are charged to expense as incurred. Research and development costs include salaries and personnel- related costs, consulting fees, fees paid for contract clinical trial research services, the costs of laboratory consumables, equipment and facilities, license fees and other external costs. Costs incurred to acquire licenses for intellectual property to be used in research and development activities with no alternative future use are expensed as incurred as research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Clinical Trial Accruals Expense accruals related to clinical trials are based on actual the Company's estimates of services received and efforts expended pursuant to contracts with third party service providers that which conduct and manage clinical trials on the Company's behalf. The financial terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing The Company accrues costs based on the Company estimates actual services rendered in the period over which services were will be performed and the level of effort to be expended in each period based upon patient enrollment, clinical site activations, or information provided to the Company by its vendors on their actual costs incurred. Any estimates of the level of services performed or the costs of these services could differ from actual results.

**Income Taxes** In December 2023, the FASB issued..... s consolidated financial statements and disclosures. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company measures deferred tax assets and liabilities using the enacted tax rates for the years and jurisdictions in which the temporary differences are expected to be recovered. A change to the tax rates used to measure the Company's deferred taxes is recognized in income during the period in which the new rate (s) were enacted. The Company recognizes deferred tax assets to the extent the Company's assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including the future reversals of existing taxable temporary differences, projected future taxable income exclusive of reversing temporary differences and carryforwards, tax- planning strategies, taxable income in prior carryback years if permitted under tax law, and the results from prior years. If the Company determines it is more likely than not, that all or a portion of a deferred tax asset will not be realized a valuation allowance is recorded with a charge to income tax expense. Alternatively, if the Company determines that all or a portion of a deferred tax asset previously not meeting the more likely than not threshold will be realized, the Company reduces its valuation allowance and recognizes a benefit in income tax expense. The Company recognizes and measures uncertain tax benefits in accordance with ASC 740 based on a two- step process in which (1) the Company determines whether it is more likely than not that the tax position will be sustained based on the technical merits of the position, and (2) for those tax positions that meet the more- likely- than- not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than fifty percent likely to be realized upon ultimate settlement with the related tax authority. The Company's policy is to recognize interest and penalties, if any, in income tax expense.

**Share- Based Compensation** The Company accounts for its share- based compensation awards in accordance with ASC Topic 718, Compensation- Stock Compensation ("ASC 718"). ASC 718 requires all share- based payments to employees, including grants of employee stock options, to be recognized in the statements of operations based on their grant date fair values. For stock options granted to employees and to members of the board of directors for their services on the board of directors, the Company estimates the grant date fair value of each option award using the Black- Scholes option- pricing model. The use of the Black- Scholes option- pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk- free interest rates, and expected dividend yields of the common stock. To determine the fair value of its common stock, the Company uses the closing price of the Company's common stock as reported by NASDAQ. For awards subject to service- based vesting conditions, the Company recognizes share- based compensation expense, equal to the grant date fair value of stock options, on a straight- line basis over the requisite service period. The Company accounts for forfeitures as they occur rather than on an estimated basis. Share- based compensation expense recognized for the years ended December 31, 2024, and 2023, and 2022 was included in the following line items on the consolidated Consolidated statements Statements of operations Operations (in thousands). Year Ended December 31, Research and development \$ 1, 127 \$ 2, 797 \$ 3, 641 General and administrative 1, 421 Total share- based compensation expense \$ 1, 753 \$ 3, 262 \$ 5, 062 The fair value

of each option is estimated on the date of grant using the Black- Scholes method with the following assumptions: Year Ended December 31, Weighted- average grant date fair value per share \$ ~~3.96~~ \$ ~~2.89~~ \$ ~~4.92~~ Expected volatility ~~79 % - 83 %~~ 80 % - 82 % ~~82 % - 83 %~~ Risk- free interest rate ~~3.6 % - 4.4 %~~ ~~3.3 % - 4.6 %~~ ~~1.5 % - 4.1 %~~ Expected life (in years) ~~5.38 - 6.25~~ ~~5.38 - 6.25~~ Dividend yield-- Cash and Cash Equivalents The Company considers highly liquid investments with a maturity of 90 days or less when purchased to be cash equivalents. Cash and cash equivalents consisted primarily of cash on deposit in U. S., German, and Canadian banks. Cash and cash equivalents are stated at cost which approximates fair value. Interest Bearing Time Deposits **During As of December 31, 2022-2023**, the Company held guaranteed investment certificates ~~from with~~ a financial institution. The guaranteed investment certificates had a 12 -month term at origination with interest ~~payable~~ **receivable** at maturity. The **guaranteed investment certificates matured** ~~Company obtained both the principal amount and accrued interest~~ in July 2023 ~~upon maturity~~. **There has been no related activity in 2024**. Concentrations of Credit Risk Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly- rated financial institutions, and limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off- balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements. Fair Value Measurements The consolidated financial statements include financial instruments for which the fair value of such instruments may differ from amounts reflected on a historical cost basis. Financial instruments of the Company consist of cash deposits, time deposits, accounts and other receivables, accounts payable, and certain accrued liabilities. These financial instruments are held at cost, which generally approximates fair value due to their short- term nature. The Company follows ASC Topic 820, Fair Value Measurements and Disclosures, which establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market date (observable inputs) and the Company' s own assumptions (unobservable inputs). The hierarchy consists of three levels: ~~•~~ Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities. ~~•~~ Level 2 — Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. ~~•~~ Level 3 — Unobservable inputs that reflect the Company' s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. At December 31, **2024 and 2023 and 2022**, the Company did not have any assets or liabilities that are measured at fair value on a recurring basis. The carrying amounts reflected in the consolidated balance sheets for cash and cash equivalents, ~~interest bearing time deposits~~, prepaid expenses and other current assets, accounts payable, and accrued expenses **and debt** approximate their fair values at December 31, **2024 and 2023 and 2022**, ~~due to their short- term nature~~. Property and Equipment Property and equipment, which consists of land, construction in process, furniture and fixtures, computers and office equipment, scientific equipment, ~~leasehold improvements~~, vehicles, **mobile facility** and building are stated at cost and depreciated ~~using the straight- line method~~ over the estimated useful lives of the assets, with the exception of land and construction in process which are not depreciated, **using the straight line method**. The useful lives are as follows: ~~•~~ Furniture and fixtures ~~7- fixtures 7 years~~ ~~•~~ Office equipment ~~5- equipment years~~ ~~•~~ Scientific equipment ~~5 years~~ ~~•~~ Vehicles ~~5 years~~ ~~•~~ Mobile facility ~~27- 5 years~~ ~~•~~ **Scientific equipment 5 years • Vehicles 5 years • Mobile facility 27.5 years • Building 39** ~~years~~ Costs of major additions and betterments are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized. Impairment of Long- Lived Assets The Company periodically evaluates its long- lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment. Potential impairment is assessed when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The recoverability of these assets is assessed based on undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends and product development cycles. If impairments are identified, assets are written down to their estimated fair value. The Company has not recognized any impairment through December 31, ~~2023~~ **2024**. Foreign Currency Transactions Certain transactions are denominated in a currency other than the Company' s functional currency of the U. S. dollar, and the Company generates assets and liabilities that are fixed in terms of the amount of foreign currency that will be received or paid. At each balance sheet date, the Company adjusts the assets and liabilities to reflect the current exchange rate, resulting in a translation gain or loss. **The only significant assets denominated in a foreign currency were certain cash accounts, which were remeasured into the functional currency (U. S. dollar) as of the end of the year, resulting in a foreign exchange loss of \$ 5.5 million for the year ended by December 31, 2024 and a foreign exchange gain of \$ 1.9 million for the year ended by December 31, 2023.** The Transaction gains and losses are also realized upon a settlement of a foreign currency transaction in determining net loss for the period in which the transaction is settled. Comprehensive Income (Loss) ASC Topic 220, Comprehensive Income, requires that all components of comprehensive income (loss), including net income (loss), be reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non- owner sources, including foreign currency translation adjustments. Segment and Geographic Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision- making group, in making decisions on how to allocate resources and assess performance. The Company' s chief operating decision maker is the Chief Executive Officer. The Company and the chief operating decision maker view the Company' s operations and manage its business as one operating segment. Substantially all of the Company' s operations are in the U. S. geographic segment. Net ~~Income~~ / Loss per Share Net income / loss per share (" EPS ") is computed by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted EPS is computed by dividing net income / loss by the weighted average number of common shares and common share equivalents outstanding (if dilutive) during each period. The number of common share equivalents, which include stock options, is computed using the treasury stock method. **The Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti- dilutive. For the year ended December 31, 2024, all stock options were not included in the computation of diluted net loss per share, as the impact of these items was anti- dilutive. In addition, 1,921,828 shares of common stock issuable upon conversion of the related party convertible loan (which was the maximum convertible amount based on ownership restrictions) were excluded from the computation of diluted net loss per share as their impact is anti- dilutive. For the year ended December 31, 2023, all stock options were not included in the computation of diluted net loss per share, as the impact of these items was anti- dilutive.** Subsequent Events The Company considered events or transactions occurring after the balance sheet date but prior to the date the consolidated financial statements were available to be issued for potential recognition or disclosure in its consolidated financial statements. Recent Accounting Pronouncements Recently Issued Accounting Pronouncements

In **December 2023**, June 2016, the Financial Accounting Standard Board ("FASB") issued Accounting Standards Update ("ASU" or "standard") No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. Subsequently, the FASB issued several clarifying standard updates **ASU 2023-09, "Income Taxes (Topic 740): Improvements to clarify Income Tax Disclosures"** ("ASU 2023-09"), which enhances the transparency and improve decision usefulness of income tax disclosures. Adjustments to the annual disclosure of income taxes include: (1) A tabular rate reconciliation comprised of eight specific categories, (2) **Incomes- Income** taxes paid, disaggregated between significant **federal national**, state, and foreign jurisdictions, (3) Eliminates requirements to disclose the nature and estimate of reasonably possible changes to unrecognized tax benefits in the next 12 months or that an estimated range cannot be made, and (4) Adds a requirement to disclose income (or loss) from continuing operations before income tax expense (or benefit) and income tax expense (or benefit) from continuing operations disaggregated between domestic and foreign. The ASU **is effective for public business**. These ASUs significantly change how entities will measure credit losses for most financial assets **fiscal years beginning on or after December 15, 2024 with early adoption permitted. The amendments in ASU 2023-09 should be applied on a prospective basis and retrospective application** certain other instruments that are not measured at fair value through net income. The most significant change in this standard is **permitted** a shift from the incurred loss model to the expected loss model that will be based on an estimate of current expected credit loss ("CECL"). Under the standard, disclosures are required to provide users of the financial statements with useful information in analyzing an entity's exposure to credit risk and the measurement of credit losses. The Company adopted **is in process of evaluating** the standard effective January 1, **impact of adoption of ASU 2023-09 on**. The impact of the **Company's** adoption was not considered material to the consolidated financial statements and disclosures.

X- References No definition available. Details Name: us-gaap\_DisclosureTextBlockAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition The entire disclosure for all significant accounting policies of the reporting entity. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/+1943274/2147483426/235-10-50-1> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-235-Name-Accounting-Standards-Codification-Publisher-FASB-URI-https://asc.fasb.org/+235/tableOfContent> Details Name: us-gaap\_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationNote 3- Revenue 12 Months Ended Dec. ....: na Period Type: durationNote 4- Property and Equipment and Building Construction in Progress 12 Months Ended Dec. 31, **2023-2024** Notes to Financial Statements Property, Plant and Equipment Disclosure [Text Block] **4-3**. Property and Equipment and Building Construction in Progress Property and equipment consisted of the following as of December 31, **2024 and 2023 and 2022** (in thousands): Computer and office equipment \$ \$ Furniture and fixtures Land 1, 418 1, 418 Scientific equipment 16, **491 16,** 367 **16, 059 Vehicle Vehicles** Building 24, 173 24, 173 Mobile facility Construction in process **1, 705** Accumulated depreciation ( **19, 985**) ( 18, 239 ) ( 16, 495 ) \$ 24, **526 \$ 24,** 897 **\$ 26, 260** Depreciation expenses related to property and equipment amounted to approximately **both \$ 1. 7 million and \$ 2. 6 million**, for the years ended December 31, **2024, and 2023 , and 2022, respectively.** Construction in process is related to research and development and **manufactory manufacturing** equipment. Depreciation expense is **recorded to allocated between** research and development and general and administrative expense line items on the **Consolidated consolidated Statements statements** of Operations operations (in thousands). X- References No definition available. Details Name: us-gaap\_DisclosureTextBlockAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-360-Name-Accounting-Standards-Codification-Publisher-FASB-URI-https://asc.fasb.org/+360/tableOfContent> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-SubTopic-360-Topic-958-Publisher-FASB-URI-https://asc.fasb.org/+1943274/2147480321-2147477798/958-360-50-6> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(d\)-SubTopic-360-Topic-958-Publisher-FASB-URI-https://asc.fasb.org/+1943274/2147480321-2147477798/958-360-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(d)-SubTopic-360-Topic-958-Publisher-FASB-URI-https://asc.fasb.org/+1943274/2147480321-2147477798/958-360-50-1) Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-SubTopic-360-Topic-958-Publisher-FASB-URI-https://asc.fasb.org/+1943274/2147480321-2147477798/958-360-50-7> Details Name: us-gaap\_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap\_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationNote 5-4- Accrued Expenses 12 Months Ended Dec. 31, **2023-2024** Notes to Financial Statements Accounts Payable and Accrued Liabilities Disclosure [Text Block] **5-4**. Accrued Expenses Accrued expenses consist of the following as of December 31, **2024, and 2023 , and 2022** (in thousands): Accrued compensation and related expenses \$ \$ Accrued professional fees Accrued clinical trial expenses **1, 502 2, 826 Accrued convertible loan interest-** Other \$ **2, 632 \$ 3, 501 \$ 1, 603**-X- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02-\(20\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02-(20))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02-\(19-\(a\)-20-24\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02-(19-(a)-20-24))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 3- Definition Face (par) amount of debt instrument at time of issuance. References Reference 1: <http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic-835-720-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-45-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/+1943274/2147482900-2147483384/835-720-30-50-45-1> Reference 2-4: [http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic-470-210-SubTopic-20-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-1B-1-Subparagraph-\(SX-210.5-02-\(19\)\(a\)\)-Publisher-FASB-URI-https://asc.fasb.org/+1943274/2147481139/470-210-10-S99-1](http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic-470-210-SubTopic-20-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-1B-1-Subparagraph-(SX-210.5-02-(19)(a))-Publisher-FASB-URI-https://asc.fasb.org/+1943274/2147481139/470-210-10-S99-1) Details Name: us-gaap\_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us- URI https: **gaap** Data Type: **://asc-xbrli:monetaryItemType** Balance Type: **debit** Period Type: **instant**X- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions. References Reference 1: [http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic-405-740-SubTopic-40-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-1-Subparagraph-\(a\)-\(2\)-Publisher-FASB-URI-https://asc.fasb.org/+1943274/2147477092-2147482685/405-740-40-10-50-1](http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic-405-740-SubTopic-40-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-1-Subparagraph-(a)-(2)-Publisher-FASB-URI-https://asc.fasb.org/+1943274/2147477092-2147482685/405-740-40-10-50-1) Reference 6 Reference 6-2: [http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic-405-SubTopic-40-Name-Accounting-Standards-Codification-Topic-740-SubTopic-10-Section-50-Paragraph-8-1-Subparagraph-\(a\)-\(1\)-Publisher-FASB-URI-https://asc.fasb.org/+1943274/2147477092-2147482685/405-740-40-10-50-1](http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic-405-SubTopic-40-Name-Accounting-Standards-Codification-Topic-740-SubTopic-10-Section-50-Paragraph-8-1-Subparagraph-(a)-(1)-Publisher-FASB-URI-https://asc.fasb.org/+1943274/2147477092-2147482685/405-740-40-10-50-1) Reference 7-8 Details Name: **us** <http://www.xbrl.org/2003/role/disclosureRef-gaap-DeferredTaxAssetsUnrealizedCurrencyLosses> Namespace Prefix: us-gaap\_Data

Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_DisclosureTextBlockAbstract Namespace Prefix: us- gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationNote 6- Common Stock 12 Months Ended Dec. 31, ~~2023~~ **2024** Notes to Financial Statements Equity [ Text Block ] 6. Common Stock Pursuant to its Articles, the Company has an unlimited number of shares available for issuance with no par value. **During the year ended December 31, 2024, 50,767 shares of common stock were issued upon the exercise of stock options, at prices ranging from \$ 3.38 to \$ 5.62 per share, for total proceeds of \$ 200 thousand.** On May 17, 2023, XBiotech announced that it had commenced a “modified Dutch auction” tender offer to purchase up to \$ 80.0 million of its common shares, or such lesser number of common shares as are properly tendered and not properly withdrawn, at a price not less than \$ 3.80 nor greater than \$ 4.00 per common share, to the seller in cash. The tender offer expired on June 15, 2023. On June 20, 2023, the Company announced the final results of its “modified Dutch Auction” tender offer. The Company accepted for purchase 3,561 shares of its common stock, at a price of \$ 4.00 per share, for an aggregate cost of approximately \$ 14 thousand, excluding fees and expenses related to the tender offer. These shares represented an immaterial percent of the shares outstanding. ~~The These~~ repurchased shares were retired and have been classified to reduce common stock in the accompanying consolidated balance sheet as of December 31, 2023. During the year ended December 31, 2023, 1,250 shares of common stock were issued upon the exercise of stock options at a price of \$ 3.84 per share for total proceeds of \$ 4,800. ~~No stock options were exercised from January 1, 2022 through December 31, 2022.~~X- ReferencesNo definition available. Details Name: us-gaap\_DisclosureTextBlockAbstract Namespace Prefix: us- gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for equity. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-13)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph\(h\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph(h)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph14-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph14-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-14)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic235-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481062/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic235-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481062/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic235-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(d\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481062/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic235-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(d)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481062/946-235-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic505-NameAccountingStandardsCodification-Section50-Paragraph6-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481004/946-505-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic505-NameAccountingStandardsCodification-Section50-Paragraph6-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481004/946-505-50-6)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic815-SubTopic40-NameAccountingStandardsCodification-Section50-Paragraph6-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic815-SubTopic40-NameAccountingStandardsCodification-Section50-Paragraph6-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480237/815-40-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.3-04\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480008/505-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.3-04)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480008/505-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.4-08\(e\)\(1\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.4-08(e)(1))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480678/235-10-S99-1)Reference 10: <http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic505-NameAccountingStandardsCodification-PublisherFASB-URIhttps://asc.fasb.org/#505/tableOfContentReference11>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-13>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph\(g\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph(g)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-13)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph\(i\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph13-Subparagraph(i)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph14-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph14-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-14)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph14-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph14-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-14)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph16-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-16](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph16-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-16)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph18-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph18-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-18)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph18-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph18-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-18)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph18-Subparagraph\(d\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic505-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph18-Subparagraph(d)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481112/505-10-50-18)Details Name: us-gaap\_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us- gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationNote 7- Common Stock Options 12 Months Ended Dec. 31, ~~2023~~ **2024** Notes to Financial Statements Share- Based Payment Arrangement [ Text Block ] 7. Common Stock Options On November 11, 2005, the Board of Directors of the Company adopted the XBiotech Inc. 2005 Incentive Stock Option Plan (the “2005 Plan”), and on March 24, 2015, the **board Board of directors Directors** of the Company adopted the XBiotech Inc. 2015 Equity Incentive Plan (the “2015 Plan” **and, together with the 2005 Plan, the “Plans”**) pursuant to which the Company may grant incentive stock and non-qualified stock options to directors, officers, employees or consultants of the Company or an affiliate or other persons as the Compensation Committee may approve. All options under **both the** Plans will be non-transferable and may be exercised only by the participant, or in the event of the death of the participant, a legal representative until the earlier of the options’ expiration date or the first anniversary of the participant’s death, or such other date as may be specified by the Compensation Committee. The term of the options is at the discretion of the Compensation Committee, but may not exceed 10 years from the grant date. The options expire on the earlier of the expiration date or the date three months following the day on which the participant ceases to be an officer or employee of or consultant to the Company, or in the event of the termination of the participant with cause, the date of such termination. Options held by non-employee Directors have an exercise period coterminous with the term of the options. The number of common shares reserved for issuance to any one person pursuant to the 2005 Plan shall not, in aggregate, exceed 5% of the total number of outstanding common shares. The exercise price per common share under each option will be the fair market value of such shares

at the time of the grant. Upon stock option exercise, the Company issues new shares of common stock. A summary of changes in common stock options issued under the 2005 Plan and under the 2015 Plan is as follows: Options Exercise Price Weighted- Average Exercise Price Options outstanding at December 31, 2021 4, 656, 677 \$ 2. 71- \$ 21. 74 \$ 10. 68 Granted 152, 600 3. 65- 11. 25 7. 07 Exercised 128, 600 3. 38- 6. 04 4. 2. 12- 8. 89 Forfeitures (250, 375) 3. 27- 21. 74 12. 31 Options outstanding at December 31, 2022 4, 558, 902 \$ 2. 71- \$ 21. 74 \$ 10. 47 Granted 809, 600 3. 38- 6. 04 4. 2. 12- 8. 89 Exercised (1, 250) 3. 84 3. 84 Forfeitures (327, 734) 3. 84- 19. 09 10. 43 Options outstanding at December 31, 2023 5, 039, 518 \$ 2. 71- \$ 21. 74 \$ 9. 46 Granted 262, 000 4. 05- 11. 81 6. 31 Exercised (50, 767) 3. 38- 5. 62 3. 92 Forfeitures (919, 166) 3. 84- 19. 92 11. 52 Options outstanding at December 31, 2024 4, 331, 585 \$ 2. 71- \$ 21. 74 \$ 8. 89 The weighted average fair value of the options issued to directors, employees and consultants during the fiscal years ended December 31, 2024, and 2023, and 2022, was \$ 2. 3. 89- 9. 96 and \$ 4. 2. 92- 8. 89, respectively. The total intrinsic value of options exercisable and total options outstanding at December 31, 2023- 2024, was approximately \$ 50 thousand 2. 2 million and \$ 70 thousand 4. 1 million. The total intrinsic value of options exercisable and total options outstanding at December 31, 2022 was immaterial. The total fair value of options vested during the years ended December 31, 2024, and 2023, and 2022 was \$ 3. 1. 5- 6 million, and \$ 3. 5- 6 million, respectively. A summary of the activity in the Company's nonvested shares is as follows: Year Ended December 31, Shares Weighted Average Granted Date Fair Value Shares Weighted Average Granted Date Fair Value Nonvested at January 1, 571, 925 \$ 3. 30 429, 950 4. 50 \$ 8. 25 1, 131, 458 8. 59 Granted during the period 262, 000 3. 96 809, 600 2. 89 152, 600 4. 92 Vested during the period ( 502, 675) 3. 42 ( 569, 100) 6. 17 ( 716, 491) 7. 86 Forfeited during the period ( 73, 750) 4. 42 ( 98, 025) 5. 14 ( 137, 617) 9. 40 Nonvested at end of period 257, 500 \$ 3. 35 571, 925 2. 3. 30 429, 950 8. 25 As of December 31, 2023- 2024, there was approximately \$ 4. 0. 4 million of unrecognized compensation cost, related to stock options granted under the Plan which will be amortized to stock compensation expense over the next 1. 4- 0 years. The weighted- average remaining contractual term of outstanding options as of December 31, 2023- 2024 is 5. 39- 5 years. Total exercisable stock options as of December 31, 2023- 2024 is 4. 5- 1 million. The weighted- average exercise price of options exercisable as of December 31, 2023- 2024 is \$ 10. 9. 07- 15 per share and the weighted- average remaining contractual term is 4. 5. 93- 3 years. X- DefinitionThe entire disclosure for share- based payment arrangement. ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic718-NameAccountingStandardsCodification-PublisherFASB-URIhttps://asc.fasb.org/#718/tableOfContentReference3:http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(h\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(h)(2)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(i\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(i)(2)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(l\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(l)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480429/718-10-50-2)Details Name: us- gaap\_ DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us- gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us- gaap\_ DisclosureTextBlockAbstract Namespace Prefix: us- gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationNote 8- Net Loss Per Share 12 Months Ended Dec. 31, 2023- 2024 Notes to Financial Statements Earnings Per Share [ Text Block ] 8. Net Loss Per Share The following summarizes the computation of basic and diluted net income (loss) per share for the years ended December 31, 2024, and 2023, and 2022 (in thousands, except share and per share data): Year Ended December 31, Net loss \$ ( 38, 531) \$ ( 24, 557) \$ ( 32, 900) Weighted- average number of common shares — basic 30, 460, 980 30, 438, 459 30, 439, 275 Net loss per share — basic \$ ( 1. 26) \$ ( 0. 81) \$ ( 1. 08) Weighted- average number of common shares — diluted 30, 460, 980 30, 438, 459 30, 439, 275 Net loss per share — diluted \$ ( 1. 26) \$ ( 0. 81) \$ ( 1. 08) The following potentially dilutive securities outstanding, prior to the use of the treasury stock method or if- converted method, have been excluded from the computation of diluted weighted- average common shares outstanding, because including them would have had an anti- dilutive effect due to the losses reported. Year Ended December 31, Stock options 5, 039, 518 4, 558, 902 X- ReferencesNo definition available. Details Name: us- gaap\_ DisclosureTextBlockAbstract Namespace Prefix: us- gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for earnings per share. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482662/260-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482662/260-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic260-NameAccountingStandardsCodification-PublisherFASB-URIhttps://asc.fasb.org/#260/tableOfContentReference3:http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482662/260-10-50-2)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482662/260-10-50-3>Details Name: us- gaap\_ EarningsPerShareTextBlock Namespace Prefix: us- gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationNote 9- Income Taxes 12 Months Ended Dec. 31, 2023- 2024 Notes to Financial Statements Income Tax Disclosure [ Text Block ] 9. Income Taxes The components of income before income taxes are as follows (in thousands): Years Ended December 31, United States \$ ( 26, 313) \$ ( 27, 144) \$ ( 28, 161) Foreign ( 12, 250) 2, 831 ( 5, 427) Total \$ ( 38, 563) \$ ( 24, 313) \$ ( 33, 588) The components of the provision for income taxes are as follows for the years ended December 31, 2024, and 2023, and 2022 (in thousands): Current United States \$ ( 49) \$ Foreign ( 329) Total ( 32) Deferred United States-- Foreign ( 59) ( 816) Total ( 59) ( 816) Total income tax expense (benefit) \$ ( 32) \$ ( 688) The provision for income taxes differs from the amount computed by applying the Canada statutory rate to pre- tax income as follows for the years ended December 31, 2024, and 2023, and 2022: Income tax benefit computed at federal tax rate 27. 0 % 27. 0 % Foreign operations ( 3. 4) % ( 5. 4) % ( 4. 1) % Change in valuation allowance ( 22. 8) % ( 26. 1) % ( 14. 6) % Tax credits generated 7. 0 % 8. 6 % 3. 5 % Prior year adjustments 3. 0 % ( 2. 3) % 0. 4 % Changes in uncertain tax positions ( 0. 1) % ( 0. 4) % ( 0. 3) % Foreign exchange gain and loss ( 3. 9) % 2. 1 % ( 1. 6) % Stock compensation ( 1. 1) % ( 2. 4) % ( 2. 3) % Non- deductible compensation ( 5. 8) % ( 6. 8) % ( 5. 8) % Foreign Liquidation 0. 0 % 4. 5 % 0. 0 % Other 0. 2 % 0. 3 % ( Total 0. 1 2) % Total ( 1. 0) % 2. 0 % The effective tax rate for the year periods ended December 31, 2024 and December 31, 2023 varied from the Canadian statutory rate primarily due to losses in jurisdictions for which a valuation allowance is recorded and a benefit may not be recognized. The effective tax rate for the year ended December 31, 2022 varied from the Canadian statutory rate primarily due to losses in jurisdictions for which a valuation allowance is recorded and a benefit may not be recognized, a shift in income between jurisdictions related to certain transfer pricing

adjustments which impacted the benefit associated with available loss carrybacks, and non-deductible compensation. The tax effect of temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases that give rise to deferred tax assets and liabilities is as follows: Net operating loss carryforwards \$ 2,799 \$ 1,288 - Research and other credits 9,150 5,851 3,820 Stock based compensation 1,760 2,530 2,703 Capitalized research expenses 12,654 7,800 5,210 Share issuance costs - Accrued liabilities Foreign exchange-Deferred tax assets before valuation allowance 26,777 18,204 12,994 Valuation allowance (26,382) (17,576) (-11,225) Deferred tax assets 1,719 Depreciation Prepaid assets Uncollectible debts-Deferred tax liability 1,777 Net deferred tax asset (liability) \$ - (-59) For the year ended December 31, 2023-2024, the Company has a USA federal net operating loss carryforward of \$ 6.3. 2M which will carryforward indefinitely. The Company has \$ 6.9. 6M-4 million of USA federal research and development tax credits carryforwards which are presented in the financial statements net of \$ 1. 4M-7 million of related uncertain tax positions, which will begin to expire in 2037. In addition, the Company has \$ 0.1. 8M-8 million of Texas research and development tax credits carryforwards which are presented in the financial statements net of \$ 0. 2M-4M of related uncertain tax positions, which will begin to expire in 2042. **The Company has a Canada net operating loss carryforward of \$ 1. 6 million, which will begin to expire in 2044. This amount excludes the \$ 0. 3 million expected to be carried back to the 2023 tax year.** Also, after weighing all available and positive and negative evidence the Company determined a full valuation allowance for all jurisdictions was necessary. For the year ended December 31, 2023-2024, the Company has not recorded any outside basis difference deferrals given its intention to indefinitely reinvest earnings from its foreign operations. In addition, given the Company's estimated outside tax basis in its USA investment is in excess of book basis, **therefore** there is no unrecognized deferred tax liability. The Company is subject to income tax in multiple jurisdictions, including Canada, USA, and the state of Texas. The Company has Canadian, USA, and Texas income tax returns that are open to examination for the **2021, 2021, and 2020 -2020, and 2019** tax years, respectively. In addition, the utilization of tax carryforwards, from **periods-years** prior to those previously mentioned may also be audited by the taxing authorities once utilized. As a result, the Company continuously monitors its current and prior filing positions in order to determine if any unrecognized tax positions need to be recorded. The analysis involves considerable judgement and is based on the best information available. A reconciliation of the beginning and ending amount of unrecognized tax benefits as of December 31, **2024 and 2023 and 2022** are as follows (in thousands): Balance as of January 1 \$ 2,864-973 \$ 2,389-864 Additions based on tax positions related to the current year Additions for tax positions of prior years Reductions for tax positions of prior years (4) -Settlements & statute of limitations (305) (-536) -Balance at December 31 \$ 2-3. 973-434 \$ 2,864-973 The Company recognized interest and penalties related to unrecognized tax benefits of \$ 93-98 thousand and \$ 63-93 thousand as a component of income tax expense for the years ended December 31, **2024 and 2023 and 2022**, respectively. As of December 31, **2024 and December 31, 2023 and 2022**, there are **both** \$ 1. 7 million 7M and \$ 1. 6M, respectively, of unrecognized tax benefits that if recognized would affect the annual effective tax rate. In addition, it is reasonably possible that approximately \$ 0. 4M-1 million of the unrecognized tax benefits may be recognized in the next 12 months as a result of a lapse of the statute of limitations. No other positions are expected to significantly decrease within the next 12 months. X- ReferencesNo definition available. Details Name: us- gaap\_DisclosureTextBlockAbstract Namespace Prefix: us- gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-946-740-SubTopic-20-10> - Name Accounting Standards Codification- Section 50- Paragraph 13-12 - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480990-2147482685/946-740-20-10-50-13> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic-235-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-55-Paragraph-231-Subparagraph-\(SX-210-4-08-\(h\)-\(2\)\)](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic-235-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-55-Paragraph-231-Subparagraph-(SX-210-4-08-(h)-(2))) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480678-2147482663/235-740-10-S99-55-1-Reference-231-Reference-3>: <http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-12C-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482685/740-tableOfContentReference-10-50-12CReference-4>: <http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-14-12B-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482685/740-10-50-14Reference-12BReference-5>: <http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-270-Name-Accounting-Standards-Codification-Section-50-Paragraph-21-1-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482685-2147477891/740-10-270-50-21Reference-1Reference-6>: [http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-270-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-1-Subparagraph-\(SAB-Topic-6.1.5.Q1\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482526-2147479360/740-270-10-50-S99-1-Reference-7](http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-270-10-Name-Accounting-Standards-Codification-Section-50-S99-Paragraph-1-Subparagraph-(SAB-Topic-6.1.5.Q1)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482526-2147479360/740-270-10-50-S99-1-Reference-7): [http://www.xbrl.org/2003/role/disclosureRef-Topic-740-946-SubTopic-10-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-17-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482685-2147480990/740-946-10-20-50-17Reference-13Reference-8](http://www.xbrl.org/2003/role/disclosureRef-Topic-740-946-SubTopic-10-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-17-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482685-2147480990/740-946-10-20-50-17Reference-13Reference-8): [http://www.xbrl.org/2003/role/disclosureRef-Topic-740-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-SAB-TOPI-6.1.5-Q1-4-08-\(h\)-\(2\)\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147479360-2147480678/740-235-10-S99-1-Reference-9](http://www.xbrl.org/2003/role/disclosureRef-Topic-740-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-SAB-TOPI-6.1.5-Q1-4-08-(h)-(2))-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147479360-2147480678/740-235-10-S99-1-Reference-9): <http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Publisher-FASB-Namespace-Prefix-us-URI-https-gaap-Data-Type-://asc-xbrli:monetaryItemType-Balance-Type:debit-Period-Type:instantX-DefinitionAmount-before-allocation-of-valuation-allowances-of-deferred-tax-asset-attributable-to-deductible-temporary-differences-from-unrealized-losses-on-foreign-currency-transactions>. ReferencesReference 1: <http://www.xbrl.org/740/tableOfContentReference-10>: <http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef> - Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 14-6 - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482685/740-10-50-14Reference-6Reference-11-2>: <http://fasb-www.xbrl.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Name-Accounting-Standards-Codification-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-21-8> - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482685/740-10-50-21Reference-12-8> Details Name: us [http://www.xbrl.org/2003/role/disclosureRef-gaap-DeferredTaxAssetsUnrealizedCurrencyLosses-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-17-Subparagraph-\(b\)-Section-S99-Paragraph-2-Subparagraph-\(SAB-Topic-11-C\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147479360/740-10-S99-2Reference-10-14](http://www.xbrl.org/2003/role/disclosureRef-gaap-DeferredTaxAssetsUnrealizedCurrencyLosses-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-17-Subparagraph-(b)-Section-S99-Paragraph-2-Subparagraph-(SAB-Topic-11-C)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147479360/740-10-S99-2Reference-10-14): [http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482603/740-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482603/740-30-50-2) Details Name: us- gaap\_IncomeTaxDisclosureTextBlock Namespace Prefix: us- gaap\_ Data Type: dtl- types: textBlockItemType Balance Type: na Period Type: durationNote 10- Subsequent Event 12 Months Ended Dec. 31, 2023-2024 Notes to Financial Statements Subsequent Events [ Text

Block 10. Subsequent Event On January 3-31, 2024-2025, the Company entered into a Convertible Loan Agreement (the "Loan") with dated as of January 3, 2024, between XBiotech Inc. and John Simard, the Company's Founder, President, Chief Executive Officer, and Chairman. The Loan was terminated upon full repayment of the Loan and provides \$10 million in immediate funding for the construction of interest by the Company. As a new result, all conversion rights state-of-the-art research and development facility at the Company's property at 5217 Winnebago Lane in Austin, Texas. The Loan is secured by the real estate and cash holdings of the Company, with interest to accrue at a simple rate equal to eight percent per year and interest-only payments to be made at six-month intervals after the Loan is funded. At Mr. Simard's election, the balance may be converted to XBiotech stock at any time the Loan balance is outstanding at a fixed conversion price equal to the average Nasdaq Official Closing Price of the common stock (as reflected on Nasdaq.com) for the five trading days immediately preceding the signing of this Agreement, which is \$4.048 per share associated with. The conversion feature is subject to a 19.9% cap limiting the number of shares that could be converted under the Agreement based on Mr. Simard's total stock ownership in the Company at the time of conversion. The Loan were extinguished also allows Mr. Simard to obtain immediate cash repayment of the Loan balance at his election one year after the loan is funded or upon certain other conditions set forth in the Loan. The Loan was negotiated, evaluated, and approved on behalf of the Company by a committee of independent and disinterested directors.

X-ReferencesNo definition available. Details Name: us-gaap-DisclosureTextBlockAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic855-NameAccountingStandardsCodification-PublisherFASB-URIhttps://asc.fasb.org/#855/tableOfContentReference> 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic855-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483399/855-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic855-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483399/855-10-50-2) Details Name: us-gaap-SubsequentEventsTextBlock Namespace Prefix: us-gaap-Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationSignificant Accounting Policies durationNote 11-Selected Quarterly Financial Data (Unaudited Policies) 12 Months Ended Dec. 31, 2023-2024 Notes to Financial Statements Quarterly Financial Information..... Months Ended Dec. 31, 2023

Accounting Policies [ Abstract ] Basis of Accounting, Policy [ Policy Text Block ] Basis of Presentation These consolidated financial statements have been prepared in conformity with U. S. Generally Accepted Accounting Principles ("US GAAP"). In the opinion of management, the accompanying consolidated financial statements reflect all adjustments (consisting only of normal recurring items) considered necessary to present fairly the Company's financial position at December 31, 2024 and 2023 and 2022, the results of its operations and comprehensive loss for the years ended December 31, 2024, and 2023, and 2022, and the cash flows for the years ended December 31, 2024, and 2023, and 2022. Consolidation, Policy [ Policy Text Block ] Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions have been eliminated upon consolidation. Use of Estimates, Policy [ Policy Text Block ] Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the U. S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates. Revenue from Contract with Customer [ Policy Text Block ] Revenue Revenue from the Janssen Agreements The Company recognized revenues from its Janssen Agreements as follows: The Company entered into its clinical manufacturing and clinical trial services arrangements in connection with its sale of certain intellectual property on December 30, 2019. These contracts commenced January 1, 2020. The Company executed an addendum related to manufacturing agreement, which generated revenue through November 2022. While these agreements are not considered contracts with a customer based on the terms thereof, the Company has applied the revenue recognition guidance by analogy. XBiotech is still in the research and development phase. The eventual output of the Company's intended ordinary activities will be the licensing of intellectual property and/or sale of commercialized compounds for use in pharmaceutical treatment of disease, not the performance of manufacturing of development stage compounds or clinical trials for others. Although Janssen was not a customer, as these services are not the output of XBiotech's ordinary activities, the Company evaluated the terms of the agreements and analogized to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers ("ASC 606") for clinical manufacturing and clinical trial services revenue recognition. Under ASC 606, an entity recognizes revenue when (or as) its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606 (or for those analogized to it), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts (including by analogy) when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the counterparty. At contract inception, once the contract is determined to be within the scope of or analogized to ASC 606, the Company assesses the goods or services promised within each contract and determine those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Manufacturing Revenue The Company had a Clinical Manufacturing Agreement that it accounted for by analogy to ASC 606. In 2022 the Company executed a new manufacturing agreement with a Janssen related company. The agreement generated \$4.0 million in revenue through termination in November 2022. Research and Development Expense, Policy [ Policy Text Block ] Research and Development Costs All research and development costs are charged to expense as incurred. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract clinical trial research services, the costs of laboratory consumables, equipment and facilities, license fees and other external costs. Costs incurred to acquire licenses for intellectual property to be used in research and development activities with no alternative future use are expensed as incurred as research and development costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Clinical Trial Accruals [ Policy Text Block ] Clinical Trial Accruals Expense accruals related to clinical trials are based on actual the Company's estimates of services received and efforts expended pursuant to contracts with third party service providers that which conduct and manage clinical trials on the Company's behalf. The financial terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing The Company accrues costs, based on the Company estimates actual

**services rendered in** the period over which services **were** will be performed and the level of effort **to be** expended in each period based upon patient enrollment, clinical site activations, or information provided to the Company by its vendors on their actual costs incurred. Any estimates of the level of services performed or the costs of these services could differ from actual results. Income Tax, Policy [ Policy Text Block ] Income Taxes **In December 2023, the FASB issued..... s consolidated financial statements and disclosures.** The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company measures deferred tax assets and liabilities using the enacted tax rates for the years and jurisdictions in which the temporary differences are expected to be recovered. A change to the tax rates used to measure the Company' s deferred taxes is recognized in income during the period in which the new rate (s) were enacted. The Company recognizes deferred tax assets to the extent the Company' s assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including the future reversals of existing taxable temporary differences, projected future taxable income exclusive of reversing temporary differences and carryforwards, tax- planning strategies, taxable income in prior carryback years if permitted under tax law, and the results from prior years. If the Company determines it is more likely than not, that all or a portion of a deferred tax asset will not be realized a valuation allowance is recorded with a charge to income tax expense. Alternatively, if the Company determines that all or a portion of a deferred tax asset previously not meeting the more likely than not threshold will be realized, the Company reduces its valuation allowance and recognizes a benefit in income tax expense. The Company recognizes and measures uncertain tax benefits in accordance with ASC 740 based on a two- step process in which (1) the Company determines whether it is more likely than not that the tax position will be sustained based on the technical merits of the position, and (2) for those tax positions that meet the more- likely- than- not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than fifty percent likely to be realized upon ultimate settlement with the related tax authority. The Company' s policy is to recognize interest and penalties, if any, in income tax expense. Share- Based Payment Arrangement [ Policy Text Block ] Share- Based Compensation The Company accounts for its share- based compensation awards in accordance with ASC Topic 718, Compensation- Stock Compensation (" ASC 718 "). ASC 718 requires all share- based payments to employees, including grants of employee stock options, to be recognized in the statements of operations based on their grant date fair values. For stock options granted to employees and to members of the board of directors for their services on the board of directors, the Company estimates the grant date fair value of each option award using the Black- Scholes option- pricing model. The use of the Black- Scholes option- pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk- free interest rates, and expected dividend yields of the common stock. To determine the fair value of its common stock, the Company uses the closing price of the Company' s common stock as reported by NASDAQ. For awards subject to service- based vesting conditions, the Company recognizes share- based compensation expense, equal to the grant date fair value of stock options, on a straight- line basis over the requisite service period. The Company accounts for forfeitures as they occur rather than on an estimated basis. Share- based compensation expense recognized for the years ended December 31, **2024, and 2023** ,and ~~2022~~ was included in the following line items on the ~~consolidated~~ **Consolidated statements Statements of operations-Operations** (in thousands). Year Ended December 31, Research and development \$ **1, 127 \$** ~~2, 797~~ ~~\$ 3, 641~~ General and administrative ~~1, 421~~ Total share- based compensation expense \$ **1, 753 \$** ~~3, 262~~ ~~\$ 5, 062~~ The fair value of each option is estimated on the date of grant using the Black- Scholes method with the following assumptions: Year Ended December 31, Weighted- average grant date fair value per share \$ **3. 96 \$** ~~2. 89~~ ~~\$ 4. 92~~ Expected volatility **79 %- 83 %** ~~80 %- 82 %~~ ~~82 %- 83 %~~ Risk- free interest rate ~~3. 6 %- 4. 4 %~~ **3. 3 %- 4. 6 %** ~~1. 5 %- 4. 1 %~~ Expected life (in years) ~~5. 38- 6. 25~~ ~~5. 38- 6. 25~~ Dividend yield-- Cash and Cash Equivalents, Policy [ Policy Text Block ] Cash and Cash Equivalents The Company considers highly liquid investments with a maturity of 90 days or less when purchased to be cash equivalents. Cash and cash equivalents consisted primarily of cash on deposit in U. S., German, and Canadian banks. Cash and cash equivalents are stated at cost which approximates fair value. Investment, Policy [ Policy Text Block ] Interest Bearing Time Deposits **During As of December 31, 2022-2023** ,the Company held guaranteed investment certificates ~~from with~~ a financial institution. The guaranteed investment certificates had a 12 -month term at origination with interest ~~payable~~ **receivable** at maturity. The **guaranteed investment certificates matured** Company obtained both the principal amount and accrued interest in July 2023 ~~upon maturity~~. **There has been no related activity in 2024**. Concentration Risk, Credit Risk, Policy [ Policy Text Block ] Concentrations of Credit Risk Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly- rated financial institutions, and limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off- balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements. Fair Value Measurement, Policy [ Policy Text Block ] Fair Value Measurements The consolidated financial statements include financial instruments for which the fair value of such instruments may differ from amounts reflected on a historical cost basis. Financial instruments of the Company consist of cash deposits, time deposits, accounts and other receivables, accounts payable, and certain accrued liabilities. These financial instruments are held at cost, which generally approximates fair value due to their short- term nature. The Company follows ASC Topic 820, Fair Value Measurements and Disclosures, which establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market date (observable inputs) and the Company' s own assumptions (unobservable inputs). The hierarchy consists of three levels: ● ~~Level 1~~ — Unadjusted quoted prices in active markets for identical assets or liabilities. ● ~~Level 2~~ — Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. ● ~~Level 3~~ — Unobservable inputs that reflect the Company' s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. At December 31, **2024 and 2023** and ~~2022~~, the Company did not have any assets or liabilities that are measured at fair value on a recurring basis. The carrying amounts reflected in the consolidated balance sheets for cash and cash equivalents, ~~interest bearing time deposits~~, prepaid expenses and other current assets, accounts payable, and accrued expenses **and debt** approximate their fair values at December 31, **2024 and 2023** and ~~2022~~, due to their short- term nature. Property, Plant and Equipment, Policy [ Policy Text Block ] Property and Equipment Property and equipment, which consists of land, construction in process, furniture and fixtures, computers and office equipment, scientific equipment, ~~leasehold improvements~~, vehicles, **mobile facility** and building are stated at cost and depreciated using the straight- line method over the estimated useful lives of the assets, with the exception of land and construction in process which are not depreciated, **using the straight line method**. The useful lives are as follows: ● ~~Furniture and fixtures 7- fixtures 7~~ years ● ~~Office equipment 5- equipment 5~~ years ● ~~Scientific equipment 5~~ years ● ~~Vehicles 5~~ years ● ~~Mobile facility 27. 5~~ years ● ~~Scientific equipment 5~~ years ● ~~Vehicles 5~~ years ● ~~Mobile facility 27. 5~~ years ● ~~Building 39~~ years

**Building 39** years Costs of major additions and betterments are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized. Impairment or Disposal of Long-Lived Assets, Policy [ Policy Text Block ] Impairment of Long- Lived Assets The Company periodically evaluates its long- lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment. Potential impairment is assessed when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The recoverability of these assets is assessed based on undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends and product development cycles. If impairments are identified, assets are written down to their estimated fair value. The Company has not recognized any impairment through December 31, 2023-2024. **Debt, Policy [ Policy Text Block ]** Foreign Currency Transactions and Translations Policy [ Policy Text Block ] Foreign Currency Transactions Certain transactions are denominated in a currency other than the Company' s functional currency of the U. S. dollar, and the Company generates assets and liabilities that are fixed in terms of the amount of foreign currency that will be received or paid. At each balance sheet date, the Company adjusts the assets and liabilities to reflect the current exchange rate, resulting in a translation gain or loss. **The only significant assets denominated in a foreign currency were certain cash accounts, which were remeasured into the functional currency (U. S. dollar) as of the end of the year, resulting in a foreign exchange loss of \$ 5. 5 million for the year ended by December 31, 2024 and a foreign exchange gain of \$ 1. 9 million for the year ended by December 31, 2023. The** Transaction gains and losses are also realized upon a settlement of a foreign currency transaction in determining net loss for the period in which the transaction is settled. Comprehensive Income, Policy [ Policy Text Block ] Comprehensive Income (Loss) ASC Topic 220, Comprehensive Income, requires that all components of comprehensive income (loss), including net income (loss), be reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non- owner sources, including foreign currency translation adjustments. Segment Reporting, Policy [ Policy Text Block ] Segment and Geographic Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision- making group, in making decisions on how to allocate resources and assess performance. The Company' s chief operating decision maker is the Chief Executive Officer. The Company and the chief operating decision maker view the Company' s operations and manage its business as one operating segment. Substantially all of the Company' s operations are in the U. S. geographic segment. Earnings Per Share, Policy [ Policy Text Block ] Net ~~Income~~ Loss per Share Net income / loss per share (" EPS ") is computed by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted EPS is computed by dividing net income / loss by the weighted average number of common shares and common share equivalents outstanding (if dilutive) during each period. The number of common share equivalents, which include stock options, is computed using the treasury stock method. **The Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti- dilutive. For the year ended December 31, 2024, all stock options were not included in the computation of diluted net loss per share, as the impact of these items was anti- dilutive. In addition, 1, 921, 828 shares of common stock issuable upon conversion of the related party convertible loan (which was the maximum convertible amount based on ownership restrictions) were excluded from the computation of diluted net loss per share as their impact is anti- dilutive. For the year ended December 31, 2023, all stock options were not included in the computation of diluted net loss per share, as the impact of these items was anti- dilutive. Subsequent Events, Policy [ Policy Text Block ] Subsequent Events The Company considered events or transactions occurring after the balance sheet date but prior to the date the consolidated financial statements were available to be issued for potential recognition or disclosure in its consolidated financial statements.** New Accounting Pronouncements, Policy [ Policy Text Block ] Recent Accounting Pronouncements Recently Issued Accounting Pronouncements In **December 2023** June 2016, the Financial Accounting Standard Board (" FASB ") issued Accounting Standards Update (" ASU " or " standard ") No. 2016- 13, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. Subsequently, the FASB issued several clarifying standard updates **ASU 2023- 09," Income Taxes (Topic 740): Improvements to clarify Income Tax Disclosures" (" ASU 2023- 09"), which enhances the transparency and improve decision usefulness of income tax disclosures. Adjustments to** the annual disclosure of income taxes include:(1) A tabular rate reconciliation comprised of eight specific categories,(2) ~~Incomes-~~ **Income** taxes paid,disaggregated between significant federal,national, state,and foreign jurisdictions,(3) Eliminates requirements to disclose the nature and estimate of reasonably possible changes to unrecognized tax benefits in the next 12 months or that an estimated range cannot be made,and (4) Adds a requirement to disclose income (or loss) from continuing operations before income tax expense (or benefit) and income tax expense (or benefit) from continuing operations disaggregated between domestic and foreign.The ASU **is effective for public business** .These ASUs significantly change how entities will measure credit losses for most financial assets **fiscal years beginning on or after December 15, 2024 with early adoption permitted. The amendments in ASU 2023- 09 should be applied on a prospective basis and retrospective application** certain other instruments that are not measured at fair value through net income. The most significant change in this standard is **permitted** a shift from the incurred loss model to the expected loss model that will be based on an estimate of current expected credit loss (" CECL "). Under the standard, disclosures are required to provide users of the financial statements with useful information in analyzing an entity' s exposure to credit risk and the measurement of credit losses. The Company adopted **is in process of evaluating** the standard effective January 1, **impact of adoption of ASU 2023 - 09 on** .The impact of the **Company' s adoption was not considered material to the consolidated financial statements and disclosures.** X- ReferencesNo definition available. Details Name: us- gaap\_ AccountingPoliciesAbstract Namespace Prefix: us- gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). ReferencesNo definition available. Details Name: us- gaap\_ BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us- gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity' s use of its cash and cash equivalents, (2) whether the entity' s cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. ReferencesReference 1: http: // fasb. org / us- gaap / role / ref / legacyRef- Name Accounting Standards Codification- Topic 230- SubTopic 10- Section 50- Paragraph 1- Publisher FASB- URI https: // asc. fasb. org / #1943274 / 2147482913 / 230- 10- 50- 1 Details Name: us- gaap\_ CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us- gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for comprehensive income. ReferencesNo definition available. Details

Name: us-gaap-ComprehensiveIncomePolicyPolicyTextBlock Namespace Prefix: us-gaap- Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for credit risk. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic942-SubTopic825-Section50-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480981-2147478898/> 942-825-50-1Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(d\)-SubTopic10-Topic275-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(d)-SubTopic10-Topic275-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482861/275-10-50-1) Details Name: us-gaap-ConcentrationRiskCreditRisk Namespace Prefix: us-gaap- Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic235-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph4-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef-Topic235-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph4-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483426/235-10-50-4)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic810-SubTopic10-Section50-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481203/810-10-50-1> Details Name: us-gaap-ConsolidationPolicyTextBlock ~~//1943274/2147480566/210-10-S99-1~~ Details Name: us-gaap-CommonStockNoParValue Namespace Prefix: us-gaap- Data Type: dtr- types: perShareItemType **textBlockItemType** Balance Type: na Period Type: **instantX-durationX** - Definition**The cash inflow from DefinitionDisclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the additional capital contribution to the entity effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.** ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-50-Paragraph1-Subparagraph\(a\)-SubTopic10-Topic230-470-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482740-2147481544/230-470-10-45-50-14-1](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-50-Paragraph1-Subparagraph(a)-SubTopic10-Topic230-470-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482740-2147481544/230-470-10-45-50-14-1) Details Name: us-gaap-DebtPolicyTextBlock **gaap-ProceedsFromIssuanceOfCommonStock** Namespace Prefix: us-gaap- Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. ReferencesReference 1: [http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph1-Subparagraph\(e-d\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482662/260-10-50-1](http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph1-Subparagraph(e-d)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482662/260-10-50-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph2-1-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482662/260-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph2-1-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482662/260-10-50-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph2-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482662/260-10-50-2> Details Name: us-gaap-EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap- Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. ReferencesNo definition available. Details Name: us-gaap-FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap- Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic830-NameAccountingStandardsCodification-PublisherFASB-URIhttps://asc.fasb.org/#830/tableOfContent> Details Name: us-gaap-ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix: us-gaap- Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic360-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph\(SABTopic5.CC\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480091/360-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic360-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph(SABTopic5.CC)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480091/360-10-S99-2)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section05-Paragraph4-SubTopic10-Topic360-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482338/360-10-05-4> Details Name: us-gaap-ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap- Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-740-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph3-Subparagraph\(SX210-20-6-03\(h\)\(1\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479886-2147482685/946-740-10-S99-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic946-740-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph3-Subparagraph(SX210-20-6-03(h)(1))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479886-2147482685/946-740-10-S99-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph19-17-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph19-17-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482685/740-10-50-17)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-45-Paragraph9-25-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482685-2147482525/740-10-50-45-9>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic740-946-SubTopic10-NameAccountingStandardsCodification-Section45-S99-Paragraph25-3-Subparagraph\(SX210-6-03\(h\)\(1\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482525-2147479886/740-946-10-45-S99-25](http://www.xbrl.org/2003/role/disclosureRef-Topic740-946-SubTopic10-NameAccountingStandardsCodification-Section45-S99-Paragraph25-3-Subparagraph(SX210-6-03(h)(1))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482525-2147479886/740-946-10-45-S99-25)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section45-50-Paragraph28-17-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482525-2147482685/740-10-45-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section45-50-Paragraph28-17-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482525-2147482685/740-10-45-50-28)Reference

**17Reference** 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph19-9> - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482685/740-10-50-19Reference-9Reference>

**9Reference** 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic220-740-SubTopic10-NameAccountingStandardsCodification-Section50-45-Paragraph1-28> - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482765-2147482525/740-10-45-28Reference8>

**Reference** 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic220-10-50-1Reference8>: <http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph20-1> - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482685-2147482765/740-220-10-50-20-1> Details Name: us-gaap\_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for investment in financial asset. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.7-04\(3\)\(b\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483586-2147477250/944-220-S99-1Reference2](http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.7-04(3)(b))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483586-2147477250/944-220-S99-1Reference2): [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph\(SX210.6-03\(d\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479886/946-10-S99-3Reference3](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph(SX210.6-03(d))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479886/946-10-S99-3Reference3): [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph\(SX210.6-03\(f\)\(1\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479886/946-10-S99-3Reference4](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph(SX210.6-03(f)(1))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479886/946-10-S99-3Reference4): [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph\(SX210.6-03\(f\)\(2\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479886/946-10-S99-3Reference5](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph(SX210.6-03(f)(2))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479886/946-10-S99-3Reference5): [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph\(SX210.6-03\(f\)\(3\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479886/946-10-S99-3Reference6](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph(SX210.6-03(f)(3))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479886/946-10-S99-3Reference6): [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic320-NameAccountingStandardsCodification-SectionS99-Paragraph12-Subparagraph\(i\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480032-2147477271/946-320-S99-12Reference7](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic320-NameAccountingStandardsCodification-SectionS99-Paragraph12-Subparagraph(i)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480032-2147477271/946-320-S99-12Reference7): [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic320-NameAccountingStandardsCodification-SectionS99-Paragraph19-Subparagraph\(2\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480032-2147477271/946-320-S99-19](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic320-NameAccountingStandardsCodification-SectionS99-Paragraph19-Subparagraph(2)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480032-2147477271/946-320-S99-19) Details Name: us-gaap\_InvestmentPolicyTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. ReferencesNo definition available. Details Name: us-gaap\_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for long- lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. ReferencesReference 1: <http://asc.fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph1-SubTopic10-Topic360-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482099/360-10-50-1Reference2>: [http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.7-03\(a\)\(8\)\(a\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479440-2147478777/944-210-S99-1Reference3](http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.7-03(a)(8)(a))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479440-2147478777/944-210-S99-1Reference3): <http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph6-SubTopic360-Topic958-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480321-2147477798/958-360-50-6Reference4>: [http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(d\)-SubTopic360-Topic958-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480321-2147477798/958-360-50-1](http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(d)-SubTopic360-Topic958-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480321-2147477798/958-360-50-1) Details Name: us-gaap\_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic730-SubTopic10-NameAccountingStandardsCodification-Section05-Paragraph1-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483044/730-10-05-1](http://www.xbrl.org/2003/role/disclosureRef-Topic730-SubTopic10-NameAccountingStandardsCodification-Section05-Paragraph1-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483044/730-10-05-1) Details Name: us-gaap\_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap\_ Data..... Details Name: us-gaap\_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for segment reporting. ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section55-50-Paragraph47-41-Subparagraph\(b-a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482785-2147482810/280-10-55-50-47Reference41Reference2](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section55-50-Paragraph47-41-Subparagraph(b-a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482785-2147482810/280-10-55-50-47Reference41Reference2): [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph29-47-Subparagraph\(d-bb\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482785/280-10-50-55-29Reference47Reference3](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph29-47-Subparagraph(d-bb)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482785/280-10-50-55-29Reference47Reference3): [http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph41-29-Subparagraph\(a-f\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810/280-10-50-41Reference29Reference4](http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph41-29-Subparagraph(a-f)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810/280-10-50-41Reference29Reference4): [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph29-54-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810-2147482785/280-10-50-55-29Reference54Reference5](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph29-54-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810-2147482785/280-10-50-55-29Reference54Reference5): [http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph36-29-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810/280-10-50-36Reference36Reference6](http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph36-29-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810/280-10-50-36Reference36Reference6): [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph29-47-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810-2147482785/280-10-50-55-29Reference47Reference7](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph29-47-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810-2147482785/280-10-50-55-29Reference47Reference7): [http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph29-Subparagraph\(e-d\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810/280-10-50-29Reference8](http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph29-Subparagraph(e-d)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810/280-10-50-29Reference8): [http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph29-Subparagraph\(e\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810/280-10-gaap\\_DataType:xbrli:monetaryItemTypeBalanceType:debitPeriodType:instantX-50-29Reference9](http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph29-Subparagraph(e)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810/280-10-gaap_DataType:xbrli:monetaryItemTypeBalanceType:debitPeriodType:instantX-50-29Reference9) DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions. ReferencesReference 1: <http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-740-SubTopic10->

Name Accounting Standards Codification- Section 50- Paragraph **6 29- Subparagraph (a)-** Publisher FASB- URI <https://asc.fasb.org/1943274/2147482810-2147482685/280-740-10-50-29>Reference **6Reference 10 2** :<http://fasb.www.xbrl.org/2003-us-gaap/role/ref/legacyRef> disclosureRef- Topic 280- SubTopic 10- Name Accounting Standards Codification- **Topic 740- SubTopic 10-** Section 50- Paragraph **8 29- Subparagraph (b)-** Publisher FASB- URI <https://asc.fasb.org/1943274/2147482810-2147482685/280-740-10-50-29>Reference **11 8 Details Name : us** [http://www.xbrl.org/2003/role/disclosureRef-gaap\\_DeferredTaxAssetsUnrealizedCurrencyLosses](http://www.xbrl.org/2003/role/disclosureRef-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses) Topic 280- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 29- Subparagraph- / 1943274 / 2147482810 / 280- 10- 50- 29 Details Name: us- gaap\_ SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us- gaap\_ Data Type: dt- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for award under share- based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(f\)\(12\)\(i\)-](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(f)(12)(i)-) Publisher FASB- URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(f\)\(2\)\(ii\)-](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(f)(2)(ii)-) Publisher FASB- URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(f\)\(2\)\(v\)-](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(f)(2)(v)-) Publisher FASB- URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(f\)\(2\)\(v\)-](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(f)(2)(v)-) Publisher FASB- URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SABTopic14.C.Q3\)-](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SABTopic14.C.Q3)-) Publisher FASB- URI <https://asc.fasb.org/1943274/2147479830/718-10-S99-1>Reference **5 6** : [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SABTopic14.D.1.Q5\)-](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SABTopic14.D.1.Q5)-) Publisher FASB- URI <https://asc.fasb.org/1943274/2147479830/718-10-S99-1>Reference **6 7** : [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SABTopic14.D.3.Q2\)-](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SABTopic14.D.3.Q2)-) Publisher FASB- URI <https://asc.fasb.org/1943274/2147479830/718-10-S99-1>Reference **7 8** : [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SABTopic14.D.2.Q6\)-](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SABTopic14.D.2.Q6)-) Publisher FASB- URI <https://asc.fasb.org/1943274/2147479830/718-10-S99-1>Reference **8 9** : <http://www.xbrl.org/2003/role/disclosureRef-Topic718-NameAccountingStandardsCodification-PublisherFASB-URIhttps://asc.fasb.org/718/tableOfContentReference910> : [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(b\)-](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(b)-) Publisher FASB- URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference **10 11** : [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(f\)\(12\)-](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(f)(12)-) Publisher FASB- URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(f\)\(2\)-](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(f)(2)-) Publisher FASB- URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> Details Name: us- gaap\_ ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us- gaap\_ Data Type: dt- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for reporting subsequent events. ReferencesNo definition available. Details Name: us- gaap\_ SubsequentEventsPolicyPolicyTextBlock Namespace Prefix: us- gaap\_ Data Type: dt- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic275-SubTopic10-Section50-Paragraph9-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482861/275-10-50-9>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic275-SubTopic10-Section50-Paragraph4-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482861/275-10-50-4>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(b\)-SubTopic10-Topic275-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(b)-SubTopic10-Topic275-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482861/275-10-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(c\)-SubTopic10-Topic275-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(c)-SubTopic10-Topic275-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482861/275-10-50-1)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph11-SubTopic10-Topic275-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482861/275-10-50-11>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph12-SubTopic10-Topic275-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482861/275-10-50-12>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic275-SubTopic10-Section50-Paragraph8-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482861/275-10-50-8> Details Name: us- gaap\_ UseOfEstimates Namespace Prefix: us- gaap\_ Data Type: dt- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionDisclosure of accounting policy for clinical trial accruals. ReferencesNo definition available. Details Name: xbit\_ ClinicalTrialAccrualsPolicyTextBlock Namespace Prefix: xbit\_ Data Type: dt- types: textBlockItemType Balance Type: na Period Type: durationNote 2- Significant Accounting Policies (Tables) 12 Months Ended Dec. 31, **2023 2024** Notes Tables Share- Based Payment Arrangement, Expensed and Capitalized, Amount [ Table Text Block ] Year Ended December 31, Research and development \$ **1,127 \$ 2,797 \$ 3,641** General and administrative **1,421** Total share- based compensation expense \$ **1,753 \$ 3,262 \$ 5,062** Schedule of Share- Based Payment Award, Stock Options, Valuation Assumptions [ Table Text Block ] Year Ended December 31, Weighted- average grant date fair value per share \$ **3.96 \$ 2.89 \$ 4.92** Expected volatility **79 % - 83 %** 80 % - 82 % **82 % - 83 %** Risk- free interest rate 3. **6 % - 4.4 % 3.3 %** - 4. 6 % **1.5 % - 4.1 %** Expected life (in years) 5. **38 00** - 6. 25 5. 38 - 6. 25 Dividend yield-- X- DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share- based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic718-SubTopic10-Section50-Paragraph2-Subparagraph\(h\)\(1\)-](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic718-SubTopic10-Section50-Paragraph2-Subparagraph(h)(1)-) Publisher FASB- URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> Details Name: us- gaap\_ ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us- gaap\_ Data Type: dt- types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity' s shares, (c) expected dividends, (d) risk- free rate (s), and (e) discount for post-

vesting restrictions. Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic718-SubTopic10-Subparagraph\(f\)\(2\)-NameAccountingStandardsCodification-Paragraph2-Section50-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic718-SubTopic10-Subparagraph(f)(2)-NameAccountingStandardsCodification-Paragraph2-Section50-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2) Details Name: us-gaap\_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_TableTextBlock Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationNote 4-3- Property and Equipment and Building Construction in Progress (Tables) 12 Months Ended Dec. 31, 2023-2024 Notes Tables Property, Plant and Equipment [ Table Text Block ] Computer and office equipment \$ \$ Furniture and fixtures Land 1, 418 1, 418 Scientific equipment 16, 491 16, 367 16, 059 Vehicle Vehicles Building 24, 173 24, 173 Mobile facility Construction in process 1, 705 Accumulated depreciation ( 19, 985 ) ( 18, 239 ) ( 16, 495 ) \$ 24, 526 \$ 24, 897 \$ 26, 260-X- DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph1-SubTopic10-Topic360-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482099/360-10-50-1> Details Name: us-gaap\_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_TableTextBlock Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationNote 5-4- Accrued Expenses (Tables) 12 Months Ended Dec. 31, 2023-2024 Notes Tables Schedule of Accrued Liabilities [ Table Text Block ] Accrued compensation and related expenses \$ \$ Accrued professional fees Accrued clinical trial expenses 1, 502 2, 826 Accrued convertible loan interest- Other \$ 2, 632 \$ 3, 501 \$ 1, 603-X- DefinitionTabular disclosure of the components of accrued liabilities. Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph1-SubTopic10-Topic360-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482099/360-10-50-1> Details Name: us-gaap\_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_TableTextBlock Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationNote 7- Common Stock Options (Tables) 12 Months Ended Dec. 31, 2023-2024 Notes Tables Share- Based Payment Arrangement, Option, Activity [ Table Text Block ] Options Exercise Price Weighted- Average Exercise Price Options outstanding at December 31, 2021 4, 656, 677 \$ 2. 71- \$ 21. 74 \$ 10. 68 Granted 152, 600 3. 65- 11. 25 7. 07 Exercised- Forfeitures (250, 375) 3. 27- 21. 74 12. 31 Options outstanding at December 31, 2022 4, 558, 902 \$ 2. 71- \$ 21. 74 \$ 10. 47 Granted 809, 600 3. 38- 6. 04 4-2. 12-89 Exercised (1, 250) 3. 84 3. 84 Forfeitures (327, 734) 3. 84- 19. 09 10. 43 Options outstanding at December 31, 2023 5, 039, 518 \$ 2. 71- \$ 21. 74 \$ 9. 46 Granted 262, 000 4. 05- 11. 81 6. 31 Exercised (50, 767) 3. 38- 5. 62 3. 92 Forfeitures (919, 166) 3. 84- 19. 92 11. 52 Options outstanding at December 31, 2024 4, 331, 585 \$ 2. 71- \$ 21. 74 \$ 8. 89 Schedule of Nonvested Share Activity [ Table Text Block ] Year Ended December 31, Shares Weighted Average Granted Date Fair Value Shares Weighted Average Granted Date Fair Value Nonvested at January 1, 571, 925 \$ 3. 30 429, 950 450 \$ 8. 25 1, 131, 458 8. 59 Granted during the period 262, 000 3. 96 809, 600 2. 89 152, 600 4. 92 Vested during the period ( 502, 675 ) 3. 42 ( 569, 100 ) 6. 17 ( 716, 491 ) 7. 86 Forfeited during the period ( 73, 750 ) 4. 42 ( 98, 025 ) 5. 14 ( 137, 617 ) 9. 40 Nonvested at end of period 257, 500 \$ 3. 35 571, 925 2 \$ 3. 30 40 429, 950 8. 25-X- DefinitionTabular disclosure of the changes in outstanding nonvested shares. Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Topic718-SubTopic10-Section50-Paragraph2-Subparagraph\(c\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Topic718-SubTopic10-Section50-Paragraph2-Subparagraph(c)(2)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2) Details Name: us-gaap\_ScheduleOfNonvestedShareActivityTableTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted- average grant date fair value. Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Topic718-SubTopic10-Section50-Paragraph2-Subparagraph\(c\)\(1\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Topic718-SubTopic10-Section50-Paragraph2-Subparagraph(c)(1)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(d\)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(d)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2) Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(e\)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(e)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2) Details Name: us-gaap\_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_TableTextBlock Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationNote 8- Net Loss Per Share (Tables) 12 Months Ended Dec. 31, 2023-2024 Notes Tables Schedule of Earnings Per Share, Basic and Diluted [ Table Text Block ] Year Ended December 31, Net loss \$ ( 38, 531 ) \$ ( 24, 557 ) \$ ( 32, 900 ) Weighted- average number of common shares — basic 30, 460, 980 30, 438, 459 30, 439, 275 Net loss per share — basic \$ ( 1. 26 ) \$ ( 0. 81 ) \$ ( 1. 08 ) Weighted- average number of common shares — diluted 30, 460, 980 30, 438, 459 30, 439, 275 Net loss per share — diluted \$ ( 1. 26 ) \$ ( 0. 81 ) \$ ( 1. 08 ) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [ Table Text Block ] Year Ended December 31, Stock options 5, 039, 518 4, 558, 902-X- DefinitionTabular disclosure of securities (including..... Type: na Period Type: durationX- DefinitionTabular disclosure of an entity' s basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per- share computations for income from continuing operations. Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482662/260-10-50-1) Details Name: us-gaap\_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX- ReferencesNo definition available. Details Name: us-gaap\_TableTextBlock Namespace Prefix: us-gaap\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationNote 9- Income Taxes (Tables) 12 Months Ended Dec. 31, 2023-2024 Notes Tables Schedule of Income before Income Tax, Domestic and Foreign [ Table Text Block ] Years Ended December 31, United States \$ ( 26, 313 ) \$ ( 27, 144 ) \$ ( 28, 161 ) Foreign ( 12, 250 ) 2, 831 ( 5, 427 ) Total \$ ( 38, 563 ) \$ ( 24, 313 ) \$ ( 33, 588 ) Schedule of Components of Income Tax Expense (Benefit) [ Table Text Block ] Current United States \$ ( 49 ) \$ Foreign ( 329 ) Total ( 32 ) Deferred United States-- Foreign ( 59 ) ( 816 ) Total ( 59 ) ( 816 ) Total income tax expense (benefit) \$ ( 32 ) \$ ( 688 ) Schedule of Effective Income Tax Rate Reconciliation [ Table Text Block ] Income tax benefit computed at federal tax rate 27. 0 % 27. 0 % Foreign operations ( 3. 4 ) % ( 5. 4 ) % ( 4. 1 ) % Change in valuation allowance ( 22. 8 ) % ( 26. 1 ) % ( 14. 6 ) % Tax credits generated 7. 0 % 8. 6 % 3. 5 % Prior year adjustments 3. 0 % ( 2. 3 ) % 0. 4 % Changes in uncertain tax positions ( 0. 1 ) % ( 0. 4 ) % ( 0. 3 ) % Foreign exchange gain and loss ( 3. 9 ) % 2. 1 % ( 1. 6 ) % Stock compensation ( 1. 1 ) % ( 2. 4 ) % ( 2. 3 ) % Non- deductible compensation ( 5. 8 ) % ( 6. 8 ) % ( 5. 8 )

% Foreign Liquidation **0.0%** 4.5% ~~0.0%~~ Other **0.2%** ~~0.3%~~ ~~(Total 0.1%)~~ ~~2%~~ ~~Total (1.0%)~~ % ~~2.0%~~ Schedule of Deferred Tax Assets and Liabilities [ Table Text Block ] Net operating loss carryforwards \$ **2,799** \$ ~~1,288~~ \$- Research and other credits **9,150** \$ ~~5,851~~ \$ ~~3,820~~ Stock based compensation **1,760** \$ ~~2,530~~ \$ ~~2,703~~ Capitalized research expenses **12,654** \$ ~~7,800~~ \$ ~~5,210~~ Share issuance costs - Accrued liabilities ~~Foreign exchange~~-Deferred tax assets before valuation allowance **26,777** \$ ~~18,204~~ \$ ~~12,994~~ Valuation allowance **(26,382)** \$ ~~(17,576)~~ \$ ~~(11,225)~~ Deferred tax assets ~~1,719~~ Depreciation Prepaid assets ~~Uncollectible debts~~-Deferred tax liability **1,777** \$ ~~Net deferred tax asset (liability) \$-~~ \$ ~~(59)~~ Schedule of Unrecognized Tax Benefits Roll Forward [ Table Text Block ] Balance as of January 1 \$ **2,864,973** \$ ~~2,389,864~~ Additions based on tax positions related to the current year Additions for tax positions of prior years Reductions for tax positions of prior years ~~(4)~~ -Settlements & statute of limitations **(305)** \$ ~~(536)~~ -Balance at December 31 \$ **2-3,973,434** \$ ~~2,864,973~~ X-

Definition Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning- of- the- year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. References Reference 1: <http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph9-Section50-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-9> Details Name: us-gaap\_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- Definition Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. References Reference 1: <http://fasb-www.xbrl.org/2009-us-gaap/role/commonPracticeRef/ref/legacyRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Section50-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-2> Details Name: us-gaap\_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- Definition Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations. References Reference 1: <http://fasb-www.xbrl.org/2003-us-gaap/role/exampleRef/ref/legacyRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph231-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482900-2147482663/835-740-30-10-50-55-1> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-740-SubTopic20-10-NameAccountingStandardsCodification-Section50-Paragraph12A-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139-2147482685/470-740-20-10-50-12A-Subparagraph\(a\)-Reference12AReference3](http://www.xbrl.org/2003/role/disclosureRef-Topic470-740-SubTopic20-10-NameAccountingStandardsCodification-Section50-Paragraph12A-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139-2147482685/470-740-20-10-50-12A-Subparagraph(a)-Reference12AReference3) Reference 3: <http://www.xbrl.org/2003-2009/role/exampleRef-commonPracticeRef-Topic470-740-SubTopic20-10-NameAccountingStandardsCodification-Section55-50-Paragraph12-Section50-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-12> Details Name: us-gaap\_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- Definition Tabular disclosure of income before income tax between domestic and foreign jurisdictions. References Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.4-08\(h\)\(1\)\(Note1\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.4-08(h)(1)(Note1))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235-10-S99-1) Details Name: us-gaap\_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- Definition Tabular disclosure of the change in unrecognized tax benefits. References Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph217-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482663/740-10-55-217> Reference 2: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15A](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15A) Details Name: us-gaap\_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock Namespace Prefix: us-gaap\_ Data Type: dtr- types: textBlockItemType Balance Type: na Period Type: durationX- References No definition available. Details Name: us-gaap\_TableTextBlock Namespace Prefix: us-gaap\_ Data Type: xbrli: stringItemType Balance Type: na Period Type: durationNote 11- Selected Quarterly Financial Data (..... Type: na Period Type: durationNote 1- Organization (Details Textual)- USD (\$ ) \$ in Thousands Dec. 31, 2024 Dec. 31, 2023 Cash and Cash Equivalents, at Carrying Value \$ **172,677** \$ **200,023** Note 2- Significant Accounting Policies (Details Textual) \$ in Thousands 12 Months Ended Dec. 31, 2019 Dec. 2024 USD (\$) shares Dec. 31, 2023 USD ( Dec. 31, 2022 Cash and Cash Equivalents, at Carrying Value \$ **200** ) Impairment , **023** Long- Lived Asset, Held- for- Use \$ **157-0** Gain (Loss) , **306** True Human Foreign Currency Transaction, before Tax **5,529** \$ **(1,893)** Gain (Loss), Foreign Currency Transaction, before Tax \$ **(5,529)** \$ **1,893** Number of Operating Segments Convertible Debt Securities [ Member ] Antidilutive Securities Sale of Product, Consideration Received \$ **750,000** Potential Milestone Payments \$ **600,000** X- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short- term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes Excluded from Computation of Earnings Per Share, Amount | shares cash and cash equivalents within disposal group and discontinued operation. References Reference 1 : [http://www.....MonthsEnded12MonthsEndedNov.30,9212022USD\(\\$\)-Dec.31,8282023USD\(\\$\)-Dec.31,2022USD\(\\$\)-RevenuefromContractwithCustomer,IncludingAssessedTax\\$0\\$4,010](http://www.....MonthsEnded12MonthsEndedNov.30,9212022USD($)-Dec.31,8282023USD($)-Dec.31,2022USD($)-RevenuefromContractwithCustomer,IncludingAssessedTax$0$4,010) Impairment, Long- Lived Asset, Held- for- Use \$ **0** Number of Operating Segments Furniture and Fixtures [ Member ] Property, Plant and Equipment, Useful Life (Year) 7 years Office Equipment [ Member ] Property, Plant and Equipment, Useful Life (Year) 5 years Equipment [ Member ] Property, Plant and Equipment, Useful Life (Year) 5 years Vehicles [ Member ] Property, Plant and Equipment, Useful Life (Year) 5 years Mobile Facility [ Member ] Property, Plant and Equipment, Useful Life (Year) 27 years 6 months Building [ Member ] Property, Plant and Equipment, Useful Life (Year) 39 years Fair Value, Recurring [ Member ] Assets, Fair Value Disclosure \$ **0** Janssen [ Member ] Manufacturing Revenue [ Member ] Revenue from Contract with Customer, Including Assessed Tax \$ **0X** **4,000** X- Definition Fair value....., **518** **4,558,902X** - Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. References Reference 1: <http://>

www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482662/260-10-50-1-Details Name: us-gaap\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX- **gaap\_AssetsFairValueDisclosure** Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- Definition Amount, before **allocation of valuation allowances of deferred tax, of realized and asset attributable to deductible temporary differences from unrealized gain (loss losses on ) from foreign currency transaction transactions**. References Reference 1: http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic 946-740-SubTopic 220-10-Name Accounting Standards Codification-Section S99-50-Paragraph 1-Subparagraph (SX 210-6-07 (7))-Publisher FASB-URI https://asc.fasb.org/#1943274/2147479134-2147482685/946-740-220-10-S99-50-1-Reference 6-Reference 2: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 830-SubTopic 20-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 35-50-Paragraph 1-8-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482014-2147482685/830-740-20-10-35-50-1-Reference 3-8-Details Name: us-gaap\_DeferredTaxAssetsUnrealizedCurrencyLosses Details Name: us-gaap\_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = us-gaap\_EmployeeStockOptionMember-gaap\_ConvertibleDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_PropertyPlantAndEquipmentByTypeAxis = us-gaap\_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_PropertyPlantAndEquipmentByTypeAxis = us-gaap\_OfficeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_PropertyPlantAndEquipmentByTypeAxis = us-gaap\_PropertyPlantAndEquipmentByTypeAxis = us-gaap\_EquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_PropertyPlantAndEquipmentByTypeAxis = us-gaap\_VehiclesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_PropertyPlantAndEquipmentByTypeAxis = xbit\_MobileFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_PropertyPlantAndEquipmentByTypeAxis = us-gaap\_BuildingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_FairValueByMeasurementFrequencyAxis = us-gaap\_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Note 9-2- **Income Taxes-Significant Accounting Policies-Share-based Compensation Expense** (Details Textual)- USD (\$) \$ in Thousands 12 Months Ended Dec. 31, **048Debt Conversion, Convertible---Converted, Acceleration Feature, Cash Position \$ 65,000,000 Payments of Debt Instrument Interest \$ 400,000 Interest Payable \$ 400,000 Debt Instrument, Rate 19, Convertible, Number of Equity Instruments 1,930-90%, 983 Repayments of Convertible Debt \$ 2,183,381 X- Definition The price per **Definition Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash share--- are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the conversion feature embedded transaction not resulting in the debt instrument cash receipts or cash payments**. References Reference 1: http://www.fasb.xbrl.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 50-Paragraph 3-1B-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481139-2147482913/470-20-230-50-10-50-1-Reference 3-Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 50-Paragraph 5-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147481139-2147482913/470-20-230-10-50-5-Details Name: us-gaap\_DebtInstrumentConvertibleConversionPrice1-gaap\_DebtConversionConvertedInstrumentRate Namespace Prefix: us-gaap\_Data Type: dtr-types: perShareItemType percentItemType Balance Type: na Period Type: durationX instantX- Definition The number of equity instruments-2023 Dec. 31, **048Debt Conversion, Converted Instrument, Rate 19.90 % X- Definition Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portions- portion of options outstanding and currently exercisable the transaction not resulting in cash receipts or cash payments**. References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-230-SubTopic 10-Section 50-Paragraph 2-3-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429-2147482913/718-230-10-50-3-Reference 2-Details Name: us-gaap\_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- Definition Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-230-SubTopic 10-Section 50-Paragraph 2-5-Publisher FASB-URI https://asc.fasb.org/#1943274/2147480429-2147482913/718-230-10-50-2-5-Details Name: us-gaap\_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-gaap\_DebtConversionConvertedInstrumentRate Namespace Prefix: us-gaap\_Data Type: xbrli-dtr-types: durationItemType percentItemType Balance Type: na Period Type: durationX 2022 Dec. 31, **2021Tax-2024Tax Credit Carryforward, Amount \$ 1,400 Unrecognized-700 Unrecognized Tax Benefits \$ 2,973 \$ 2,864 3 \$ 2,389 Unrecognized-434 Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Unrecognized Tax Benefits that Would Impact Effective Tax Rate 1,700 \$ 1,600-700 Decrease in Unrecognized Tax Benefits is Reasonably Possible \$ 100 Domestic Tax Authority-Jurisdiction [ Member ] Operating Loss Carryforwards 1,600 Operating Loss Carryforward, Amount Carried Back to Previous Year Domestic Tax Jurisdiction [ Member ] | Research Tax Credit Carryforward [ Member ] Tax Credit Carryforward, Amount 6-9, 600 Domestic-400 Domestic Tax Authority Jurisdiction [ Member ] | Internal Revenue Service (IRS) [ Member ] Operating Loss Carryforwards 6-3, 200 State-200 State and Local Jurisdiction [ Member ] | Texas Controller Office [ Member ] | Research Tax Credit Carryforward [ Member ] Tax Credit Carryforward, Amount 1, Unrecognized-800 Unrecognized Tax Benefits \$ 400 X-200 X- Definition Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit. References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-OtherTransitionRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 15-Subparagraph (d) (3)-Publisher FASB-URI https://asc.fasb.org/#1943274/2147482685/740-10-50-15-Details Name: us-gaap\_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- Definition Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. References Reference 1: http://fasb-www.xbrl.org/2003-us-gaap/role/ref/legacyRef****

**disclosureRef- Topic 740- SubTopic 10** - Name Accounting Standards Codification- ~~Topic 740- SubTopic 10~~-Section 50- Paragraph 3- Subparagraph (a)- Publisher FASB- URI <https://asc.fasb.org/#/1943274/2147482685/740-10-50-3> Details Name: us-gaap\_OperatingLossCarryforwards Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionThe amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. ReferencesReference 1: <http://fasb-www.xbrli.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic740-SubTopic10> - Name Accounting Standards Codification- ~~Topic 740- SubTopic 10~~-Section 50- Paragraph 3- Subparagraph (a)- Publisher FASB- URI <https://asc.fasb.org/#/1943274/2147482685/740-10-50-3> Details Name: us-gaap\_TaxCreditCarryforwardAmount Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of unrecognized tax benefits. ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph217-15A-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482685/740-10-50-55-15AReference217Reference2](http://www.xbrli.org/2003/role/disclosureRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph217-15A-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482685/740-10-50-55-15AReference217Reference2): [http://www.xbrli.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15AReference3](http://www.xbrli.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15AReference3): [https://asc.fasb.org/#/1943274/2147482525/740-10-45-10B](http://www.xbrli.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph10B-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482525/740-10-45-10B) Details Name: us-gaap\_UnrecognizedTaxBenefits Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return. ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph217-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482663/740-10-55-217Reference2>: [http://www.xbrli.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482685/740-10-50-15](http://www.xbrli.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482685/740-10-50-15) Details Name: us-gaap\_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionThe total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate. ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph217-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482663/740-10-55-217Reference2>: [https://asc.fasb.org/#/1943274/2147482685/740-10-50-15A](http://www.xbrli.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482685/740-10-50-15A) Details Name: us-gaap\_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Namespace Prefix: us-gaap\_Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionThe amount of operating loss carryforwards carried back to the previous year. ReferencesNo definition available. Details Name: xbit\_OperatingLossCarryforwardAmountCarriedBackToPreviousYear Namespace Prefix: xbit\_Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- Details Name: us-gaap\_IncomeTaxAuthorityAxis = us-gaap\_DomesticCountryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_TaxCreditCarryforwardAxis = us-gaap\_ResearchMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_IncomeTaxAuthorityNameAxis = us-gaap\_InternalRevenueServiceIRSMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_IncomeTaxAuthorityAxis = us-gaap\_StateAndLocalJurisdictionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_IncomeTaxAuthorityNameAxis = xbit\_TexasControllerOfficeMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 9- Income Taxes- Components of Income Before Income Taxes (Details)- USD (\$) \$ in Thousands 12 Months EndedDec. 31, 2023 2024 Dec. 31, 2022 Total 2023 Total \$ (38,563) \$ (24,313) \$(33,588) UNITED STATES Income Before Income Taxes (26,313) (27,144) (28,161) Other Foreign [ Member ] Income Before Income Taxes \$ (12,250) \$ 2,831 831X \$(5,427) X- DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. ReferencesReference 1: [http://www.xbrli.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic944-280-SubTopic220-10-NameAccountingStandardsCodification-SectionS99-50-Paragraph22-1-Subparagraph\(SX210-7-04\(11\)\)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147483586-2147482810/944-280-220-10-S99-50-1Reference22Reference2](http://www.xbrli.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic944-280-SubTopic220-10-NameAccountingStandardsCodification-SectionS99-50-Paragraph22-1-Subparagraph(SX210-7-04(11))-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147483586-2147482810/944-280-220-10-S99-50-1Reference22Reference2): <http://www.xbrli.org/2003/role/disclosureRef-exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph22-48-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482810-2147482785/280-10-50-55-22Reference48Reference3>: [http://www.xbrli.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph30-32-Subparagraph\(b-f\)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482810/280-10-50-30Reference32Reference4](http://www.xbrli.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph30-32-Subparagraph(b-f)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482810/280-10-50-30Reference32Reference4): [http://www.xbrli.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-30-Subparagraph\(f-b\)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482810/280-10-50-32Reference30Reference5](http://www.xbrli.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-30-Subparagraph(f-b)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482810/280-10-50-32Reference30Reference5): [http://www.xbrli.org/2003-2009/role/exampleRef-commonPracticeRef-Topic280-270-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph31-1-Subparagraph\(i\)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482810-2147482964/280-270-10-50-31Reference-1Reference6](http://www.xbrli.org/2003-2009/role/exampleRef-commonPracticeRef-Topic280-270-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph31-1-Subparagraph(i)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482810-2147482964/280-270-10-50-31Reference-1Reference6): [http://www.xbrli.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph\(e-ee\)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482810/280-10-50-32Reference7](http://www.xbrli.org/2003-2009/role/disclosureRef-commonPracticeRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph(e-ee)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147482810/280-10-50-32Reference7): [http://www.fasb.xbrli.org/2003-us-gaap/role/disclosureRef-ref/otherTransitionRef-Topic942-280-SubTopic235-10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-32-Subparagraph\(cSX210-9-05\(b\)\(2\)\)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147479557-2147482810/942-280-235-10-S99-50-1Reference32Reference8](http://www.fasb.xbrli.org/2003-us-gaap/role/disclosureRef-ref/otherTransitionRef-Topic942-280-SubTopic235-10-NameAccountingStandardsCodification-SectionS99-50-Paragraph1-32-Subparagraph(cSX210-9-05(b)(2))-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147479557-2147482810/942-280-235-10-S99-50-1Reference32Reference8): [http://fasb-www.xbrli.org/2003-us-gaap/role/exampleRef-ref/legacyRef-Topic220-280-SubTopic10-NameAccountingStandardsCodification-SectionS99-50-Paragraph31-2-Subparagraph\(SX210-5-03\(10\)\)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147483621--2147482810/220-280-10-S99-50-2Reference31Reference10](http://fasb-www.xbrli.org/2003-us-gaap/role/ref/legacyRef-disclosureRef-Topic944-SubTopic220-NameAccountingStandardsCodification-Section25-S99-Paragraph1-SubTopicSubparagraph(SX20-210.7-Topic940-04(11))-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147481913-2147477250/940-944-20-220-25-S99-1Reference9): [http://fasb-www.xbrli.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic942-SubTopic220-235-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210-9-04-05\(+b\)\(2\)\)-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147483589-2147477314https://942/asc.fasb.org/#/1943274/2147481568/470-20-235-55-S99-69CReference1Reference5-11](http://fasb-www.xbrli.org/2003-us-gaap/role/disclosureRef-ref/legacyRef-Topic942-SubTopic220-235-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210-9-04-05(+b)(2))-PublisherFASB-URIhttps://asc.fasb.org/#/1943274/2147483589-2147477314https://942/asc.fasb.org/#/1943274/2147481568/470-20-235-55-S99-69CReference1Reference5-11): <http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-Topic835-SubTopic30-Section45>



**2147482810 / 250-280** - 10-50-9**Reference 3**: <http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph10-12> - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482685/740-10-50-10Reference-12Reference> 4: [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph231-1-Subparagraph\(SABTOPIC6.I.7\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479360-2147482663/740-10-50-99-55-1Reference-231Reference](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph231-1-Subparagraph(SABTOPIC6.I.7)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479360-2147482663/740-10-50-99-55-1Reference-231Reference) 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic280-250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph9-22-Subparagraph\(h\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810-2147483443-280-250-10-50-22Reference-9Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic280-250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph9-22-Subparagraph(h)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482810-2147483443-280-250-10-50-22Reference-9Reference) 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic944-740-SubTopic220-10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210-SABTopic6.I.7-04\(9\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483586-2147479360/944-740-220-10-50-99-1Reference-7](http://www.xbrl.org/2003/role/disclosureRef-Topic944-740-SubTopic220-10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210-SABTopic6.I.7-04(9))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147483586-2147479360/944-740-220-10-50-99-1Reference-7) 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section45-50-Paragraph2-8-PublisherFASB-Subparagraph\(a\)-SubTopic-URIhttps://asc.fasb.org/1943274/2147483443/20-250-10-50-8Reference-8](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section45-50-Paragraph2-8-PublisherFASB-Subparagraph(a)-SubTopic-URIhttps://asc.fasb.org/1943274/2147483443/20-250-10-50-8Reference-8) 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482659/740-20-45-2Reference-8> 9: <http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph1-10-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482900-2147482685/835-740-30-10-50-1Reference-10Reference-2-9> 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-280-SubTopic20-10-NameAccountingStandardsCodification-Section50-Paragraph1B-22-Subparagraph\(a-h\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481139-2147482810/470-280-20-10-50-1BReference-22Reference-3-10](http://www.xbrl.org/2003/role/disclosureRef-Topic470-280-SubTopic20-10-NameAccountingStandardsCodification-Section50-Paragraph1B-22-Subparagraph(a-h)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481139-2147482810/470-280-20-10-50-1BReference-22Reference-3-10) 11: [http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic470-944-SubTopic20-220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.50-7-Paragraph1-04\(9\)\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482900-2147477250/835-944-30-220-50-S99-1Reference-2-11](http://www.xbrl.org/2003/role/exampleRef-disclosureRef-Topic470-944-SubTopic20-220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.50-7-Paragraph1-04(9))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482900-2147477250/835-944-30-220-50-S99-1Reference-2-11) 12: [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic470-SubTopic20-NameAccountingStandardsCodification-Section50-45-Paragraph1B-2-Subparagraph\(a\)-SubTopic20-Topic740-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481139-2147482659/470-740-20-50-45-1BReference-2Reference-3-12](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic470-SubTopic20-NameAccountingStandardsCodification-Section50-45-Paragraph1B-2-Subparagraph(a)-SubTopic20-Topic740-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481139-2147482659/470-740-20-50-45-1BReference-2Reference-3-12) 13: [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph231-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482663/740-10-55-231](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic470-SubTopic20-NameAccountingStandardsCodification-Section55-S99-Paragraph69B-1-Subparagraph(SX210.4-08(h))-SubTopic10-Topic235-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480678/235-10-S99-1DetailsName:us-gaap_IncomeTaxExpenseBenefitNamespacePrefix:us-gaap_DataType:xbrli:monetaryItemTypeBalanceType:debitPeriodType:durationX-DefinitionAmountofothercurrentincometaxexpense(benefit)pertainingtoincome(loss)fromcontinuingoperations.ReferencesNodefinitionavailable.DetailsName:xbit_CurrentOtherTaxExpenseBenefitNamespacePrefix:xbit_DataType:xbrli:monetaryItemTypeBalanceType:debitPeriodType:durationNote9-IncomeTaxes-ReconciliationofCanadianFederalStatutoryIncomeTaxRate(Details)12MonthsEndedDec.31,2023-2024Dec.31,2022Income-2023Income taxbenefitcomputedatfederaltaxrate27.00%27.00%Foreignoperations(5-3,40%)(4-5,40-40%)Changeinvaluationallowance(22.80%)(26.10%)(14.60%)Taxcreditsgenerated7.00%8.60%3-50%Prioryearadjustments3.00%(2.30%)0-40%Changesinuncertaintaxpositions(0.10%)(0.40%)(0-30%)Foreignexchangegainandloss(3.90%)2.10%(1-60%)Stockcompensation(1.10%)(2.40%)(2-30%)Non-deductiblecompensation(6-5,80%)(5-6,80%)ForeignLiquidation0.00%4.50%0-00%Other0.20%0.30%(Total0.20-10%)Total(1.00%)2-00%-X-DefinitionPercentageofcurrentincometaxexpense(benefit)anddeferredincometaxexpense(benefit)pertainingtocontinuingoperations.ReferencesReference1:http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph12-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482685/740-10-50-12-12Reference2:http://www.xbrl.org/2003/role/exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph231-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482663/740-10-55-231) 14: <http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph12-231-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147480678-2147482685/235-740-10-S99-50-1Reference-12Reference> 15: <http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph12-231-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482685-2147482663/740-10-50-55-12Reference-231Reference> 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SABTOPIC6.I.Fact1.4Q1\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479360/740-10-S99-1Reference-4](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SABTOPIC6.I.Fact1.4Q1)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479360/740-10-S99-1Reference-4) 17: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph12-231-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482685-2147482663/740-10-50-55-12Reference-231Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.4-08(h)(2))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235-10-S99-1DetailsName:us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateNamespacePrefix:us-gaap_DataType:dtr-types:percentItemTypeBalanceType:naPeriodType:durationX-DefinitionPercentageofthedifferencebetweenreportedincome tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss).ReferencesReference1:http://www.xbrl.org/2009-2003/role/commonPracticeRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph12-231-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147482685-2147482663/740-10-50-55-12Reference-231Reference) 18: [http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1B-12A-Subparagraph\(a\)\(6\)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481139-2147482685/470-740-20-10-50-1BReference-12AReference](http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1B-12A-Subparagraph(a)(6)-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481139-2147482685/470-740-20-10-50-1BReference-12AReference) 19: <http://www.xbrl.org/2003-2009/role/exampleRef-commonPracticeRef-Topic470-740-SubTopic20-10-NameAccountingStandardsCodification-Section55-50-Paragraph69B-12-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147481568-2147482685/470-740-20-10-55-50-69BReference-12Reference> 20: [http://www.xbrl.org/2009](http://www.xbrl.org/2003-2009/role/exampleRef-commonPracticeRef-Topic470-235-SubTopic20-10-NameAccountingStandardsCodification-Section55-S99-Paragraph1-Subparagraph(SX210-SABTOPIC6.I.Fact.4-08(h)(2))-PublisherFASB-URIhttps://asc.fasb.org/#1943274/2147479360-2147480678/740-235-10-S99-1DetailsName:us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowanceNamespacePrefix:us-gaap_DataType:dtr-types:percentItemTypeBalanceType:naPeriodType:durationX-DefinitionPercentageofthedifferencebetweenreportedincome tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.ReferencesReference1:http://www.xbrl.org/2009)

**2003** / role / **commonPracticeRef-disclosureRef** - Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **12-12A - Subparagraph (b) (1)** - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482685/740-10-50-12Reference-12AReference-2>: <http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef> - Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph **12-12A - Subparagraph (a) (7)** - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481139-2147482685/470-740-20-10-50-12Reference-12AReference-3>: <http://www.xbrl.org/2003-2009/role/exampleRef-commonPracticeRef> - Topic **470-740 - SubTopic 20-10** - Name Accounting Standards Codification- Section **55-50 - Paragraph 69B-12** - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481568-2147482685/470-740-20-10-55-50-69BReference-12Reference-4>: <http://www.xbrl.org/2003-2009/role/exampleRef-commonPracticeRef> - Topic **470-235 - SubTopic 20-10** - Name Accounting Standards Codification- Section **55-S99- Paragraph 1- Subparagraph (SX 210 SAB Topic 6. I. Fact. 4 - 08 (h) (2))** - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479360-2147480678/740-235-10-S99-1> Details Name: us-gaap\_EffectiveIncomeTaxRateReconciliationNondeductibleExpense Namespace Prefix: us-gaap\_ Data Type: dt- types: percentItemType Balance Type: na Period Type: durationX- DefinitionPercentage of the **reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to the other mean-reconciling items**. The volatility **Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country** a share price is the standard deviation of **domicile** the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any **tax credit**, over the period **nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law**. ReferencesReference 1: <http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef> - Topic **718-740 - SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 2-12 - Subparagraph (fb) (3 2)(ii)** - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147480429-2147482685/718-740-10-50-2-12> Details Name: us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate **gaap\_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent** Namespace Prefix: us-gaap\_ Data Type: dt- types: percentItemType Balance Type: na Period Type: durationX- DefinitionThe risk- **DefinitionPercentage of the difference** between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations **that is attributable to revisions of previously reported income tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments**. **ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 12- Subparagraph (b) (3)- Publisher FASB- URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference-12Reference-2: http://www.1-http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef** - Topic **835-740 - SubTopic 30-10** - Name Accounting Standards Codification- Section 50- Paragraph **1-12** - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482900-2147482685/835-740-30-10-50-1Reference-12Reference-2-3>: <http://www.xbrl.org/2003-2009/role/disclosureRef-commonPracticeRef> - Topic **470-235 - SubTopic 20-10** - Name Accounting Standards Codification- Section **50-S99 - Paragraph 1B-1 - Subparagraph (a-SX 210.4- 08 (h) (2))** - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481139-2147480678/470-235-20-10-50-S99-1> **1BReference-3** Details Name: us-gaap\_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent **gaap\_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes** Namespace Prefix: us-gaap\_ Data Type: dt- types: percentItemType Balance Type: na Period Type: durationX- DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to **revisions the repatriation of foreign earnings previously reported income tax expense**. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 12- Subparagraph \(b\) \(3\)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482685/740-10-50-12Reference-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 12- Subparagraph (b) (3)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482685/740-10-50-12Reference-2): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 599-50 - Paragraph 12-1- Subparagraph \(SAB Topic 6. I. Fact. 4\)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147479360-2147482685/740-10-S99-50-12Reference-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 599-50 - Paragraph 12-1- Subparagraph (SAB Topic 6. I. Fact. 4)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147479360-2147482685/740-10-S99-50-12Reference-3) Details Name: us-gaap\_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes Namespace Prefix: us-gaap\_ Data Type: dt- types: percentItemType Balance Type: na Period Type: durationX- DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-235 - SubTopic 10- Name Accounting Standards Codification- Section 50-S99 - Paragraph 12-1- Subparagraph \(SX 210.4- 08 \(h\) \(2\)\) - Publisher FASB- URI https://asc.fasb.org/#1943274/2147482685-2147480678/235-740-10-50-12Reference-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-235 - SubTopic 10- Name Accounting Standards Codification- Section 50-S99 - Paragraph 12-1- Subparagraph (SX 210.4- 08 (h) (2)) - Publisher FASB- URI https://asc.fasb.org/#1943274/2147482685-2147480678/235-740-10-50-12Reference-2): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 599- Paragraph 1- Subparagraph \(SAB Topic 6. I. Fact. 4\)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 599- Paragraph 1- Subparagraph (SAB Topic 6. I. Fact. 4)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147479360/740-10-S99-1) Details Name: us-gaap\_EffectiveIncomeTaxRateReconciliationRepatriationOffForeignEarnings Namespace Prefix: us-gaap\_ Data Type: dt- types: percentItemType Balance Type: na Period Type: durationX- DefinitionPercentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement. ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 12- Subparagraph \(b\) \(3\)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482685/740-10-50-12Reference-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 12- Subparagraph (b) (3)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482685/740-10-50-12Reference-2): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 12- Subparagraph \(b\) \(3\)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482685/740-10-50-12Reference-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 12- Subparagraph (b) (3)- Publisher FASB- URI https://asc.fasb.org/#1943274/2147482685/740-10-50-12Reference-3): <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718-740- SubTopic 10- Name Accounting Standards Codification- Section 35- Paragraph 2- SubTopic 740- Topic 718- Publisher FASB- URI https://asc.fasb.org/#1943274/2147480887-2147479176/718-740-35-2> Details Name: us-gaap\_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent Namespace Prefix: us-gaap\_ Data Type: dt- types: percentItemType Balance Type: na Period Type: durationX- DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal

statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.

ReferencesReference 1: <http://www.xbrl.org/2009-2003/role/commonPracticeRef-exampleRef> - Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50-55 - Paragraph 12-231 - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482685-2147482663/740-10-50-55-12Reference-231Reference> 2: <http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef> - Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 12-12A - Subparagraph (a) (8) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481139-2147482685-470-740-20-10-50-12Reference-12AReference> 3:<http://www.xbrl.org/2003-2009/role/exampleRef-commonPracticeRef> - Topic 470-740 - SubTopic 20-10 - Name Accounting Standards Codification- Section 55-50 - Paragraph 69B-12 - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481568-2147482685/470-740-20-10-55-50-69BReference-12Reference> 4:<http://www.xbrl.org/2003-2009/role/exampleRef-commonPracticeRef> - Topic 470-235 - SubTopic 20-10 - Name Accounting Standards Codification- Section 55-S99- Paragraph 1- Subparagraph (SX 210 SAB-Topic 6-I-Fact. 4 -08 (h) (2)) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479360-2147480678/740-235-10-S99-1-Details-Name-us-gaap-EffectiveIncomeTaxRateReconciliationTaxContingencies> Namespace Prefix: us- gaap\_ Data Type: dtr- types: percentItemType Balance Type: na Period Type: durationX- DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits. ReferencesReference 1: <http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef> - Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 12-12A - Subparagraph (b) (1) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482685/740-10-50-12Reference-12AReference> 2: <http://www.xbrl.org/2009-2003/role/commonPracticeRef-disclosureRef> - Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 50- Paragraph 12-12A - Subparagraph (a) (5) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481139-2147482685/470-740-20-10-50-12Reference-12AReference> 3:<http://www.xbrl.org/2003-2009/role/exampleRef-commonPracticeRef> - Topic 470-740 - SubTopic 20-10 - Name Accounting Standards Codification- Section 55-50 - Paragraph 69B-12 - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147481568-2147482685/470-740-20-10-55-50-69BReference-12Reference> 4:<http://www.xbrl.org/2003-2009/role/exampleRef-commonPracticeRef> - Topic 470-235 - SubTopic 20-10 - Name Accounting Standards Codification- Section 55-S99- Paragraph 1- Subparagraph (SX 210 SAB-Topic 6-I-Fact. 4 -08 (h) (2)) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147479360-2147480678/740-235-10-S99-1-Details-Name-us-gaap-EffectiveIncomeTaxRateReconciliationTaxCredits> Namespace Prefix: us- gaap\_ Data Type: dtr- types: percentItemType Balance Type: na Period Type: durationX- DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign exchange gain (loss). ReferencesNo definition available. Details Name: xbit\_EffectiveIncomeTaxRateReconciliationForeignExchangeGainLossPercent Namespace Prefix: xbit\_ Data Type: dtr- types: percentItemType Balance Type: na Period Type: durationX- DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign liquidation. ReferencesNo definition available. Details Name: xbit\_EffectiveIncomeTaxRateReconciliationForeignLiquidationPercent Namespace Prefix: xbit\_ Data Type: dtr- types: percentItemType Balance Type: na Period Type: durationNote 9- Income Taxes- Significant Components of Deferred Tax Assets and Liabilities (Details)- USD (\$) \$ in Thousands Dec. 31, 2023-2024 Dec. 31, 2022Net 2023Net operating loss carryforwards \$ 2,799 \$ 1,288 \$ 0Research 288Research and other credits 9,150 5,851 3,820Stock 851Stock based compensation 1,760 2,530 2,703Capitalized- 530Capitalized research expenses 12,654 7,800 5,210Share 800Share issue costsAccrued liabilitiesDeferred liabilitiesForeign exchangeDeferred tax assets before Valuation allowance 26,777 18,204 12,994Valuation 204Valuation allowance (26,382) (17,576) (11,225) Deferred tax assets 1,719DepreciationPrepaid assetsDepreciationPrepaid assetsUncollectible debtsDeferred- assetsDeferred tax liability liabilityNet 1,777Net deferred tax asset (liability) \$ 0 Net deferred tax asset (liability) \$ 0X (59) X- DefinitionAmount of deferred tax liability attributable to taxable temporary differences. ReferencesReference 1: <http://www.fasb.org/2003-us-gaap/role/disclosureRef-ref/legacyRef> - Topic 740-210 - SubTopic 10- Name Accounting Standards Codification- Section 50-S99 - Paragraph 2-1 - Subparagraph (a SX 210. 5- 02 (26) (b)) - Publisher FASB- URI <https://asc.fasb.org/#1943274/2147482685-2147480566/210-10-S99-1Reference-2> <http://www.xbrl.org/2003/role/disclosureRef-Topic-740-10-50-2Reference-2>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-50-Paragraph-1-2-Subparagraph-\(SX-210-5-02-\(26\)-\(a\)\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147480566-2147482685-740-210-10-10-50-S99-1Reference-2Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-50-Paragraph-1-2-Subparagraph-(SX-210-5-02-(26)-(a))-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147480566-2147482685-740-210-10-10-50-S99-1Reference-2Reference) 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-\(26\)-\(b-a\)\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147480566/210-10-S99-1Reference-4](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-(26)-(b-a))-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147480566/210-10-S99-1Reference-4): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-9-03-\(15\)-\(2\)\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147479853-2147478546/942-210-S99-1-Details-Name-us-gaap-DeferredIncomeTaxLiabilities](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-9-03-(15)-(2))-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147479853-2147478546/942-210-S99-1-Details-Name-us-gaap-DeferredIncomeTaxLiabilities) Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482685/740-10-50-2-Details-Name-us-gaap-DeferredTaxAssetsGross](http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482685/740-10-50-2-Details-Name-us-gaap-DeferredTaxAssetsGross) Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount before allocation of valuation allowances- allowance, of deferred tax asset attributable to deductible temporary differences- difference from in- process research and development costs- cost expensed acquired in connection with a business combination or from joint venture formation or both. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482685/740-10-50-6-6Reference-2>: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-740-SubTopic-10-Section-50-Paragraph-8-Publisher-FASB-URI-https://asc.fasb.org/#1943274/2147482685/740-10-50-8-Details-Name-us-gaap-DeferredTaxAssetsInProcessResearchAndDevelopment> Namespace Prefix: us- gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic-740-SubTopic-10-Name-Accounting-Standards>

Codification- Section 50- Paragraph 2- Publisher FASB- URI <https://asc.fasb.org/1943274/2147482685/740-10-50-2> Details Name: us-gaap\_DeferredTaxAssetsLiabilitiesNet Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-2> Details Name: us-gaap\_DeferredTaxAssetsNet Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph6-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic740-SubTopic10-Section50-Paragraph8-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-8> Details Name: us-gaap\_DeferredTaxAssetsOperatingLossCarryforwards Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph6-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-6>Reference 2: <http://.....740-10-50-3> Details Name: us-gaap\_DeferredTaxAssetsTaxCreditCarryforwardsResearch Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph6-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic740-SubTopic10-Section50-Paragraph8-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-8> Details Name: us-gaap\_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph6-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic740-SubTopic10-Section50-Paragraph8-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-8> Details Name: us-gaap\_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-2) Details Name: us-gaap\_DeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic740-SubTopic10-Section45-Paragraph6-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482525/740-10-45-6> Details Name: us-gaap\_DeferredTaxLiabilities Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses. ReferencesNo definition available ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph6-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-6> Details Name: us-gaap\_DeferredTaxLiabilitiesPrepaidExpenses Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph6-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic740-SubTopic10-Section50-Paragraph8-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-8> Details Name: us-gaap\_DeferredTaxLiabilitiesPropertyPlantAndEquipment Namespace Prefix: us-gaap\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share issuance costs. ReferencesNo definition available. Details Name: xbit\_DeferredTaxAssetsShareIssuanceCosts Namespace Prefix: xbit\_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: instantX- DefinitionAmount of deferred tax consequences attributable to taxable temporary differences derived from uncollectible debts. ReferencesNo definition available. Details Name: xbit\_DeferredTaxLiabilitiesUncollectibleDebts Namespace Prefix: xbit\_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantNote 9- Income Taxes- Reconciliation of Unrecognized Tax Benefit Balances (Details)- USD (\$) \$ in Thousands 12 Months Ended Dec. 31, 2023 2024 Dec. 31, 2022 Balance 2023 Balance \$ 2, 864 973 \$ 2, 389 Additions- 864 Additions based on tax positions related to the current year Additions for tax positions of prior years Reductions for tax positions of prior years (4) Settlements & statute of limitations ( 305 ) ( 536 ) Balance \$ 2-3, 973-434 \$ 2, 864 X-973X- DefinitionAmount of unrecognized tax benefits. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph217-15A-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685-2147482663/740-10-50-55-15A-Reference217Reference2:http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15A-Reference3:http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph10B-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482525/740-10-45-10B](http://www.xbrl.org/2003/role/disclosureRef-exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-55-Paragraph217-15A-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685-2147482663/740-10-50-55-15A-Reference217Reference2:http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15A-Reference3:http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph10B-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482525/740-10-45-10B) Details Name: us-

gaap\_UnrecognizedTaxBenefits Namespace Prefix: us-gaap Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: instantX- DefinitionAmount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-exampleRef> - Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 217- Publisher FASB- URI <https://asc.fasb.org/1943274/2147482663/740-10-55-217>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph\(a\)\(1\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15A](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph(a)(1)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15A) Details Name: us-gaap\_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Namespace Prefix: us-gaap Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-exampleRef> - Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 217- Publisher FASB- URI <https://asc.fasb.org/1943274/2147482663/740-10-55-217>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph\(a\)\(3\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15A](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph(a)(3)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15A) Details Name: us-gaap\_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities Namespace Prefix: us-gaap Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: durationX- DefinitionAmount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-exampleRef> - Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 217- Publisher FASB- URI <https://asc.fasb.org/1943274/2147482663/740-10-55-217>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph\(a\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15A](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph(a)(2)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15A) Details Name: us-gaap\_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Namespace Prefix: us-gaap Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationX- DefinitionAmount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-exampleRef> - Topic 740- SubTopic 10- Name Accounting Standards Codification- Section 55- Paragraph 217- Publisher FASB- URI <https://asc.fasb.org/1943274/2147482663/740-10-55-217>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph\(a\)\(1\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15A](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-Subparagraph(a)(1)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15A) Details Name: us-gaap\_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Namespace Prefix: us-gaap Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: durationNote 10- Subsequent Event (Details Textual) - **Jan. 03, 2024 \$ / Convertible SharesConvertible** Debt [ Member ] - Subsequent Event [ Member ] \$ / shares in Units, \$ in Millions Jan. 03, 2024 USD (\$) \$ / sharesDebt Instrument, Face Amount | \$ 10Debt - Debt Instrument, Convertible, Conversion Price (in dollars per share) | \$ / shares \$ 4. **048X** 048Debt Conversion, Converted Instrument, Rate..... Type: na Period Type: durationX- DefinitionThe price per share of the conversion feature embedded in the debt instrument. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph1B-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph1B-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic470-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph5-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-5](http://fasb.org/us-gaap/role/ref/legacyRef-Topic470-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph5-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481139/470-20-50-5) Details Name: us-gaap\_DebtInstrumentConvertibleConversionPriceI Namespace Prefix: us-gaap Data Type: dt- types: perShareItemType Balance Type: na Period Type: instantX- DefinitionFace (par) amount of debt..... credit Period Type: instantX- Details Name: us-gaap\_ShortTermDebtTypeAxis = us-gaap\_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap\_SubsequentEventTypeAxis = us-gaap\_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: Note 11- Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Details) - USD (\$) \$ / shares in Units, \$ in Thousands 3 Months Ended 12 Months Ended Dec. 31, 2023 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Dec. 31, 2022 Sep. 30, 2022 Jun. 30, 2022 Mar. 31, 2022 Dec. 31, 2023 Dec. 31, 2022 Loss from operations \$ (8, 588) \$ (8, 520) \$ (13, 258) \$ (7, 145) \$ (8, 162) \$ (6, 389) \$ (12, 094) \$ (7, 845) \$ (37, 510) \$ (34, 490) Net loss \$ (4, 635) \$ (7, 364) \$ (8, 742) \$ (3, 816) \$ (3, 203) \$ (12, 658) \$ (11, 644) \$ (5, 395) \$ (24, 557) \$ (32, 900) Net loss per share - basic (in dollars per share) \$ (0. 15) \$ (0. 24) \$ (0. 29) \$ (0. 13) \$ (0. 1) \$ (0. 42) \$ (0. 38) \$ (0. 18) \$ (0. 81) \$ (1. 08) X- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph15-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic815-SubTopic40-NameAccountingStandardsCodification-Section65-Paragraph1-Subparagraph\(e\)\(4\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic815-SubTopic40-NameAccountingStandardsCodification-Section65-Paragraph1-Subparagraph(e)(4)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic815-SubTopic40-NameAccountingStandardsCodification-Section65-Paragraph1-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic815-SubTopic40-NameAccountingStandardsCodification-Section65-Paragraph1-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph11-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph11-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph11-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph11-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph7-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph7-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph2-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph60B-Subparagraph\(d\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph60B-Subparagraph(d)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph4-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph10-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482662/260-10-45-10>



fasb.org//1943274/2147480097/470-10-S99-1BReference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30): [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31): [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32): <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 31-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34): <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35>: <http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37): [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38): [http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(20\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39](http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(20))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39): [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 2](http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(22))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-DefinitionThe net result for the period of deducting operating expenses from operating revenues. ReferencesReference 1: <a href=): [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 3](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 3): [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 4](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 4): <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 31-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 5>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Details Name: us-gaap\\_OperatingIncomeLoss Namespace Prefix: us-gaap\\_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration)